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INTRODUCTION 
 
 
Modern society is becoming increasingly demanding when it comes up to 
health. Patients expect the doctor to tell them exactly what is going wrong 
and, more importantly, how to cure the disease. Therefore, it is of utmost 
importance to perform a fast and reliable diagnosis. To execute this task, the 
medical doctor can use a wide variety of diagnostic tools. One of the most 
powerful tools today is magnetic resonance imaging or MRI, an imaging 
technique that yields impressive images of the body. These images are 
topological representations of NMR parameters such as proton density and 
relaxation rates of (mainly) water protons in various tissues. The 
development of the MRI technique has prompted the need for a new class of 
pharmaceuticals, which would be administered to the patient in order to 
enhance the image contrast between normal and diseased tissue and/or 
indicate the status of organ function or blood flow. Complexes of 
paramagnetic transition metal and lanthanide ions, which decrease the 
relaxation times of nearby nuclei, have received the most attention as 
potential contrast agents. Paramagnetic contrast agents are unique among 
diagnostic agents, since these agents are not directly visualised on the MR 
image but are detected by virtue of changes in proton relaxation behaviour. 
The development of new contrast agents offers intriguing challenges for 
investigators in the chemical, physical and biological sciences, including the 
design and synthesis of stable, non-toxic and tissue specific metal complexes 
and the understanding of their effect on relaxation behaviour in solution and 
tissue. 
 
 
 
 
Aim of this work 
 
This work deals with the above mentioned challenges to develop new 
contrast agents in the field of MRI, and to understand their behaviour. More 
specifically, the goal was to make complexes of lanthanide ions with 
derivatives of DTPA as ligands. 
At first, ligands were designed in such a way to make supramolecular 
assemblies, e.g. micelles or liposomes, feasible (chapter 5). Another thought 
pathway was trying to form supramolecular entities by self-assembly of 
gadolinium(III) complexes around iron(III) or iron(II) ions (chapter 7). By 
making supramolecular entities we tried to achieve higher relaxivity rates in 
MRI (as compared to the commercially available Gd(DPTA) contrast agent).  
Secondly, tissue specificity (especially necrosis avidity) was sought by 
making a contrast agent with high albumin binding affinity (chapter 6), or by 
synthesizing ligands that are potentially receptor specific (chapter 8). 
 
Chapter 1 
 
 
NMR SPECTROSCOPY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is, of course, a bit of a drawback that science was invented after I left school.  
    - Lord Carrington –  
- NMR Spectroscopy - 
1.1 Introduction 
NMR spectroscopy is a technique that is mainly used to determine the 
structure of organic molecules. This is accomplished by monitoring the 
chemical shift of a nucleus of interest in a homogenous magnetic field. Since 
its discovery in 1946 by Felix Bloch and Eduard Purcell it has become an 
indispensable tool for chemists, biochemists, physicists and recently, with 
the introduction of MRI, also for medical scientists. Before investigating the 
MRI working principles, the physical basis of NMR will be discussed in 
some detail. 
 
1.2 The nucleus 
Quantum mechanics shows that certain nuclei appear to spin around their 
axes, which causes them to interact with magnetic fields. The intrinsic spin 
of a nucleus I can take only an integer or half–integer value that depends on 
the number of protons and neutrons in the nucleus. The intrinsic spin of a 
nucleus gives rise to an angular momentum P, which points along the spin 
axis. The magnitude of the angular momentum P associated with the spin is 
quantized: 
 ( ) h⋅+= 1IIP  (1-1) 
The nucleus also possesses an electric charge, and the rotation of this charge 
gives rise to an associated magnetic dipole moment µ: 
 µ = γ P (1-2) 
where the gyromagnetic ratio γ, is a constant for a given type of nucleus. For 
protons, γ = 26.75 x 107 rad s-1 T-1. 
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1.3 Nuclei in a static magnetic field 
The magnetic dipole moment causes the nucleus to behave like a tiny bar 
magnet and gives rise to interactions with an external magnetic field. When a 
nucleus with µ ≠ 0 is placed in a static magnetic field B0, the magnetic dipole 
moment tries to align with this field. However, the nucleus also possesses an 
angular momentum P, which forces the nucleus to precess arout B0 (figure 1-
1). Due to directional quantization, the angular momentum takes up an 
orientation so that its component Pz along the direction of the field is an 
integral or half-integral multiple of ħ:  
 Pz = m ħ  (1-3) 
Here m is the magnetic or directional quantum number, and can take any of 
the values m = I, I-1,…,-I. For protons, I=1/2, this results in two m-values: 
+1/2 and -1/2. Combining equations (1-2) and (1-3) yields the components of 
the magnetic moment along the field direction z: 
 µz = m γ ħ (1-4) 
3 
L
In the classical representation the precession frequency or Larmor frequency 
υ  of the magnetical dipoles about the magnetic field B0 is expressed by: 
 
0L B2π
γυ =  (1-5) 
- NMR Spectroscopy - 
 
Figure 1-1: Precession of nuclear dipoles with spin I = ½ around B0 
(coinciding with z-axis). The precession frequency matches the Larmor 
frequency . Due to directional quantization, for protons, the half-angle of 
the double cone is fixed at 54°44’. 
Lυ
 
1.4 Energy of the nucleus in the magnetic field 
The energy of a magnetic dipole in a magnetic field with a flux density B0 is: 
 E = -µz B0 (1-6) 
Combining this equation with equation (1-4) yields: 
 E = -m γ ħ B0 (1-7) 
For the proton this results in two energy states α and β, which correspond to 
the m-values +1/2 and -1/2 respectively (figure 1-2). The orientation of the α 
state is parallel to the field direction, whereas the orientation of the β state is 
antiparallel. 
4 
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Figure 1-2: Energy level scheme for a proton. 
The energy difference, ∆E, between the two states is proportional to the 
strength of the magnetic field B0 (figure 1-3) and is given by: 
 Eα – Eβ = ∆E = γ ħ B0 (1-8) 
 
Figure 1-3: Energy difference ∆E between the two energy levels as a 
function of the magnetic field strength B0. 
5 
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Transitions between the two states can be induced by applying an 
electromagnetic field, perpendicular with respect to B0, with an energy or 
frequency υL, given by: 
 υL = 
0B2π
γ
 (1-9) 
This is the resonance condition, since only radiation of the correct frequency 
(energy) will cause the nucleus’s orientation to flip.  
 
1.5 Population of the energy levels 
Although the lower energy level is preferred, thermal motion induces 
transitions, so that at thermal equilibrium there is only a small excess of 
spins in the lower energy state. The equilibrium populations Nα and Nβ of the 
lower α and the upper β states are given by the Boltzmann distribution: 
 
TK
E1
TK
Eexp
N
N
BB
∆∆
α
β −≈


−=   (1-10) 
For protons at room temperature, with B0 = 1T, the fractional excess is only 7 
× 10-6, so NMR is an insensitive technique. To increase sensitivity, one could 
either decrease the temperature (impractical with patients in MRI) or increase 
the magnetic field strength B0. 
 
1.6 Bulk magnetization 
In practice only the combined effect of all the nuclei of interest in the sample 
is observed, rather than a single magnetic moment. This bulk magnetization 
6 
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is called M0 and represents the summation of the small excess of aligned 
spins predicted by equation (1-10). At equilibrium, the bulk magnetization 
only has a longitudinal component (i.e. along the B0 direction). Although the 
individual magnetic moments all precess around B0, there is no phase 
coherence between them at equilibrium, so there is no transverse 
magnetization component. 
 
1.7 Basic NMR experiment 
1.7.1 Radiofrequency pulse 
In an NMR experiment one irradiates the nuclei with an electromagnetic 
field B1, perpendicular to B0, with frequency νL to fulfil the resonance 
condition. The nuclei will then undergo a transition between the two energy 
levels. A transition from the lower to the upper energy level corresponds to 
an absorption of energy, and those in the reverse direction to an emission of 
energy. Both transitions are possible, and they are equally probable. Each 
transition is associated with a reversal of the spin orientation. Due to the 
population excess in the lower level, the absorption of energy from the 
irradiating field is the dominant process. This is observed as a signal, whose 
intensity is proportional to the population difference Nα - Nβ.  
On a macroscopic scale, the application of the B1 field causes M0 to tilt away 
from B0, and to follow a spiral path as shown in figure 1-4. The tilt angle Θ 
depends on both the amplitude of the B1 field and the time, τp, over which 
the pulse is applied: 
 Θ = γ B1 τp (1-11) 
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Figure 1-4: Spiral path that is followed by the vector M0, after application of 
the B1 field. 
1.7.2 Free induction decay 
Once the magnetization is tipped away from the B0 direction, its transverse 
component generates a rotating magnetic field. This is then detected as a 
small induced voltage in the RF (Radio Frequency) coil (by the dynamo 
effect) (figure 1-5). 
 
Figure 1-5: The precessing magnetization, M, induces a signal in the coil 
which is detected by a sensitive radio receiver. This is called Free Induction 
Decay (FID). 
8 
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1.8 The rotating frame of reference 
NMR experiments involve the application of a sequence of RF pulses. 
Visualizing the resulting complex motion in a fixed coordinate system is 
very difficult. Instead, it is easier to use a rotating coordinate system, which 
rotates around an axis parallel with B0 and is synchronized with the 
precessing nuclear magnetic moments. This is called the rotating frame of 
reference x’, y’, z. 
1.9 Relaxation 
When a sample is irradiated at the resonance frequency, the thermal 
equilibrium of the spin system is disturbed, altering the population ratios and 
causing transverse magnetic field components, Mx and My, to appear. 
When the perturbation ceases, the system relaxes again to equilibrium. This 
process is called relaxation. 
Two types of relaxation processes are possible: 
(1) The relaxation along the direction of the applied field B0, which is 
characterized by the spin-lattice or longitudinal relaxation time T1. 
This is an energetic process: to reassert the equilibrium condition Mz 
= M0, energy is transferred from the system to the surroundings. 
(2) The relaxation perpendicular to the field direction, which is 
characterized by the spin-spin or transverse relaxation time T2. This 
relaxation is an entropic process in which the phase coherence is 
lost. Mx´ and My´ drop to their initial zero value. 
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1.9.1 Spin-lattice relaxation 
When the equilibrium is disturbed by a 90o or a 180o pulse, the macroscopic 
magnetization vector M0 is rotated into the y´-axis or into the (-z) direction 
respectively (figure 1-6). In both cases the population ratio changes. A 90o 
pulse equalizes the populations of the two energy levels, whereas a 180o 
pulse inverts the population ratio. After the perturbation the equilibrium 
condition Mz=M0 reasserts itself. The rate at which this occurs is determined 
by the spin-lattice relaxation time T1. Felix Bloch described this process by 
the differential equation: 
 
1
ozz
T
MM
dt
dM −−=  (1-12) 
From a kinetic point of view, this process is first order, with T1-1 as the rate 
constant. Spin-lattice relaxation describes a loss of energy from the spin 
system to its surroundings. Various intra- and intermolecular interactions are 
recognized as contributing to the 1H spin-lattice relaxation including: 
• Dipole-dipole (DD) relaxation 
• Spin-rotation (SR) relaxation 
The theoretical description of dipolar relaxation leads to the proportionality 
relationship T1-1 ∝ τR, i.e. the faster a molecule moves the greater T1 
becomes. Here, τR is the rotational correlation time, and corresponds roughly 
to the interval between two successive reorientations or positional changes of 
the molecule. The dipole-dipole relaxation mechanism is especially effective 
between protons bound through a carbon atom, for instance: CH2 or CH3 
groups. The DD interaction of the nuclei with unpaired electrons in 
paramagnetic molecules is of special practical importance. Owing to the 
large magnetic moment of the electron, this interaction is very strong. 
10 
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Figure 1-6: a: Effect of a 90° pulse; b: effect of a 180° pulse on M0. 
1.9.2 Determination of T1 
Sample T1 values are most commonly measured using the Inversion 
Recovery (IR) pulse sequence (figure 1-7). This is used in NMR 
spectrometers to measure the spin-lattice relaxation times of small samples 
and in MRI systems to create images that display T1 contrast (cfr. infra). The 
IR sequence’s 180° inversion pulse tips the magnetization vector so that its 
Mz component has an initial value of –M0 (figure 1-8). During the period TI 
(time interval), between the 180° and 90° pulses, Mz gradually recovers along 
the z-axis towards its equilibrium value of +M0. The rate of recovery depends 
only on the spin-lattice relaxation time of the sample, T1, since there is no 
transverse magnetization component at this stage. When the 90° pulse is 
applied, any Mz component is converted immediately into transverse 
magnetization, and generates an FID (free induction decay). The size of the 
FID is a measure of how far the magnetization has recovered towards M0 
during the period TI. The value of the longitudinal component of the 
magnetization at a time t after a 180° pulse can be expressed as follows: 
 Mz(t) = M0(1-2exp-t/T1) (1-13) 
11 
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where M0 is the equilibrium magnetization (equivalent to the proton density) 
and T1 is the spin-lattice relaxation of the sample. The signal strength, S, in 
an IR experiment is proportional to the size of Mz just before the 90° pulse, 
so 
 S ∝ Mz(TI) = M0(1-2exp-TI/T1) (1-14) 
To obtain an exact value of T1 one uses a multi TI inversion recovery pulse 
sequence: first, a 90° pulse is applied without an inverting pulse, and the 
amplitude of the resulting FID is stored in a computer. This signal is 
proportional to M0. Then, a series of IR pulse sequences (i.e. 180° - 90° pulse 
pairs) is applied with increasing values of TI, e.g. from 10 ms up to 200 ms. 
The initial amplitudes of the FID are recorded each time, and long delays are 
left between pulse pairs to ensure thermal equilibrium is re-established. Once 
the data have been collected, a least-squares fit is performed with variables 
M0 and T1, and an accurate value of T1 is obtained. A typical plot of signal 
amplitude versus TI is shown in Figure 1-9.  
 
Figure 1-7: Inversion recovery pulse sequence. 
12 
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Figure 1-8: Vector diagram for five different interval times (TI) of the 
inversion recovery pulse sequence. 
 
Figure 1-9: Result of a multi-TI inversion recovery experiment. The curve is 
fitted to the experimental data (crosses). 
Pure water exhibits T1 values between 2 and 3 seconds. In soft tissues T1 
depends on the field strength. In high protein tissues such as the liver, T1 may 
range from about 200 ms at 0.1T to 600 ms at 2T. 
13 
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1.9.3 Spin-spin relaxation (T2) 
1.9.3.1 True spin-spin relaxation 
After a 90o pulse the z-component of the macroscopic magnetization vector 
is zero, Mz = 0. This is only possible if the populations Nα and Nβ have 
become equal. Instead of an Mz component, there is now a transverse 
magnetization component My´: the nuclear dipoles are bunched together and 
precessing around the surface of the double cone. This is called phase 
coherence. The magnetization My´ is the sum of the y´-components of all the 
individual spins. The evolution of this transverse magnetization after the 
pulse is determined by the Bloch equation: 
 
2
´y´y
T
M
dt
dM −=  (1-15) 
T2 is the spin-spin or transverse relaxation time. It determines how rapidly 
the transverse magnetization component My´ decays. This means that the 
precessing nuclear spins, which are bunched together, gradually lose their 
phase coherence, so the bunch fans out. As the fanning-out process continues 
My´ becomes smaller (Figure 1-10). 
 
Figure 1-10: Decay of transverse magnetization My’ (in the rotating 
coordinate system x’,y’,z) after a 90° pulse, as the precessing bunched spins 
fan out. 
14 
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The energy of the spin system is not altered by spin-spin relaxation, as the 
level populations are not affected. Only the phase coherence between the 
bunched precessing nuclear spins is lost. Energy is transferred from one 
nucleus to another via fluctuating magnetic fields. This means that one of the 
nuclei changes from a higher to a lower energy state, while another is 
simultaneously raised from a lower to a higher level. T2 can never be greater 
than T1, because Mz cannot grow to its equilibrium value M0 until the 
transverse magnetization My´ has completely disappeared. 
 T1 ≥ T2 (1-16) 
1.9.3.2 Pseudo relaxation 
In practice, variations in the value of the magnetic field throughout the 
sample also cause dephasing of the magnetic moments, mimicking the true 
relaxation of the transverse magnetization. It is convenient to define another 
relaxation time, T2*, describing the observed rate of decay of the NMR 
signal: 
 1/T2* = 1/T2 + 1/T2inhom (1-17) 
where T2inhom describes the decay in signal due to the magnetic field 
inhomogeneity. 
1.9.4 Determination of T2 
In 1950, E.L. Hahn suggested an elegant method for determining T2, where 
the inhomogeneity contribution is eliminated. This method is known as the 
spin-echo pulse sequence. The basic sequence consists of a 90° pulse, 
followed a time TE/2 later by a 180° pulse, where TE is known as the echo 
time. The 180° pulse reverses the dephasing effects of magnetic field 
inhomogeneity or ‘pseudo relaxation’, leaving only the signal degradation 
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due to spin-spin relaxation. A 180° pulse used in this way is often referred to 
as a ‘refocusing pulse’ (figure 1-11). 
 
Figure 1-11: Spin-echo pulse sequence. 
Figure 1-12 shows how each step in this pulse sequence affects the spin 
system. Figure 12a shows the initial equilibrium condition, with the 
macroscopic magnetization in the z-direction (Mz = M0). The 90ox´ pulse 
turns M0 into the direction of the y´-axis (My´ = M0). This transverse 
magnetization My´ now rotates with an average Larmor frequency νL in the 
rotating x´, y´, z coordinate system, so the transverse magnetization My´ 
remains along the direction of the y´-axis. Due to pseudo-relaxation, (caused 
by field inhomogeneities) dephasing occurs (see figure 1-12b). 
16 
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Figure 1-12: Hahn spin-echo experiment, viewed from the rotating frame of 
reference x’, y’, z. 
Figures 1-12c-e illustrate the effect of the 180o pulse that follows. The pulse 
causes the complete ‘fan’ of magnetization vectors to rotate 180° around the 
x’ axis. At the end of the 180° pulse, the fan of magnetization vectors is still 
intact, but is now centered on the –y’ axis (figure 1-12c). The faster 
precessing magnetization vectors (from the high-field parts of the sample) 
still precess clockwise in the rotating frame, but are now moving towards the 
–y’ axis. Likewise, the magnetization vectors from the low-field regions of 
the sample still precess anticlockwise in the rotating frame, and they also 
move towards the –y’ axis (Figure 1-12d). At time TE after the 90° pulse, all 
the magnetization vectors are aligned precisely along the –y’ axis. They have 
been refocused or rephased by the 180° pulse. Figure 1-12f illustrates that 
after the refocusing 180° pulse the magnetization vectors will dephase once 
more. The T2 value of an unknown sample can thus be measured by 
performing a number of spin-echo experiments with different TE values (for 
17 
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example, from 20 ms to 100 ms in 10 ms steps), plotting the amplitude of the 
echo maximum versus TE, and performing a least-squares fit to a function of 
the form: 
 S = S0exp-TE/T2 (1-18) 
Pure water exhibits T2 values between 2 and 3 seconds. T2 in soft tissues 
ranges from 40 ms upwards. 
 
1.10 General references 
1. H. Friebolin; Basic one-and two-dimensional spectroscopy, second 
edition, 1993, VCH. 
2. Physical basis of magnetic resonance imaging, summer school 2002. 
University of Aberdeen. 
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If it stinks, it's chemistry. 
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2.1 Introduction 
Viewing the interior of the body is an objective that doctors have dreamed of 
doing for hundreds of years. Since the twentieth century, doing so has 
become common with the use of X-Rays, positron emission tomography 
(PET), ultrasound and magnetic resonance imaging (MRI). Magnetic 
Resonance Imaging provides high quality imaging of the interior of the body 
with easy understandable pictures. It is based on the principles of nuclear 
magnetic resonance (NMR) spectroscopy and started out as a tomographic 
imaging technique, i.e. it produced an image of the NMR signal in a thin 
slice through the human body. MRI has advanced beyond this tomographic 
imaging technique towards 3D volume imaging, functional imaging (i.e. 
monitoring blood oxygen level in the human brain as a measure of activity) 
and imaging of heart beating. 
2.2 Spin warp (2DFT) imaging 
Virtually all MRI imagers use the imaging technique known as spin warp 
imaging, which was developed at the university of Aberdeen in the late 
1970s. The technique combines three spatial discrimination methods: (1) 
selective excitation to define an image slice, (2) frequency encoding along 
one dimension in the slice and (3) phase encoding along the orthogonal 
dimension. 
2.2.1 Magnetic field gradient 
The essential part of any MRI system is the magnetic field gradient, since it 
allows spatial information to be obtained from analysis of the NMR signal. A 
magnetic field gradient is a variation in the magnetic field with respect to 
position. This is accomplished by applying an additional magnetic field, in 
the same direction as B0 (i.e. the z-direction), whose amplitude varies linearly 
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with position along a chosen axis (see figure 2-1). The application of a field 
gradient Gz in the z-direction, causes the magnetic field strength to vary 
according to: 
 Bz(z) = B0 + zGz (2-1) 
 
Figure 2-1: Magnetic field gradient in the z-direction. 
Additional magnetic fields are created by passing a current through specially 
constructed “gradient coils”. An imager has three gradient coils, to generate 
gradients along any of the three orthogonal axes x, y, or z. Typical gradient 
strengths used in whole-body MRI are 0.1 mTm-1 to 10 mTm-1. 
2.2.2 Selective excitation 
Selective excitation is the method by which the NMR excitation, and 
therefore the signal, is limited to a chosen slice within the sample or patient. 
It is achieved by applying the 90° excitation pulse simultaneously with a 
gradient perpendicular to the desired slice. The 90° pulse is called a 
“selective pulse” and is shaped in such a way that it contains a narrow spread 
of frequencies close to the fundamental resonance frequency of the magnet. 
Only those spins whose resonance frequency lies within this range will be 
excited. When selecting a slice in the x-y plane, the width of the slice ∆z, is 
given by: 
 ∆z = ∆υ/γGz (2-2) 
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where ∆υ is the bandwidth of frequencies contained within the selective 90° 
pulse and Gz is the strength of the applied selection gradient. 
 
Figure 2-2: Selective excitation pulse sequence. By applying a shaped 
excitation pulse in the presence of a selection gradient, only a thin slice of 
the sample is affected by the NMR excitation. Only these spins will 
contribute. 
2.2.3 Frequency encoding 
Since the NMR resonant frequency is directly proportional to the strength of 
the magnetic field, when a gradient is applied the resonant frequency is also a 
function of position along the gradient direction. If one applies a gradient Gx 
in the x-direction, the equation describing the variation of the resonant 
frequency υ with position x is:  
 υx = γ(B0 + xGx) (2-3) 
In frequency encoding, a 90° pulse is applied in order to excite the spins. 
Then the frequency encoding gradient Gx is switched on and the NMR signal 
is observed with the gradient turned on (figure 2-3). 
 22
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Figure 2-3: Schematic representation of frequency encoding. 
 
2.2.4 Gradient echo 
Problems can arise if one attempts to measure the FID immediately after 
excitation, while the frequency encoding gradient (or readout gradient) is 
present, as it is important to observe the start of the FID, which contains low 
spatial information. It is preferable to record the FID as a spin-echo, 
generated by a 180° pulse or by a reversal of the readout gradient. The latter 
is called a “gradient echo” (see figure 2-4). 
 
Figure 2-4: Use of a gradient echo to record an FID signal. 
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Because spins at different positions along the gradient direction experience 
different strengths of magnetic field, they precess at different rates and 
therefore become dephased in an orderly manner (see figure 2-5). After a 
gradient has been applied, the spins are “wound up” along the gradient 
direction. A gradient echo is formed by first “winding up” the spins with a 
negative gradient pulse, then letting them unwind in the presence of the 
positive frequency encoding or readout gradient. 
 
Figure 2-5: Diagrams showing the formation of a gradient echo by 
application of field gradients.  
2.2.5 Phase encoding gradient. 
The third method of spatial discrimination is known as phase encoding 
gradient. The phase encoding gradient is used to impart a specific phase 
angle to a region of spins in the y-direction. Imagine having three regions 
with spin in the y-direction (figure 2-6). The magnetization vector from each 
spin has been rotated into the x-y plane by a 90° pulse. The three vectors 
have the same chemical shift and hence in a uniform magnetic field they will 
possess the same Larmor frequency υL in the x-y plane. 
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Figure 2-6: Schematic representation of an image plane with three separate 
regions in the y-direction. 
If a gradient in the magnetic field is applied along the y-direction the three 
regions of spin will begin to precess with different frequencies given by: 
 υy = γ(B0+ yGy) (2-5) 
While the phase encoding gradient is on, each transverse magnetization 
vector has its own unique frequency. Thus far, the description of phase 
encoding is the same as frequency encoding. If the gradient in the y-direction 
is now turned off, the external magnetic field experienced by each spin 
vector will be identical. Therefore the frequency of each transverse 
magnetization vector will again be identical. However, the phase angle of 
each spin region, will not be identical. There are three distinct phase angles 
in this example (figure 2-7). 
25 
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Figure 2-7: Evolution of three different spin regions in the phase encoding 
direction. 
2.2.6 Obtaining the image: Fourier transform 
The central idea behind the FT method is that the simple one-dimensional 
projection of the sample (obtained by frequency encoding) is the Fourier 
transform of the FID as it evolves with time in the presence of a field 
gradient. To expand this technique to two dimensions we must let the FID 
evolve in a “second dimension of time” in the presence of a second field 
gradient at right angles of the first; this is what the phase encoding achieves. 
The real-time evolution of the FID in the presence of the frequency encoding 
(or readout) gradient is repeated many times (usually 128 or 254 times), each 
time with a different phase encoding gradient being applied (see figure 2-8). 
A two-dimensional Fourier transform will then result in a two-dimensional 
image of the sample being investigated. 
 26
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Figure 2-8: Spin warp (2DFT) imaging pulse sequence. This sequence is 
repeated many times, each time a new value for the phase encoding gradient 
Gy is chosen (dashed lines). 
2.3 Pulse sequences and image contrast 
If we have, within an NMR image, two tissues of interest that have different 
NMR properties e.g. grey and white brain or liver containing a tumour, it is 
the physicists or radiologists business to produce an image in which contrast 
between the important tissues is maximized. The maximization of contrast is 
brought about via the pulse sequence: firstly choosing the most appropriate 
sequence, secondly ensuring that the correct time settings are chosen to 
produce appropriate levels of T1 and/or T2 weighting and thirdly acquiring an 
adequate number of averages (repetitions of the image collection which are 
added together to improve the signal-to-noise ratio). To accomplish this one 
must have an understanding of (1) tissue properties and inherent tissue 
contrast (2) effect of noise on the signal and (3) the properties of the various 
pulse sequences and effects of manipulation, e.g. timing. 
27 
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2.3.1 Tissue properties and inherent tissue contrast 
2.3.1.1 Tissue properties 
Table 2-1 lists the relaxation times together with the water content for a 
number of major tissues, measured in vivo in the human body. The water 
content values give an approximate idea of the expected proton density in 
low-fat tissues. However, mobile lipids also contribute to proton density 
(PD) signal. They give a higher proton density than water due to higher 
packing density. 
Table 2-1: Human tissue relaxation times measured in vivo at 21.5 MHz  
(0.5 T) and water content of rat tissues. 
Tissue T1 (ms) T2 (ms) % H2O 
White brain 493 85 71 
Grey brain 656 88 85 
Liver 339 38 71 
Spleen 862 59 68 
Leg Muscle 573 37 77 
Adipose 185 54 5-15 
Marrow 190 44 / 
It is noticeable that the ranges of T1 and T2 values are larger than those for 
water content. This suggests that the relaxation times of tissues will provide 
greater contrast than PD (proton density) on its own. 
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2.3.1.2 Inherent tissue contrast 
The inherent contrast, derivable from one property, e.g. T1, between two 
tissues A and B can be expressed as: 
 ContrastT1 = 
AB
AB
TT
TT
11
11
+
−
 (2-6) 
Table 2-2 illustrates the inherent contrast of a liver with tumour at a 
particular measurement frequency (T1 is frequency-dependent). 
Table 2-2: NMR parameters and inherent contrast in a liver with tumour. 
 Normal liver Tumour Contrast 
T1 0.518 s 0.903 s 0.271 
T2 0.043 s 0.056 s 0.131 
PD 0.83 1.00 0.093 
From the values it can be seen that the calculated maximum inherent tissue 
contrast provided by T1 is about twice that given by T2 and three times that 
based on PD. Any pulse sequence which is weighted towards increasing the 
role of T1 will thus increase the contrast between tumour and the normal 
liver. 
2.3.2 Noise 
Every MRI image has some unwanted noise superimposed on the signal from 
the tissues. It has a Gaussian distribution, is independent of pulse sequence 
and may be termed ‘statistical’ noise. The spread of values due to noise 
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within a region of interest is due to: (1) tissue inhomogeneiety and (2) noise 
originating from the imager itself. 
Signal-to-noise-ratio (SNR) can be improved by ‘signal averaging’ i.e. by 
increasing NS (number of scans):  
 SNR ~ NS1/2 (2-7) 
2.3.3 Pulse sequence and signal size 
If sufficient time can be spent, it is possible to obtain almost pure PD, T1 and 
T2 images. In general, however, the signal obtained arises from a 
combination of two or three of these properties. For example if one uses the 
saturation recovery (SR) pulse sequence with a pulse interval TR: 
-90° -TR (signal collection) - 90° - TR (signal collection) - etc… 
During the TR interval the signal is collected and relaxation occurs. If TR is 
sufficiently long, i.e. TR > 5T1, then an almost pure PD (proton density) 
image is obtained. If, however TR < 5T1, the signal obtained will be reduced 
by an amount directly related to that proportion of T1 relaxation which has 
not occurred (assuming that TR is longer than T2*). Hence, an SR image with 
TR < 5T1 will be both PD and T1-weighted but without T2 influences. The 
signal intensity (SI) obtained using the SR pulse sequence is given by: 
 SI = M0(1-exp-TR/T1) (2-8) 
where M0 is a measure of proton density. 
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The most common practice currently used in MRI imaging involves spin-
echo pulse experiment (SRSE – saturation recovery spin-echo): 
 
In this sequence the T2 element truly relates to the tissue T2 relaxation time. 
This is due to the inherent difference between true T2, which arises from 
inter-molecular effects which are not reversible on application of a 180° RF 
pulse, and T2* effects which originate from outside the sample and are 
reversed upon application of a 180° pulse (see chapter 1, paragraph 1.9.3.). 
Here the signal intensity (SI) in each image volume element is governed by 
the following equation: 
 SI = M0 [(1 – exp-TR/T1) (2expTE/2T1 – 1)] exp-TE/T2 (2-9) 
where M0 is the concentration of water protons in the volume element (PD), 
T1 and T2 are the relaxation times and TE and TR are the echo delay time and 
the pulse repetition time. Pulse sequences are determined by TR and TE 
which are adjustable parameters determined by the operator of the 
instrument. Generally, unless T2 information is specifically required, the echo 
delay time or TE is kept as short as possible. 
2.4 Advantages of MRI 
The images produced by MRI scanners are of superior quality, which is why 
they are so popular. Unlike ultrasound views, which require a trained 
operator to conceive of what is being viewed, an MRI picture of the brain 
looks like a picture of a brain (figure 2-9). There are many characteristics 
that can be modified to provide a clearer image. Resolution (sharpness) and 
signal-to-noise ratio are two such examples. Other ways to enhance certain 
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aspects of images also exist, like contrast agents which enhance contrast of 
certain regions in the body. Other advantages MRI offers over comparative 
methods include safer contrast materials, high spatial resolution, and being 
able to repetitively view a single subject without making averaging errors.  
 
Figure 2-9: MRI image of the normal human brain. 
 
2.5 General references 
1. Physical basis of magnetic resonance imaging, summer school 2002. 
University of Aberdeen. 
2. D. D. Stark, W. G. Bradley; Magnetic resonance imaging, C.V. 
Mosby company, 1988  
3. The basics of MRI, Joseph P. Hornak; 
http://www.cis.rit.edu/books/mri/ 
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"The future, according to some scientists, will be exactly like the past, only more 
expensive." 
 - John Sladek -  
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3.1 Definition 
An MRI contrast agent is a substance that is administered to the body – by 
injection, orally or by any other route – with the intention of increasing the 
contrast between two tissues or a tissue and an abnormal region within it, in 
the MRI image. Contrast agents are routinely used in many MRI centres 
because they are able to produce reliable results that help in rapid clinical 
interpretation of images and they also increase the speed of the imaging 
procedure, hence improving patient turnover. Most of the commonly used 
contrast agents achieve their effect by manipulation of the relaxation times of 
tissues. 
3.2 Paramagnetic relaxation effects 
3.2.1 Introduction 
Paramagnetic enhancement of nuclear relaxation was first described in 1946 
by Bloch and co-workers[1] when they demonstrated a convenient practice of 
shortening the time needed to observe T1 of water by adding a paramagnetic 
solute, ferric nitrate. Studies of water relaxation in solutions of transition 
metal ions led to a mathematic formulation of paramagnetic-enhanced 
solvent relaxation first described by Solomon[2] in 1955 and later modified 
by Bloembergen[3] in 1957.  
3.2.2 Working principles 
3.2.1.1 Relaxivity or relaxation effectiveness 
The addition of a paramagnetic solute causes a decrease of both the spin-
lattice and spin-spin relaxation times of the solvent nuclei, T1 and T2, 
respectively. The observed solvent relaxation rate, in an aqueous solution, 
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1/T1,obs, is generally given by the sum of two contributions: (1) a diamagnetic 
and (2) a paramagnetic term: 
 
ipidobs,i T
1
T
1
T
1 +=    i = 1,2 (3-1) 
where 1/Tid and 1/Tip are the diamagnetic and paramagnetic relaxation rates, 
respectively. The diamagnetic term, 1/Tid, corresponds to the relaxation rate 
of the solvent (water) nuclei in the absence of a paramagnetic solute. The 
paramagnetic term, 1/Ti,p, indicates the relaxation rate enhancement caused 
by the paramagnetic substance, which is linearly proportional to its 
concentration[4-8]: 
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1
i
d,1obs,i
+=  (3-2) 
Koenig[9] has used this linear proportionality to define relaxivity. Relaxivity, 
R, is the change in relaxation rate (in s-1) produced by unit change in 
concentration (in mM). Relaxivity describes the relaxation effectiveness of 
an ion. It depends on the temperature and the NMR frequency of the 
measurement. Examples for some common ions are given in table 3-1. 
Table 3-1: Relaxivity values for common paramagnetic ions at 80 Mhz and  
0 °C. 
Ion R1 (s mM)-1 R2 (s mM)-1 
Cu2+ 0.626 0.713 
Ni2+ 0.700 0.780 
Mn2+ 5.69 71.6 
Gd3+ 10.38 11.7 
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“Relaxivity” is often used in the context of MRI contrast agents and always 
refers to “T1 proton relaxivity”, R1, since this process largely controls the 
MRI image enhancement.  
3.2.2.2 Inner- and outer-sphere contributions 
Paramagnetic relaxation of water protons originates from the dipole-dipole 
interactions between the nuclear spins and the fluctuating local magnetic 
field caused by the unpaired electron spins. Since these magnetic fields fall 
off rapidly with distance, random translational diffusion of solvent molecules 
and the complex as well as specific chemical interactions that bring the water 
protons near the metal ion are important in transmitting the paramagnetic 
effect. It is useful to classify the relevant contributions for water proton 
relaxivity into an inner-sphere, RIS, and an outer-sphere, ROS, term. The 
inner-sphere term represents the contribution due to exchange of water 
molecules in the first coordination sphere of the paramagnetic center. The 
contribution of random translational diffusion is defined as outer-sphere 
relaxation:  
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  (3-4) OSiISii RRR +=
Solvent molecules that are not directly bound in the first coordination sphere 
may also remain in the proximity of the paramagnetic metal complex for a 
relatively long time, e.g. due to hydrogen bridges with the complexing 
ligand(s) or to the solvent molecule(s) in the first coordination sphere. This 
relaxivity contribution is called second-sphere relaxivity. Nevertheless, due 
to lack of understanding of this type of interaction, it is simply referred to as 
outer-sphere relaxation. 
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For small-sized contrast agents, with one available coordination site for 
water molecules, the outer- and inner-sphere relaxation mechanisms 
contribute approximately equally to the observed proton relaxivity at the 
imaging fields.  
3.2.2.3 The inner-sphere contribution 
The inner-sphere relaxation rate is described in terms of the following set of 
equations:[9-12] 
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Here, PM is the mole fraction of the metal ion, c is the molar concentration of 
the paramagnetic complex, q is the inner sphere water coordination number 
of the contrast agent, τM is their mean residence and T1M is their longitudinal 
relaxation time in the complex. S is the electron spin quantum number; γS and 
γH are respectively the electron and the proton nuclear magnetogyric ratios, r 
is the distance between the metal ion and the protons of the coordinated 
water molecules; ωH and ωS are respectively the proton and electron Larmor 
frequencies; τR is the reorientational correlation time; τS1 and τS2 are the 
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longitudinal and transverse electron spin relaxation times respectively. These 
spin relaxation times are frequency dependent (eqns. 3-8 and 3-9) and 
characterized by the correlation time τυ of the modulation of the transient 
zero-field splitting (∆2). 
3.2.2.4 The outer-sphere contribution 
The outer-sphere relaxivity, which depends on the electronic relaxation time 
of the metal ion, on the distance of closest approach of solute and solvent (a) 
and on the sum of solvent and solute diffusion coefficients (D) is usually 
treated with the set of equations developed by Freed.[13] 
3.2.2.5 Parameters influencing relaxivity 
A schematic representation of the inner- and outer-sphere relaxation 
mechanisms operating the relaxation enhancement of the solvent water 
protons in solution by a Gd3+ complex is shown in figure 3-1. 
 
Figure 3-1: Schematic view of the paramagnetic relaxation mechanisms and 
the main relaxation parameters for an aqueous solution of a Gd3+ chelate. 
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The main parameters that affect the solvent relaxation rate are (1) the 
rotational correlation time, τR, (interval between two successive 
reorientations or positional changes of the molecule) (2) the coordination 
number and (3) the mean water residence time τM. 
The rotational correlation time, τR, is the main parameter determining 
relaxivity at the magnetic strengths currently employed in MRI (0.5 – 1.5 T, 
corresponding to proton Larmor frequencies of 20 - 60 MHz). The 
achievement of higher proton relaxation rates may therefore be pursued 
through an increase of this parameter. 
An increase of the number of metal bound water molecules will lead to an 
increase in relaxivity. However, it is likely to be accompanied by a decrease 
in stability of the metal complex which leads to the release of toxic free 
metal ions. 
The residence time of the water molecules, τM may affect relaxivity by 
limiting the efficiency of the water exchange process. For systems with one 
available water coordination site, exchange rates decrease with the presence 
of bulky substituent groups in the ligand.  
3.3 Relaxivity in tissues 
The most important effect of the paramagnetic agent is to enhance the 
longitudinal relaxation rate of the water protons in the tissue. The efficiency 
by which a complex influences tissue relaxation rates depends on two 
factors: 
a) the chemical environments encountered by the complex in vivo: the 
greatest effect is exerted by the binding of the agent to macromolecular 
structures. This can potentially cause a significant relaxivity enhancement.  
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b) compartmentalization of the complex in the tissue: generally, tissue water 
is compartmentalized into intravascular, interstitial (fluid space between cells 
and capillaries) and intracellular space.  
Cellular organelles further subdivide the intracellular component. If the water 
exchange between any of these compartments is slow relative to the 
relaxation rate in the compartment with the longest T1, then multi-
exponential longitudinal relaxation may result. This can decrease the 
effective tissue relaxivity of an agent because all of the tissue water is not 
encountering the paramagnetic center. 
For the commercially used, low-molecular weight hydrophilic metal 
complexes, [Gd(DTPA)(H2O)]2- and [Gd(DOTA)(H2O)]- (for structures, see 
figure 3-2), available data show clearly that the relaxivity enhancement in 
blood and soft tissue is within experimental error of that in aqueous 
solution.[14-15] This indicates that binding interactions between these chelates 
and proteins or membrane structures are not taking place. The hydrophilic 
nature of the complexes as well as their extracellular localization (where 
protein concentrations are lower relative to the intracellular environment), 
apparently results in unhindered rotational mobility. The effect of two 
different doses of Gd(DTPA)2- on T1 and T2 relaxation times of various tissue 
is listed in Table 3-2.[16] 
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Table 3-2: Effect of two doses of Gd(DTPA)2- on tissues. 
 % Reduction in T1 and T2 
 0.017 mM/kg 0.17 mM/kg 
Tissue T1 T2 T1 T2 
Renal Medulla 47 15 87 76 
Renal Cortex 6 1 65 50 
Heart 2 0 29 3 
Pancreas 12 0 26 0 
Lung 0 5 28 20 
Small intestine 2 6 21 0 
Skeletal muscle 1 0 21 10 
Liver 1 2 15 13 
Spleen 2 0 13 0 
Adipose tissue 0 3 0 15 
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Figure 3-2: Structures of Gd(DTPA)2- (left) and Gd(DOTA)- (right). 
3.4 Safe contrast agents: general requirements 
MRI contrast agents must be bio-compatible pharmaceuticals in addition to 
nuclear relaxation probes. The requirements relevant for metal complex-
based agents can be classified into three general categories: 
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Relaxivity: The enhancement of the proton relaxation rates of the target 
tissue must be sufficiently high. 
Specific in vivo distribution: The complex should be localized for a certain 
period of time in the target tissue or tissue compartment in preference to non-
target regions.  
In vivo stability, excretability, non-toxicity: Transition- and lanthanide metal 
ions are relatively toxic at doses required for MRI imaging; thus, dissociation 
of the complex should not occur to any significant degree. The toxicity of the 
free ligand also becomes a factor. Additionally, the contrast agent should be 
excreted within hours of administration. 
3.5 Stability and toxicity 
3.5.1 Toxicity 
Toxic effects from a metal complex can arise from (1) free metal ion, 
released by dissociation; (2) free ligand, which also arises from dissociation; 
and (3) the intact metal complex. In the latter two cases, formation of toxic 
metabolites is possible and should also be considered. 
The available toxicological data point to the importance of metal complex 
dissociation as an important source of toxicity. Table 3-3 lists acute LD50 
(lethal dose 50: lethal dose for 50% of the treated animal species) determined 
for metal ions, complexes, and ligands.[18] Both metal ions and free ligands 
tend to be more toxic than metal chelates. This is to some degree due to 
neutralization of the coordinating properties of both the ligand and the metal 
ion, decreasing their avidity for binding to proteins, enzymes or membranes. 
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Table 3-3: Acute LD50 Values for metal salts, metal complexes and free 
ligands, Iv = intravenous, Ip = intraperitoneal. MEG = N-methylglucamine, 
EGTA = Ethylene glycol(2-aminoethyl ether) tetraacetic acid, CDTA = 
trans-1,2-cyclohexylenedinitrilotetraacetic acid. 
Compound LD50 (mmol/kg) Animal Administration 
method 
GdCl3 0.5 Rat Iv 
 0.4 Mouse Iv 
Gd(OH)3 0.26 Rat Iv 
 0.1 Mouse Iv 
(MEG)[Gd(EDTA)(H2O)n] 0.3 Rat Iv 
 0.62 Mouse Ip 
(MEG)[Gd(CDTA)(H2O)n] <2.5 Rat Iv 
(MEG)[Gd(EGTA)(H2O)n] <2.5 Rat Iv 
(MEG)2[Gd(DTPA)(H2O)] 10 Rat Iv 
 >10 Mouse Iv 
Na2[Gd(DTPA)(H2O)] >10 Mouse Iv 
 20 Rat Iv 
MnCl2 0.22 Rat Iv 
 1.5 Mouse Ip 
Na2[Mn(EDTA)(H2O)] 7.0 Rat Iv 
 5.9 Mouse Ip 
Na2[Mn(DTPA)] 1.9 Rat Iv 
FeCl3 1.6 Mouse Iv 
Na[Fe(EDTA)(H2O)] 3.4 Mouse Iv 
 1.7 Mouse Ip 
Na3[Ca(DTPA)] 5.0 Rat Iv 
 3.5 Mouse Iv 
(MEG)3H2DTPA 0.15 Mouse Iv 
Na2H3DTPA 0.1 Mouse Iv 
Na2[Ca(DOTA)] >7.0 Mouse Iv 
(MEG)2H2DOTA 0.18 Mouse Iv 
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As stated previously, the degree of toxicity of a metal chelate is related to its 
degree of dissociation in vivo before excretion. A good example of how 
toxicity and in vivo stability depend on the chelating ligand is the comparison 
between [Gd(EDTA)(H2O)n]- and [Gd(DTPA)(H2O)]2-. The latter is a very 
stable complex (logKML=22.5) that is excreted intact readily by the kidneys, 
exhibiting a very low degree of toxicity. [Gd(EDTA)(H2O)n]-, on the other 
hand, has a toxicity comparable to GdCl3 despite its apparently high 
thermodynamic stability (logKML=17.4). The straightforward interpretation is 
that the latter complex quantitatively dissociates in vivo, yielding the toxicity 
of the free ion.  
Metal toxicity arises from coordination with oxygen, nitrogen, or sulfur 
heteroatoms in macromolecules and membranes, altering the dynamic 
equilibria necessary to sustain life. The toxicity of intact metal complexes 
can stem from a wide variety of specific and nonspecific effects. At the high 
doses required in LD50 determinations of relatively nontoxic hydrophilic 
chelates like [Gd(DTPA)(H2O)]2-, the nonspecific hypertonic effect is 
thought to be important. A difference in osmolality between intracellular and 
extracellular compartments is established after injection of large quantities of 
the ionic complexes and appropriate counter ions. Water is drawn out of cells 
as a result of the osmotic gradient, causing cellular and circulatory damage. 
Other possible mechanisms of chelates toxicity include enzyme inhibition, 
nonspecific protein conformational effects, or alteration of membrane 
potentials. 
3.5.2 Stability 
The requirement of metal complex stability is a kinetic, not a 
thermodynamic, requirement. The agent should be efficiently excreted from 
the body minutes or hours after administration, and stability is therefore 
required only for this residence time. Dissociation kinetics are related to the 
thermodynamics of complexation through expression 3-10: 
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 kd = ka/KML  (3-10) 
where ka and kd are the association and dissociation rate constants and KML is 
the thermodynamic association constant. A good test for in vivo stability is 
the evaluation of stability in blood serum. A variety of coordination ligands 
and proteins as well as metal ions can compete for either the paramagnetic 
metal ion or its multidentate ligand. An important thermodynamic sink for 
trivalent metal ions in blood serum is their precipitation with commonly 
occurring anions like phosphate or carbonate.  
3.6 Biodistribution and excretion 
The pharmacokinetic properties of the various types of contrast agents are of 
great importance in defining their clinical applications. Figure 3-3 illustrates 
potential distribution sites and excretion pathways of soluble metal chelates 
as contrast agents.[17] An intravenouslty administered chelate rapidly 
equilibrates in the extracellular (intravascular and interstitial) compartment. 
It may also distribute into various intracellular environments (e.g. liver and 
kidney) by passive diffusion or specific uptake processes. The excretion 
pathway is determined by the structure of the complex. Small molecular 
weight hydrophilic chelates do not bind to plasma proteins (cfr. supra) and 
are rapidly and non-specifically filtered out in the kidneys (glomerural 
filtration). If the molecule has some hydrophobic character, a fraction of it is 
taken up by the liver cells and excreted into the bile (hepatobiliary excretion) 
and its binding to the plasma albumin reduces the fraction available for renal 
excretion. If the complex is very lipophilic, it can distribute into fat storage 
sites or membranes or precipitate in blood and be taken up by 
reticuloendothelial cells in the liver and spleen, leading to chronic toxicity.  
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Figure 3-3: Main distribution sites and excretion pathways for intravenously 
administered soluble metal chelates. 
Based upon distribution properties, contrast agents can be classified into 
several categories:[18,28] 
1. Unspecific or extracellular fluid (ECF) agents.  
These agents are small, very hydrophilic chelates such as Gd(DTPA)2-. After 
i.v. injection, they are rapidly 100% renally excreted (t1/2 ~ 90 min.) after an 
early intravascular distribution and diffusion into the extracellular 
(interstitial) space (t1/2 ~ 10 min). They do not bind to plasma proteins or 
cross cell membranes or the blood-brain barrier (BBB) and are quite useful to 
study brain perfusion abnormalities, such as disruption of the BBB by 
tumours. 
2. Blood pool (BP) agents.  
These are macromolecular conjugates of paramagnetic centers (e.g. Gd3+ 
chelates) of molecular weight higher than 50,000 Daltons, such as albumin-
Gd(DTPA)n, dextran-Gd(DTPA)n. Their size restricts their diffusion into the 
interstitium, causing prolonged stay in the vasculature. This allows mapping 
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of the intravascular space using magnetic resonance angiography (MRA).[19] 
Their excretion half-life is several hours, as it is dependent on polymer 
breakdown. 
3. Liver and spleen specific agents or hepatobiliary agents.  
These include the hydrophobic Gd(DTPA)2- derivatives Gd(BOPTA)2-, 
Gd(EOB-DTPA)2- and Mn(DPDP)4-. Because they contain negative 
charge(s) and hydrophobic moieties, they are taken up by the hepatocyte 
anion transport system and have hepatobiliary excretion. They are thus used 
to image the liver.[20]  
4. Reticuloendothelial system (RES) specific agents. 
These include superparamagnetic particulate iron oxide (SPIO) (e.g. AMI-
25), which are superparamagnetic iron oxide particles of diameters 30 nm to 
5 mm, coated with polymers (e.g. dextran, starch, polyethyleneglycol). The 
biodistribution of these agents depends on their size and type of coating, and 
they cause shortening of T2 values.[18] Gadolinium labeled liposomes also 
show reticuloendothelial specificity,[21] however no liposomes are yet 
approved for clinical use.[28] 
5. Contrast agents for lymph nodes and bone marrow.  
Ultrasmall particles of diameter smaller than 30 nm can pass through the 
capillaries of the endothelium into lymph nodes and the bone marrow. They 
are eventually phagocytosed at a slow rate by macrophages, particularly 
those within lymph nodes. Examples are the USPIO (Ultrasmall 
SuperParamagnetic Iron Oxide) iron oxide particles (e.g. AMI 7227, 
ferumoxtran).[18,28] 
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6. Contrast agents for the gastrointestinal tract. 
These include Gd3+ ions incorporated in zeolites, used as oral contrast 
agents.[22] 
3.7 Commercially available contrast agents 
3.7.1 Introduction: what’s in a name? 
The most precise term for any chemical substance, including contrast agents 
for imaging is the IUPAC systematic chemical name. However, the chemical 
name for a contrast agent often consumes several lines of text, defies easy 
memorization and is virtually unpronounceable. For these reasons, the 
systematic chemical name is rarely used by researchers. For example, the 
first gadolinium chelate approved for human use has the chemical name of 1-
deoxy-1-(methylamino)-D-glucitol dihydrogen [N,N-bis[2-
[bis(carboxymethyl)amino]ethyl]-glycinato-(5-)]gadolinate (2-)(2:1). To 
facilitate dissemination of information regarding a new contrast agent, a 
pharmaceutical company usually derives an abbreviated name or company 
code name for the agent. Hence, the compound above has been referred to as 
gadolinium diethylenetriamine penta-acetate, further shortened to 
Gd(DTPA)2- in much of its early literature.[16,25,26] As development on an 
agent continues, the pharmaceutical company creates a brand name by which 
the agent will be marketed. During the process of applying to the United 
States Patent and Trademark Office for this official trademark, the symbol 
“” is applied (e.g.: Magnevist “”). Once the brand name is officially 
registered, the symbol changes to “” (e.g.: Magnevist “”). In scientific 
literature, however, the agent is usually referred to by the generic name (i.e. a 
nonproprietary or non-patented name everyone can use for the drug). 
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3.7.2 Commercially available agents 
Table 3-3 lists the commercially available MRI agents so far.[26-28] 
Table 3-3: Names and vendors of contrast agents, by classification. 
Generic name Commercial name Vendor Other terms 
Gadolinium chelates—Extracellular 
Gadopentetate 
dimeglumine 
Magnevist Berlex Laboratories (US) Gd(DTPA) 
Gadoterate 
meglumine 
Dotarem Guerbet (France) Gd(DOTA) 
Gadoteridol ProHance Bracco Diagnostics 
(Italy) 
Gd(HP-DO3A) 
Gadodiamide Omniscan Amersham Health Gd(DTPA-BMA) 
Gadobutrol Gadovist Berlex Laboratories (US) Gd(DO3A) -
butantriol 
Gadoversetamide Optimark Mallinckrodt Medical 
(US) 
MP-1177/10 
Gadolinium Chelates – Hepatobiliary excretion – Liver specific 
Gadoxetic acid Eovist Berlex Laboratories (US) 
- Schering (Germany) 
Gd(EOB-DTPA) 
Gadobenate 
dimeglumine 
MultiHance Bracco (Italy) Gd(BOPTA) 
Manganese Agents – Hepatobilairy excretion – Liver specific 
Mangafodipir 
trisodium 
Teslascan Amersham Health Mn(DPDP) / 
mangafodipir 
Iron oxide Particles (Intraveneous) – Hepatobiliary excretion – RES - specific 
Ferumoxides Feridex 
I.V./Endorem 
Berlex Laboratories 
(US)/Guerbet (France) 
AMI-25 
Ferrixan Resovist Schering (Germany) SH U 555 A/ 
ferucarbotran 
 Combidex Advanced Magnetics 
(US) 
AMI-227 
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Blood pool agents – Protein binding gadolinium complexes 
Gadophostriamine 
trisodium 
AngioMARK (clinical 
trial) 
Mallinckrodt (US) - 
EPIX Medical (US) 
MS-
325/gadofosveset 
Gadolectic acid B22956/1 Bracco (Italy)  
Blood pool agents – polymeric gadolinium complexes 
Gadomer-17 / Schering (Germany)  
P-792 Vistarem Guerbet (France)  
Lymph node specific agents 
Gadofluorine M  Schering (Germany)  
Ferumoxtran-10 Sinerem/Combidex Guerbet (France)  
AMI 7227  Advanced Magnetics  
Oral agents 
Ferric ammonium 
citrate 
FerriSelz Otsuka Pharmaceuticals 
(Japan) 
Oral magnetic 
resonance (OMR) 
Ferumoxsil oral 
suspension 
GastroMARK Mallinckrodt Medical 
(US) 
AMI-121 
 Abdoscan Nycomed AS (Norway) Oral magnetic 
particles (OMP) 
Gadopentetate 
dimeglumine 
Magnevist entereal Schering (Germany) Gd(DTPA) 
Perflubron Imagent GI Alliance Pharmaceutical 
Corp. (US) 
Perfluoro-
octylbromide 
(PFOB) 
Manganese chloride LumenHance  Bracco Diagnostics 
(Italy) 
 
Gadolinium zeolite Gadolite 60 Oral 
suspension 
Pharmacyclics (US)  
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Figure 3-4: Structures of commercially available MRI contrast agents. 
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Chapter 4 
 
 
INSTRUMENTAL TECHNIQUES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physicists do it magnetically 
Physicists do it with large expensive machinery 
- Chapter 4 - 
56 
4.1 Introduction 
 
Experimental determination of the various parameters that effect inner 
sphere relaxivity is non trivial and needs special equipment. The parameters 
are obtained by measuring solvent longitudinal relaxation rates over a wide 
range of magnetic fields with a field-cycling relaxometer. Data points 
obtained by this technique represent the so-called nuclear magnetic 
relaxation dispersion (NMRD) profile that can be fitted to yield the values of 
the relaxation parameters.  
 
One of the important parameters that determines the inner sphere relaxation, 
especially when dealing with supramolecular species like micelles or 
liposomes, is the mean size distribution of these species in solution. Only 
when these supramolecular structures are monodisperse, i.e. when the size of 
all the particles in solution is uniform, analysis of the corresponding NMRD 
profiles is possible. In order to determine the size distribution of micelles and 
liposomes, a technique called photon correlation spectroscopy (PCS), was 
used. 
 
4.2 Recording NMRD curves: the field cycling relaxometer 
 
The essence of the “field-cycling” method is the measurement of the 
relaxation rates by rapidly changing the external magnetic field H0 to a value 
HM, the “measure-field”. This is the field at which the relaxation rate is 
sought. This is accomplished through monitoring the exponential time 
variation of the magnetization of the proton spin system. The time constant 
that describes this variation, is the longitudinal or spin-lattice relaxation time 
T1 of the proton spins.  
 
- Instrumental techniques - 
Two field-cycling sequences are used, pulse-up and pulse-down, 
corresponding with high and low proton Larmor frequency ranges 
respectively. 
 
The first field cycling sequence, called pulse-down (figure 4-1, top), is used 
in the low frequency range, i.e. proton Larmor frequencies < 25 MHz. In this 
sequence, the field is brought to HM from a field HS (the soak field) which is 
set at the instrumentation limits (usually corresponding to a proton Larmor 
frequency of 50 MHz) and which is applied for a time TS (the soak-time), 
sufficient for the macroscopic magnetization to reach equilibrium 
magnetization at HS. During this operation, the initial maximum 
magnetization M, will decay during TM (the measure-time) with a minimum 
potential signal amplitude proportional to the difference in the equilibrium 
magnetization values at HS and HM, and thus to HS-HM which is never less 
than half HS. 
 
Figure 4-1: Representation of the time variation of the magnetic field (solid 
lines) during a single cycle of the field cycling relaxometer presently in use, 
and the corresponding variation of the magnetization of the sample (dashed 
curves). 
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The second field-cycling sequence, called pulse-up (figure 4-1, down), is 
used in the high proton larmor frequency range, i.e. > 25MHz. In this 
sequence, HS is kept near zero during TS. In this mode, the magnetization M 
will grow during TM with a minimum potential signal amplitude again 
proportional to HS/2. Thus, with either cycling protocol, the sensitivity of the 
relaxometer is related to the maximum magnitude of HS. 
 
Having developed a procedure for producing a nonequilibrium magnetization 
that, during the period TM, either decays from a large value to a small one or 
else grows from a small value to a large one, the next problem is to measure 
its time dependence with great accuracy. For this again we alter the field, 
after a particular value of TM has elapsed, to HR, the resonance field, at 
which standard NMR techniques are used: a spin-echo pulse sequence is 
applied (cfr chapter 1) and the amplitude of the subsequent echo, which is 
proportional to the magnetization at the end of TM, is measured. The field is 
then returned to zero, and the entire cycle is repeated after a quiescent of 
typically 1 s. 
 
The frequency of the NMR transmitter is fixed at 7.5 MHz, the value of HR. 
It must be stressed that the frequency of 7.5 MHz is unrelated to and 
independent of the field HM at which the relaxation rate is being determined.  
 
The full field-cycling sequence can now be described with reference to figure 
4-1. First during TS the field is kept at either 50 MHz or near zero, depending 
upon the value of HM. The interval TS is set at about 5 times the value of T1 
at either zero field or HS, respectively, so that the magnetization is at its 
appropriate equilibrium value when the measuring interval TM begins. 
 
The entire field-cycling sequence is generally repeated 23 times, with the 
value of TM the only parameter that is changed to obtain a single value of T1. 
For the first four and last four sequences, TM is set at seven times the 
expected value of T1 at the field HM; the average echo amplitude at these 
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points is taken as the equilibrium end-point of the time dependence of the 
magnetization during TM. In between, a sequence of 15 cycles with TM 
spanning an interval of 1.5 times the anticipated T1 in 15 equal steps is 
produced, and the echo amplitude is recorded for each TM. Finally, a least 
squares comparison is made of the 15 pairs of data points, with the end-point 
subtracted with a single exponential; this yields one point of a typical NMRD 
profile. 
 
To obtain a complete NMRD profile, the desired set of values of HM is 
entered at a computer terminal along with an estimate of the rates at the two 
extremes of the field range. The relaxometer continues automatically from 
this point, adjusting the length of TS and TM appropriately for each run, either 
using the initial estimate of the rates or a value interpolated from the NMRD 
profile as it is generated. If a measured rate is +/- 30% of its estimate, the 
relaxometer moves on to the next field value; if not, the rate is remeasured 
with the initial value used as a new estimate.  
4.3 17O measurements 
 
The analysis of NMRD curves involves multi-parameter fitting. In such an 
analysis it is desirable to fix values of the parameters that can be determined 
through independent experiments. One such an experiment is the 
determination of τM (water exchange lifetime) through determination of the 
17O NMR transverse relaxation time T2 at variable temperature. The 
paramagnetic contribution to the total relaxivity of the water molecule is 
dependent on τM or  (17O chemical shift difference between 
coordinated and bulk water):  
O
Mϖ∆
 
 ( ) 2
2
O
M
21
M
O
M2
O
M
O
M2
1
M
2O
M21
MM
O
p2
R
RRPR ϖ∆τ
ω∆ττ ++
++= −
−
−  (4-1) 
59 
- Chapter 4 - 
 



+++

= 2
2E
2
S
2E
1E
2
O
M2 1
)1S(SA
3
1R τω
ττh  (4-3) 
  (4-3) 1M
1
Si
1
Ei
−−− += τττ
 ( ) 

 

 −=
−
−
T
1
15.298
1
R
Hexp
15.298
T M
15.2981
M1
Mj
∆ττ  (4-4) 
 
where A/ħ is the Gd-17O scalar coupling constant, τEi represent the 
correlation times of the processes modulating the scalar interaction, and ∆HM 
is the activation enthalpy for the exchange process. values increase as 
the temperature increases until τM becomes short enough with respect to 
 thus causing a decrease of  with a further increase of temperature, 
this results in a bell-shaped behaviour (see figure 4-2). 
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Figure 4-2: Evolution of the 17O transverse relaxation rate versus 
temperature of compound KA080402 (cfr. Chapter 6). 
 
4.4 Photon correlation spectroscopy (laser light scattering) 
 
Photon correlation spectroscopy (PCS) is the analysis of the time 
dependence of intensity fluctuations in scattered laser light due to the 
Brownian motion of particles in solution/suspension. Since small particles 
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diffuse more rapidly than large particles, the rate of fluctuation of scattered 
light intensity varies accordingly (figure 4-3).  
 
Figure 4-3: Fluctuations in light intensity in relation to particle size. 
 
This way, the translational diffusion coefficient (D) can be measured, which 
in turn can be used to determine the mean hydrodynamic radius ( ) of the 
particles using the Stokes-Einstein equation. Data can be presented either as 
mean particle size (assuming spherical equivalence), or alternatively a more 
rigorous analysis can yield details of two or more subpopulations of particles 
in solution/suspension. A typical photon correlation spectrometer consists of 
a laser light source (helium – neon or argon) which is focused on the contents 
of a highly polished, fine quality glass cuvette. The error on the temperature 
of the goniometer cell should preferably be within +/-0.1°C. Thus 
minimizing any potential error due to variation in fluid viscosity, but more 
importantly, minimizing random convection currents superimposed on the 
Brownian movement which could lead to substantial errors in particle size 
hR
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measurement. The sample under examination can be suspended in a range of 
dispersion media, the only information required being viscosity and the 
refractive index of the medium. These can be determined using a suitable 
viscometer (e.g. U-tube) and refractometer respectively, ideally at the 
temperature at which PCS is being performed (typically 25 °C). To eliminate 
a potential light flare at the surface through which the laser beam passes, it is 
recommended to immerse the sample cell in a liquid which matches the 
refractive index of the dispersion fluid. Scattered laser light from the sample 
is detected by a photomultiplier assembly usually situated at an angle of 90° 
relative to the laser beam. Once the signal has been recorded in terms of a 
series of photomultiplier bursts over a period of time, a mathematical process 
called ‘correlation’ is carried out, in which the similarity between the signal 
and itself separated from the original by a time delay is measured. In essence 
this is performed by multiplying the amplitudes of the signal and its time-
delayed copy together at different time points to give a correlation function. 
As the signals become more and more out of phase (i.e. the time separation is 
increased), their randomness with respect to each other results in a decay of 
the correlation to a constant value (figure 4-4). The correlation function at 
any given time separation is described mathematically as 
 
 G(t) = <N>2(1-Be-Γt) (4-5) 
 
With N the intensity of the signal averaged over many sample times, B a 
constant determined by mechanical constraints of the apparatus and the 
sampling procedure, and Γ, the decay constant, equal to 2DK2, K is the 
scattering vector (dependent on the detection angle, etc.) and D is the 
diffusion coefficient of the particles causing the fluctuation. Having obtained 
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a value for the diffusion coefficient, particle radii can then be determined by 
inserting D in the Stokes – Einstein equation: 
 D = kT/6πη hR  (4-6) 
Where k = Boltzmann’s constant, T = absolute temperature, η = solvent 
viscosity,  = mean hydrodynamic radius.  hR
 
Figure 4-4: Derivation of a correlation curve. The correlation curve (from 
which the diffusion coefficient is deducted) is a measure of how quickly a 
signal becomes completely out of phase with itself. This is determined by 
multiplying the signal with a copy of itself separated from the original by a 
given period of time (i.e. a set number of channels). The product, expressed 
as the cumulative area under the curve obtained, is plotted for each time 
separation against the channel number corresponding to that separation. 
The result is a curve which decays exponentially to a mean value at a rate 
which depends on the rapidity of the signal fluctuations (and hence the 
particle size). The value to which it decays will depend on the intensity of the 
signal fluctuations. 
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Chapter 5 
 
 
MIXED MICELLAR SYSTEMS 
 
Todo estaba vacío, muerto y mudo 
Caído, abandonado y decaído 
Todo era inalienablemente ajeno, 
 
 Todo era de los otros y de nadie 
Hasta que tu belleza y tu pobreza 
Llenaron el otoño de regalos 
 
Everything was empty, dead, mute, 
Fallen abandoned, and decayed: 
Inconcievably alien, it all 
 
Belonged to someone else-to no one: 
Till your beauty and your poverty 
Filled the autumn plentiful with gifts 
 (P. Neruda) 
 
“If we knew what it was we were doing, it would not be called research, would it ?" 
- Albert Einstein – 
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5.1 Amphiphilic bis(alkylamide) derivatives of [(Gd-
DTPA)(H2O)]2- 
 
5.1.1 Introduction 
 
In recent years, complexes of lanthanides with diethylenetriamine-N,N,N’, 
N”,N”-pentaacetate (DTPA)5- and with its amide derivatives have attracted 
considerable attention. The anionic [Gd(DTPA)(H2O)]2-, the first contrast 
agent approved for use in humans, is nowadays routinely used in clinical 
magnetic resonance imaging for contrast enhancement under the name 
Magnevist® (Schering, Berlin, Germany). This paramagnetic complex 
contains one inner-sphere water molecule[1-4] that exchanges rapidly[5] with 
the bulk water in the human body, therefore providing an efficient 
mechanism for the enhancement of the relaxation rates of the water protons. 
The high solubility and rapid excretion by the kidneys make the Gd-DTPA 
complex an ideal agent for imaging leakage through the damaged blood brain 
barrier,[6-7] but is of little value for imaging the normal liver or spleen since 
the highly water soluble complex does not accumulate in these organs.[8-11] 
Moreover, due to the leakage through the blood vessel walls into the 
extravascular space and the rapid elimination through the kidneys this agent 
is not suitable for imaging the vascular system. Another disadvantage of the 
Gd-DTPA complex is its negative charge, which results in a relatively high 
osmotic load of the clinical formulation. This problem has been addressed by 
neutralizing the two negative charges of [Gd(DTPA)(H2O)]2-, through 
synthesis of bis-amide derivatives of DTPA. The bis methylamide derivative 
of Gd-DTPA, Gd-DTPA-BMA (Gadodiamide, figure 3-4), [H3DTPA-
BMA=N,N”-bis-(methylcarbamoylmethyl)carboxymethyliminobis 
(ethylenediamino) diacetic acid] has been in clinical use nearly as long as its 
parent complex.[12] The practical application of Gd-DTPA-BMA has 
stimulated extensive research on the synthesis and study of new DTPA 
amide derivative ligands. In general, the methyl groups of DTPA-BMA have 
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been replaced by various alkyl or aryl groups[13-22], and in addition, 
macromolecular bis(amide) derivatives of DTPA and the macrocyclic DO3A 
have also been successfully synthesized.[23-25] X-ray crystal structure of the 
lanthanide(III) complexes of some DTPA bis(amide) derivatives have 
revealed that the ligands coordinate to the lanthanide ion in an octadentate 
mode, while the ninth coordination site is occupied by a water molecule 
(figure 5-1).[15,16,20,22] In solution, the presence of a H2O molecule in the inner 
sphere was detected for the europium(III) complex by luminescence lifetime 
measurements[3,26] and by 17O NMR studies for some dysprosium 
complexes.[17]  
 
Figure 5-1: X-ray crystal structure of a gadolinium(III) complex of a 
bis(benzylamide) derivative of DTPA.[27] 
 
In an attempt to achieve higher proton relaxivity, the Gd(III) complexes of  
(DTPA-bisamide) alkyl copolymers with the alkyl chain consisting of 6, 10, 
or 12 –CH2-groups have been synthesized.[27] The unexpectedly high proton 
relaxivities of these polymers were attributed to the formation of rigid, 
micelle-like structures in the solution. These structures formed as a 
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consequence of hydrophobic interactions between long alkyl chains. Detailed 
17O NMR and EPR spectroscopic study showed that the rate and mechanism 
of water exchange of all Gd (DTPA-bisamide) alkyl copolymers are the same 
as in the monomer chelate unit, and the proton relaxivity difference was 
explained by difference in global motion.  
 
Bis(amide) derivatives of Gd-DTPA containing long alkyl chains were also 
incorporated into the membranes of liposomal vesicles, yielding gadolinium-
labelled liposomes. These liposomes containing paramagnetic amphiphilic 
agents significantly enhanced the proton relaxivity, and some were shown to 
be especially suitable for contrast enhancement of the liver, where the highly 
soluble parent Gd-DTPA complex does not accumulate efficiently.[28]  
Liposomes and micelles draw special attention because of their easily 
controlled properties, their good pharmacological characteristics,[29] and their 
potential as blood pool agents.  
 
Other attempts to slow down rotational motion of gadolinium based contrast 
agents and thus to improve their relaxation efficiency included synthesis of 
macromolecular gadolinium (III) chelates such as dendrimers[30] linear 
polymers[32-34] or proteins.[34-36] The strategy proved to be rather 
disappointing since the relaxivity gain obtained by increasing the molecular 
size is often far less than expected, as a result of internal flexibility or 
nonrigid attachment of the chelate to the macromolecule.[30-37] An interesting 
approach to high-relaxivity contrast agents is to synthesize amphiphilic 
gadolinium(III) complexes which can self-assemble to micelles.[37] An 
example is the the Gd-DOTA derivative (DOTA = 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) with a long alkyl chain 
(figure 5-2), reported by André et al.[38]  
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Figure 5-2: Structure of the amphiphilic DOTA derivative. 
 
In this study, the synthesis of neutral, amphiphilic bisamide derivatives of 
DTPA with the alkyl chain consisting of 14, 16, and 18 carbon atoms is 
described. The gadolinium complexes of these ligands were incorporated into 
mixed micelles to obtain a supramolecular structure with a decreased 
rotational motion, and the NMRD profiles of the paramagnetic micelles are 
reported. The solution dynamics of europium and praseodymium complexes 
were investigated by NMR, and comparison with the related Ln-DTPA 
complexes was made. 
 
5.1.2 Results and discussion  
 
5.1.2.1 The ligands and complexes 
 
The ligands DTPA-bis-tetradecylamide (DTPA-BC14), DTPA-bis-
hexadecylamide (DTPA-BC16), and DTPA-bis-octadecylamide (DTPA-
BC18) were synthesized in high yields according to scheme 5-1. 
Experimental details are given in section 5.4. 
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Scheme 5-1: Synthesis of DTPA bis(amide) derivatives. 
 
Under slightly alkaline solutions, the ligands all readily formed complexes 
with lanthanide(III) ions (Ln = Gd, La, Eu, Pr), as shown in figure 5-3. IR 
spectral data of all ligands showed strong absorptions in the regions 3350-
3360 and 1625-1670 cm-1, corresponding to NH and CO stretching modes, 
respectively.[39] Shifts of ca 20 cm-1 to lower energy were observed for the 
carbonyl stretching frequencies upon complexation, indicating amide oxygen 
coordination to the lanthanide ion. These findings are consistent with 
previous studies which have shown that DTPA bis(amide) derivatives 
coordinate to LnIII via three acetate oxygens, three nitrogen atoms and two 
carbonyl oxygens of the amide group, while the ninth coordination site is 
occupied by a water molecule.[15,16,20,22]  
 
The melting point of the ligands was determined by DSC (differential 
scanning calorimetry). Values are 173.9 °C for DTPA-BC14, 171.4 °C for 
DTPA-BC16, and 171.8 °C for DTPA-BC18. All of the complexes 
decomposed between 320 °C and 345 °C. 
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Figure 5-3: Schematic representation of the Ln-DTPA-BC18 complex. The 
ligand coordinates to lanthanide ion via three acetate oxygens, three 
nitrogen atoms and two carbonyl oxygens of the amide group, while a water 
molecule occupies the ninth coordination site The bonds between the 
lanthanide ion and the ligand have been omitted for clarity. 
 
5.1.2.2 Solution structure and dynamics of Ln-DTPA-BC14, DTPA-BC16, 
and DTPA-BC18 complexes 
 
The coordination polyhedron of the nine-coordinate lanthanide complexes 
can best be described as a tricapped trigonal prism,[34] with the bis-amide-
DTPA ligand arranged around the lanthanide ion in such a way that eight 
different enantiomers are possible. The eight possible enantiomers of the 
bound ligand give rise to the complex geometries, where four of them are the 
mirror image of the other four. Thus, in theory, for each nucleus in the bis-
amide-DTPA ligand four NMR signals could be detected.  However, rapid 
interconversion of the bis-amide-DTPA complexes on the NMR time scale 
very often leads to a reduction of the number of NMR signals.[17] In order to 
examine solution dynamics of the lanthanide complexes with  DTPA-BC14, 
DTPA-BC16, and DTPA-BC18, the 1H NMR spectra were recorded at 
various temperatures. Unfortunately, due to the low solubility of all the 
complexes in the common NMR solvents we were unable to collect 13C 
NMR spectra of good quality. The 1H NMR spectra of lanthanum(III) 
complexes with DTPA-BC14, DTPA-BC16, and DTPA-BC18 ligands at 
room temperature were quite complex due to the broadening and overlapping 
of proton resonances originating from various isomers. This made the 
interpretation of the spectra quite difficult. However, the proton NMR 
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spectra of the praseodymium(III) complexes were much more informative 
since the paramagnetic ion increased the chemical shift range and resulted in 
separate signals for CH2 protons. At room temperature (298 K), the 
praseodymium(III) complexes with DTPA-BC14, DTPA-BC16, and DTPA-
BC18 show eighteen resonances for ten acetate and eight ethylenic protons in 
the range from –35 to +35 ppm. The exact distinction between ethylenic and 
acetate resonances was not possible since this would require use of partially 
deuterated ligand. It is reasonable to assume, that analogous to the previous 
assigned proton NMR spectra of the parent Pr-DTPA and Eu-DTPA 
complexes, the acetate resonances in general experience significant down-
field shift, while the ethylenic protons are shifted up-field.[41] We extended 
our observation to the DTPA-BC14, DTPA-BC16, and DTPA-BC18 
complexes of europium(III), because we expected that an increased 
charge/size ratio would favour even higher rigidity of the system. As figure 
5-2 shows, in proton NMR spectrum of Eu-DTPA-BC16 the “frozen” 
structures could be detected already at 298 K. In theory, eight possible 
enantiomers of the bound ligand are possible, and since four of those 
geometries are mirror images of the other four, for each group of 
magnetically equivalent protons in the Eu-DTPA-BC16 ligand four signals 
can be expected. The examination of the NMR spectra shown in figure 5-4 
suggests that the spectra are consistent with the occurrence of either two 
static structures or two pairs of interconverting isomers. To test this, the 
temperature of the solution was increased to 333 K, but only the coalescence 
of two pair of peaks was detected. Unfortunately, the chloroform/methanol 
solution in which the complexes were dissolved did not allow us to record 
high temperature spectra in order to observe the coalescence process. 
However, broadening of the resonances supports the view that the observed 
spectral pattern is due to the existence of interconverting isomers.  
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Figure 5-4: Variable temperature NMR spectra of Eu-DTPA-BC16 in 
CDCl3/CD3OH solution. Only the regions containing resonances of acetate 
protons (at the high field) and ethylenic protons (at the low field) are shown. 
The relative assignment was based on the assignment of the parent Eu-DTPA 
complex reported in reference.[41] The region containing solvent peaks as 
well as aliphatic proton resonances is omitted for clarity.  
 
This dynamic behaviour of the praseodymium and europium complexes with 
DTPA-BC14, DTPA-BC16, and DTPA-BC18 is rather surprising, since the 
parent Pr-DTPA and Eu-DTPA complexes are known to undergo fast 
intramolecular rearrangement at room temperature, so that “frozen” 
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structures could be detected only at temperatures below 268 K, while the 
exchange process leading to coalescence was already observed at 338 K.[41]  
 
Detailed kinetic study on the bis-propylamide-DTPA complex of 
neodymium(III) showed that the activation barrier for the conformational 
interconversion at the middle nitrogen atom in the diethylenetriamine 
backbone (so called “wagging” process) was virtually the same to the 
activation barrier of the parent DTPA complex, indicating that the 
replacement of two carboxylate groups by the relatively weak coordinating 
amide groups has no influence on this process.[11] However, the inversion of 
the terminal diethylenetriamine nitrogen atoms, which is characterized by a 
higher activation barrier, requires partial decomplexation of the ligand. It is 
likely that due to steric reasons, the long aliphatic substituents on DTPA-
BC14, DTPA-BC16, and DTPA-BC18 ligands considerably alter the rate of 
this inversion, thus increasing the energy barrier for the intramolecular 
rearrangement around the lanthanide ion. 
 
5.1.2.3 Mixed micelle formation and size distribution 
 
The gadolinium(III) complexes of DTPA-BC14, DTPA-BC16, and DTPA-
BC18 ligands were incorporated into mixed micelles made of a phospholipid 
(DPPC), a surfactant (Tween® 80) and the gadolinium complex (see figure 
5-5 and 5-6). The micelle size was determined at room temperature by 
photon correlation spectroscopy.  
 
All micelles were monodisperse i.e. there was only one main kind of particle 
in the size distribution histogram. As can be seen from figure 5-7, the mean 
diameters of the micelles are all within the same range (15-20 nm) and can 
be considered as similar. This indicates that the size of the micelles is 
virtually independent on the length of the bisamide chain, and that the factor 
that determines the size is the phospholipid DPPC. 
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Figure 5-5: Schematic representation of a mixed micelle: 1: paramagnetic 
metal centre, 2: lipophilic chelate, 3: DPPC phospholipids, 4: non ionic 
surfactant. 
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Figure 5-6: Structures of DPPC (A) and Tween® 80. 
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Figure 5-7: Histogram representing micelle size distribution, as measured by 
photon correlation spectroscopy: a) Gd-DTPA-BC14; b) Gd-DTPA-BC16; c) 
Gd-DTPA-BC18. 
 
5.1.2.4 Nuclear magnetic relaxation dispersion (NMRD) measurements 
 
Figure 5-8 displays the proton NMRD profiles of the relaxivity (defined as 
the longitudinal relaxation rate enhancement brought by one millimole per 
litre of Gd complex) of Gd-DTPA-BC14, Gd-DTPA-BC16, Gd-DTPA-
BC18, incorporated in micelles, at 37 °C. As expected, the inclusion of the 
gadolinium complexes into micelles results in an increased relaxivity as 
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compared to the parent complex Gd-DTPA and in a maximum at high 
magnetic fields induced on the one hand by the decreased rotational mobility 
(the value of τR increases) of the paramagnetic complex and on the other by 
the increase of the electronic longitudinal relaxation time at high fields. This 
observation is typical for supramolecular structures. The relaxivities of 
micellar Gd-DTPA-BC14 and Gd-DTPA-BC16 are quite similar and larger 
than for micellar Gd-DTPA-BC18.  
 
Proton Larmor Frequency (MHz)
0.01 0.1 1 10 100 1000
r 1
 (s
-1
m
M
-1
)
0
5
10
15
 
Figure 5-8: NMRD profile of micellar Gd-DTPA-BC14 (circles), Gd-DTPA-
BC16 (triangles up) and Gd-DTPA-BC18 (squares) at 37 °C. The NMRD 
profile of Gd-DTPA (triangles down) has been added for comparison.[54] 
 
The data were analysed using the classical inner sphere[42,43] and outer 
sphere[44] theories. The distance of closest approach was set to 0.36 nm, the 
relative diffusion constant was fixed to 2.93 10-9 m2s-1, the distance for the 
inner sphere interaction was set to 0.31 nm and the number of coordinated 
water molecules was assumed to be equal to one, by analogy with other 
bisamide derivatives of Gd-DTPA.[42,45] The parameters describing the 
electronic relaxation of Gd (τSO, the electronic relaxation rate at very low 
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magnetic field and τV, the correlation time modulating the electronic 
relaxation) as well as the "global" rotational correlation time τR and the 
residence time of the coordinated water molecule τM were simultaneously 
fitted. The results are shown in table 5-1. 
 
Table 5-1: Parameters obtained from the theoretical fitting of the proton 
NMRD data (T = 37 °C). 
 τR (ns) τM (ns) τSO (ps) τV (ps) 
Gd-DTPA-BC14 3.05 1300 175 30 
Gd-DTPA-BC16 2.97 1280 209 30 
Gd-DTPA-BC18 0.62 1470 101 27 
Gd-DTPAa 0.059 143 82 23 
Gd-DTPABMAb 0.047 1050 85 24 
a: from ref [48]: τR, τSO and τV obtained from the fitting of the proton NMRD 
data, τM obtained from the fitting of the 17O transverse relaxation rates, b: 
calculated at 37 °C with the parameters obtained from the simultaneous 
fitting of EPR, 17O NMR and NMRD data by Powell et al.[46] 
 
The parameters obtained for Gd-DTPA-BC14 and Gd-DTPA-BC16 are quite 
similar with a rotational correlation time of about 3 ns, a value which is two 
orders of magnitude lower than the rotational correlation time calculated by 
the Stokes Einstein theory for a rigid sphere (τR ranging between 285 and 675 
ns depending on the micelle size). The observed difference can be related to 
the local motion of the Gd complex within the micellar structure. For 
micelles made of compound Gd-DTPA-BC18 which contains hydrophobic 
chains longer than that of DPPC, the fitted τR is smaller indicating an 
increased local mobility as compared to the other complexes. The τM values 
are similar for the three complexes and larger than for the parent compound 
Gd-DTPA. Such increase of the residence time of the coordinated water 
molecule has already been reported for numerous Gd-DTPA bisamide 
derivatives.[46,47] Moreover, the insertion of both hydrophobic chains of the 
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Gd(III) complex in the micellar structure could also prevent the exchange of 
the water molecule. 
 
5.1.3 Conclusions  
 
Amphiphilic Gd-DTPA bis(amide) complexes were incorporated into mixed 
micelles in order to obtain supramolecular structures with decreased 
mobility. As already reported for other gadolinium complexes incorporated 
into mixed micelles,[42] the relaxivity of the micellar solutions of the three 
complexes Gd-DTPA-BC14, Gd-DTPA-BC16 and Gd-DTPA-BC18 is 
higher than for the hydrophilic Gd-DPTA as a result of the reduced mobility 
of the gadolinium complexes. In the case of Gd-DTPA-BC18, the 
immobilization inside the micellar structure is less effective, probably 
because the aliphatic chains of the complex are longer than the alkyl chain of 
DPPC, in which it is inserted. The increase in relaxivity can be related to the 
lower mobility of the paramagnetic complex inside the micelle.  
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5.2 Amphiphilic bisamide derivatives with small side chain groups 
 
5.2.1 Introduction 
 
One of the reasons why liposomes - synthetically made cell-like structures 
consisting out of phospholipid bilayers enclosing an aqueous compartment -  
and micelles draw special attention is their potential as blood pool agents. In 
order to formulate a material whose distribution is limited to the blood pool, 
three properties seem necessary: (1) a size larger than fenestrated capillaries - 
minute vessels that connect arterioles or venules, their walls act as 
semipermeable membranes for the interchange of fluids between blood and 
tissue fluids - (> 10nm), (2) the paramagnetic moiety must be structurally 
incorporated in the particulate and (3) resistance to phagocytosis. The 
process of phagocytosis involves rapid physiological removal by a process 
called opsonization. The opsonization process involves the coating of 
“intruder” particles by proteins, called opsonins, recognisable by 
macrophages followed by their removal (phagocytosis) and metabolism of 
the coated particles by the Kupffer cells of the liver and the spleen, which 
makes them advantageous for imaging the latter organs but is undesirable 
when one wishes to keep the concentrations of contrast compounds in the 
blood at a relatively high level for a more extended time. One way of 
increasing blood circulation residence time is to use amphiphilic monomer 
Gd(III) chelates which are capable of self-organisation by forming micellar 
aggregates in aqueous solution.[28] Another approach is to incorporate 
lipophilic paramagnetic complexes into mixed micelles by using non-ionic 
surfactants and amphiphatic phospholipids. When these micelles are 
dispersed in an aqueous liquid, they form stable colloidal dispersions, i.e. the 
micelles resist agglomeration or aggregation into larger aggregates for a long 
period. Finally amphiphilic Gd(III) chelates can be incapsulated into 
liposome vesicles or immobilized in the liposome membrane.[55-61] These 
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compounds exhibit longer residence times in the blood than the water-
soluble metal complexes and have a potential for NMR blood pool imaging.  
 
In this study, the synthesis of neutral amphiphilic bisamide derivatives of 
DTPA is described. The aliphatic chains are based on amino acids esterified 
with aliphatic alcohols with chains bearing 14, 16 and 18 carbon atoms. The 
gadolinium complexes of these ligands were incorporated into mixed 
micelles and liposomes to test the influence of the amino acid side chain on 
micelle and liposome formation. NMRD curves were recorded to test the 
influence of the side chain on its relaxivity properties. 
 
5.2.2 Results and discussion 
 
5.2.2.1 The ligands and complexes 
 
The ligands Di(acetyl-L-tyrosineoctadecylester)-N,N´´,N´´´triacetic acid 
(DTPA-BTO), Di(acetyl-L-tyrosinehexadecylester)-N’,N’’,N’’’triacetic acid 
(DTPA-BTH), Di(acetyl-L-tyrosinetetradecylester)-N,N´´,N´´´triacetic acid 
(DTPA-BTT),  Diethylenetriamine-N,N´´´-di(acetyl-L-
phenylalanineoctadecylester)-N,N´´,N´´´triacetic acid (DTPA-BPO), 
Diethylenetriamine-N,N´´´-di(acetyl-L-phenylalaninehexadecylester)-
N,N´´,N´´´triacetic acid (DTPA-BPH) and Diethylenetriamine-N,N´´´-
di(acetyl-L-phenylalaninetetradecylester)-N,N´´,N´´´triacetic acid (DTPA-
BPT) were synthesized according to scheme 5-2. Experimental details are 
given in section 5.4. 
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Scheme 5-2: Synthesis of bisamide derivatives of DTPA with 
aliphaticderivatives of aromatic amino acids (R = OH for tyrosine esters and 
H for phenylalanine esters). 
 
Under slightly alkaline solutions, they all readily formed complexes with 
lanthanide(III) ions (Ln = Gd, La, Pr), as shown in figure 5-9. IR spectral 
data of all ligands showed strong absorptions in the regions 3375 and 1740 - 
1650 cm-1, corresponding to NH and CO stretching modes, respectively.[39] 
Shifts of ca 20 cm-1 (tyrosine esters) and 60 cm-1 (phenylalanine esters) to 
lower energy were observed for the carbonyl stretching frequencies upon 
complexation, indicating amide oxygen coordination to the lanthanide ion. 
These findings are consistent with previous studies which have shown that 
DTPA bis(amide) derivatives coordinate to LnIII via three acetate oxygens, 
three nitrogen atoms and two carbonyl oxygens of the amide group, while the 
ninth coordination site is occupied by a water molecule. [15,16,20,22] 
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Figure 5-9: Schematic representation of the Ln-DTPA-BTO (R = OH) /  
Ln-DTPA-BPO (R = H) complexes. The bonds between the lanthanide ion 
and the ligand have been omitted for clarity. 
 
5.2.2.2 Solution structure and dynamics of Ln-DTPA-BTT and Ln-DTPA-
BPO complexes 
 
Similarly to the Ln-DTPA-BC14, Ln-DTPA-BC16, and Ln-DTPA-BC18 
complexes, the nine-coordinate lanthanide complexes with DTPA-BTT and 
DTPA-BPO can best be described by a tricapped trigonal prism, with the bis-
amide-DTPA ligand arranged around the lanthanide ion in such a way that 
eight different enantiomers are possible. The room temperature NMR spectra 
of lanthanum(III) and praseodymium(III) complexes with DTPA-BTT and 
DTPA-BPO contained very broad peaks indicating fast interconversion of 
the various isomers on the NMR time scale. This behaviour was rather 
surprising, because analogous complexes with DTPA-BC14, DTPA-BC16, 
and DTPA-BC18 ligands undergo slow exchange at room temperature, so 
that “frozen” structures could be observed (cfr. 5.1.2.2). Only upon lowering 
the temperature of the Pr-DTPA-BTT solution to 278 K the detection of 
relatively sharp peaks in the range from –40 to 40 ppm could be observed 
(figure 5-10). 
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Figure 5-10: 1H NMR spectrum of Pr-DTPA-BTT at 278 K. 
 
In the above spectrum the large peak at around 1 ppm belongs to protons in 
the aliphatic chains, while the peaks which are shifted up-field or down-field 
correspond to ethylenic and acetate protons of DTPA. Like in the case of bis-
amide-DTPA complexes, the exact distinction between ethylenic and acetate 
resonances was not possible since this would require use of partially 
deuterated ligand. However, the comparison with previously assigned proton 
NMR spectra of the parent Pr-DTPA complexes suggests that the acetate 
resonances may experience significant down-field shift, while the ethylenic 
peaks are usually shifted up-field.  
 
The NMR measurements suggest that the activation barrier for the 
interconversion of lanthanide(III) complexes of DTPA-BTO and DTPA-BPO 
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isomers is lower than those for the analogous lanthanide(III)- DTPA-BC14, 
DTPA-BC16, and DTPA-BC18 complexes. Introduction of aromatic groups 
in the lanthanide(III) complexes increases the rate of inversion. The presence 
of bulky aromatic groups close to the coordination sites is likely to affect the 
binding to the of lanthanide(III) ion, due to the steric and electronic demands 
of the aromatic substituent, which on the other hand affects the stability of 
different isomers. 
 
5.2.2.3 Mixed micelle formation and size distribution 
 
The gadolinium(III) complexes of DTPA-BTO, DTPA-BTH, DTPA-BTT,  
DTPA-BPO, DTPA-BPH, DTPA-BPT ligands were incorporated into mixed 
micelles made of a phospholipid (DPPC), a surfactant (Tween 80) and the 
gadolinium complex (see figure 5-3). The micelle size was determined at 
room temperature by photon correlation spectroscopy.  
 
Unfortunately the micelles formed were polydisperse i.e. there were different 
kinds of particles in the size distribution histogram (figure 5-11). Moreover 
micelles based on the phenylalanine amino acid ester are unstable, hence the 
micelle size could not be determined. This is most likely due to the presence 
of the bulky side chains, obstructing efficient packing of compounds Gd-
DTPA-BPO and Gd-DTPA-BTO and their respective analogues. 
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Figure 5-11: Histogram representing micelle size distribution, as measured 
by photon correlation spectroscopy: a) Gd-DTPA-BTO; b) Gd-DTPA-BTT. 
 
5.2.2.4 Liposome formation with DPPC 
 
The gadolinium(III) complexes of DTPA-BPO, DTPA-BPH, DTPA-BPT 
ligands were incorporated into liposomes made of DPPC, a phospholipid (for 
experimental details, see section 5.4.9). The liposomes were monodisperse 
i.e. there is only one main kind of particles in the size distribution histogram. 
As can be seen from figure 5-12, the mean diameters increase with 
increasing chain length from about 115-127 nm for compound Gd-DTPA-
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BPT to 140-144 nm and 150-160 nm for compounds Gd-DTPA-BPH and 
Gd-DTPA-BPO respectively. 
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Figure 5-12: Histogram representing liposome size distribution, as measured 
by PCS: a) Gd-DTPA-BPT; b) Gd-DTPA-BPH; Gd-DTPA-BTO. 
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5.2.2.5 Nuclear magnetic relaxation dispersion (NMRD) measurements 
 
Figure 5-13 displays the proton NMRD profiles of the relaxivity of Gd-
DTPA-BPT, Gd-DTPA-BPH and Gd-DTPA-BPO, incorporated into 
liposomes, at 37 °C. As expected, the inclusion of the gadolinium complexes 
into liposomes results in an increased relaxivity as compared to the parent 
complex Gd-DTPA. The hump at higher field strengths, corresponding to 
proton Larmor frequencies of 20 - 60 MHz, is induced by a combination of 
decreased rotational mobility (the value of τR increases) of the paramagnetic 
complex and an increase of the electronic longitudinal relaxation time at high 
fields. This observation is typical for supramolecular structures. The 
relaxivities decrease with increasing length of the amino acid ester chain arm 
of the compound by which the liposome is labelled.  
   
Figure 5-13: NMRD profile of micellar Gd-DTPA-BPT (hexagonals), Gd-
DTPA-BPH (squares) and Gd-DTPA-BPO (triangles) at 37 °C. The NMRD 
profile of Gd-DTPA (hexagonals underneath) has been added for 
comparison.[54] 
 
The data were analysed using the classical inner sphere[42,43] and outer 
sphere[44] theories. The assumption was made that the complex is included in 
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the outer layer of the liposome membrane. Since this is most likely untrue, 
only approximate values are obtained. The distance of closest approach was 
set to 0.36 nm, the relative diffusion constant was fixed to 3.3 10-9 m2s-1, the 
distance for the inner sphere interaction was set to 0.31 nm and the number 
of coordinated water molecules was assumed to be equal to one, by analogy 
with other bisamide derivatives of Gd-DTPA.[42,45] The parameters 
describing the electronic relaxation of Gd (τSO, the electronic relaxation rate 
at very low magnetic field and τV, the correlation time modulating the 
electronic relaxation) as well as the "global" rotational correlation time τR 
and the residence time of the coordinated water molecule τM were 
simultaneously fitted. The results are shown in table 5-2. 
 
Table 5-2: Parameters obtained from the theoretical fitting of the proton 
NMRD data (T = 37 °C). 
 τR (ns) τM (ns) τSO (ps) τV (ps) 
Gd-DTPA-BPT 0.468 640 159 40 
Gd-DTPA-BPH 0.42 790 135 32 
Gd-DTPA-BPO 0.28 730 60 25 
Gd-DTPAa 0.059 143 82 23 
Gd-DTPABMAb 0.047 1050 85 24 
a: from ref [48]: τR, τSO and τV obtained from the fitting of the proton NMRD 
data, τM obtained from the fitting of the 17O transverse relaxation rates, b: 
calculated at 37 °C with the parameters obtained from the simultaneous 
fitting of EPR, 17O NMR and NMRD data by Powell et al.[46] 
 
The rotational correlation time τR decreases with increasing length of the 
amino acid ester chain arm. The most dramatic change occurs when altering 
the amino acid ester chain length from 16 carbon atoms to 18, resulting in a 
33 % decrease of τR, causing a significant decrease of relaxivity. The latter 
liposomes contain hydrophobic chains longer than that of DPPC, resulting in 
an increased local mobility as compared to the other complexes. The τM 
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values are similar for the three complexes and larger than for the parent 
compound Gd-DTPA. Such increase of the residence time of the coordinated 
water molecule has already been reported for numerous Gd-DTPA bisamide 
derivatives.[46,47] Moreover, the insertion of both hydrophobic chains of the 
Gd complex in the liposome structure could also prevent the exchange of the 
water molecule.  
 
All values presented in table 5-2 are inferior to the ones in table 5-1, which is 
reflected by a subsequent decrease in relaxivity of liposomal incorporated 
Gd-DTPA-BPT, Gd-DTPA-BPH and Gd-DTPA-BPO relative to micellar 
Gd-DTPA-BC14, Gd-DTPA-BC16 and Gd-DTPA-BC18. 
 
5.2.3 Conclusions  
 
Amphipilic Gd-DTPA bis(amide) complexes with aromatic side chains were 
incorporated into mixed micelles and liposomes in order to obtain 
supramolecular structures with decreased mobility. The presence of the bulky 
aromatic side groups results in an unefficient packing of the compounds into 
micelles, yielding unstable or polydisperse micelles. The incorporation of 
compounds Gd-DTPA-BPO, Gd-DTPA-BPH and Gd-DTPA-BPT into 
liposomes yielded stable and monodisperse liposomes. The relaxivities of 
solutions of these supramolecular structures are higher than of solutions of 
Gd-DTPA as a result of the reduced mobility of the gadolinium complexes. 
Moreover, the relaxivity gain is lower compared to compounds Gd-DTPA-
BC18, Gd-DTPA-BC16 and Gd-DTPA-BC14, most likely due to a less 
efficient packing or increased local mobility, a phenomenon which is 
supported by NMR. In the case of Gd-DTPA-BPO, the immobilization inside 
the liposomal structure is less effective, probably because the aliphatic chains 
of the complex are longer than the alkyl chains of DPPC, in which it is 
inserted, resulting in a relatively higher local mobility. 
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5.3 Gadolinium DTPA-monoamide complexes  
 
5.3.1 Introduction 
 
Lipophilic compounds were synthesized by introducing aliphatic chains 
through amidation of monoacid tetraester DTPA derivatives (i.e. DTPA with 
only the middle carboxylic acid group available for amidation) and the 
potential of these compounds for detection of tumors and of myocardial 
infarction, or as shift reagents for in vivo NMR spectroscopy was 
investigated.[56-65] Furthermore some of those compounds have been 
incapsulated into the aqueous core of liposomes, for improved characteristics 
as contrast agents.[62-71] Liposomes bearing gadolinium complexes with 
lipophilic fatty acyl groups are expected to be less toxic and more tissue 
specific,[61-62] and the potential as a means to deliver various MRI contrast 
enhancement agents to selective sites has been investigated.[69, 72-75] Another 
approach is to incorporate the contrast agent itself in liposomal vesicles or 
micelles, so that the paramagnetic agent becomes an integral part of the 
liposomal lamella[35, 76-77] or micelle. These structure types show potential for 
contrast enhancement of the liver, spleen and bone marrow, and display 
longer in vivo lifetimes.  
 
In this study the synthesis of amphiphilic monoamide derivatives of DTPA 
with the alkyl chain consisting of 14, 16 and 18 carbon atoms is described. 
The gadolinium complexes of these ligands were incorporated into mixed 
micelles to obtain a supramolecular structure with a decreased rotational 
motion, and the NMRD profiles of the paramagnetic micelles are reported.  
- Chapter 5 - 
5.3.2 Results and discussion 
 
5.3.2.1 Ligands and complexes 
The ligands DTPA-mono-myristylamide (DTPA-MA), DTPA-mono-
palmitoylamide (DTPA-PA) and DTPA-mono-stearylamide (DTPA-SA) 
were synthesized according to scheme 5-3 and 5-4. Experimental details are 
given in section 5.4. 
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Scheme 5-3: Synthesis of N,N-bis[2-[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]-
amino]ethyl]glycine or monofunctional DTPA. 
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Scheme 5-4: Synthesis of DTPA monoamide derivatives R = C14H29, C16H33 
and C18H37. 
 
Under slightly alkaline solutions, they readily formed complexes with the 
paramagnetic Gd3+ ion, as shown in figure 5-14. IR spectral data of all 
ligands showed strong absorptions in the regions 3410 and 1745 - 1670 cm-1, 
corresponding to NH and CO stretching modes, respectively.[39] Upon 
complexation, the CO stretch vibration of the free acid groups disappears, 
whereas the CO stretch mode of the amide shifts with ca 40 cm-1, indicating 
amide oxygen coordination to the lanthanide ion.  
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Figure 5-14: Schematic representation of the Gd-DTPA-MA complex. 
 
5.3.2.2 Solution studies of the lanthanum(III), praseodynium(III) and 
europium(III) complexes with DTPA-MA, DTPA-PA and DTPA-SA 
 
Due to the low solubility of the lanthanum(III), praseodymium(III) and 
europium(III) complexes with DTPA-MA, DTPA-PA and DTPA-SA the 
scope of solution studies has been limited. A range of deuterated solvents 
including D2O, CDCl3, CD2Cl2, DMSO-d6, CD3OH, CD3CN, (CD3)2CO, as 
well as various combinations of those solvents, were used in an attempt to 
obtain solutions of the complexes suitable for NMR measurements. 
Unfortunately, the concentration of most of the solutions was insufficient for 
obtaining good quality NMR spectra. However, in the case of La-DTPA-SA 
complex it was possible to obtain relatively good proton NMR spectrum in 
DMSO/CD3OH solution that showed that DTPA resonances were 
significantly broadened compared to the free ligand. As previously described 
for the bis-amide-DTPA complexes, the broadening of DTPA resonances is 
an indication for the presence of several interconverting isomers in the 
solution. The variable temperature NMR studies on this complex did not 
provide more information about the exchange process, since the strong 
solvent peaks which occur at 2.61 ppm (DMSO) and 3.28 ppm (CD3OH) 
largely covered some of the DTPA resonances.  
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5.3.2.3 Mixed micelle formation and size distribution 
 
The gadolinium(III) complexes of DTPA-MA, DTPA-PA, and DTPA-SA 
ligands were incorporated into mixed micelles made of a phospholipid 
(DPPC), a surfactant (Tween 80) and the gadolinium complex. The micelle 
size was determined at room temperature by photon correlation spectroscopy. 
The micelles of DTPA-PA and DTPA-SA were monodisperse. As can be 
seen from figure 5-15, the mean diameters of the micelles are all within the 
same range (11-19 nm) and can be considered as similar. This indicates that 
the size of the micelles is virtually independent on the length of the 
monoamide chain, and that the factor that determines the size is the 
phospholipid DPPC. 
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Figure 5-15: Histogram representing micelle size distribution, as measured 
by photon correlation spectroscopy: a) Gd-DTPA-MA; b) Gd-DTPA-PA; c) 
Gd-DTPA-SA. 
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5.3.2.4 Nuclear magnetic relaxation dispersion (NMRD) measurements 
 
Figure 5-16 displays the proton NMRD profiles of the relaxivity of Gd-
DTPA-MA, Gd-DTPA-PA and Gd-DTPA-SA, incorporated into micelles at 
37 °C. As expected, the inclusion of the gadolinium complexes into micelles 
results in an increased relaxivity as compared to the parent complex Gd-
DTPA. The hump at higher field strengths (20-60 MHz), which is typical for 
supramolecular structures, is also seen here. As previously explained, this is 
induced by a decrease of rotational mobility of the paramagnetic complex 
and by an increase of the electronic longitudinal relaxation time at high 
fields.  
 
Figure 5-16: NMRD profile of micellar Gd-DTPA-MA (circles), Gd-DTPA-
PA (squares) and Gd-DTPA-SA (triangles up) at 37 °C. The NMRD profile 
of Gd-DTPA (circles underneath) has been added for comparison.[54] 
 
The data were analysed using the classical inner-sphere[42,43] and outer-
sphere[44] theories. The distance of closest approach was set to 0.36 nm, the 
relative diffusion constant was fixed to 3.3 10-9 m2s-1, the distance for the 
inner sphere interaction was set to 0.31 nm and the number of coordinated 
 97
- Chapter 5 - 
 98
water molecules was assumed to be equal to one, by analogy with other 
derivatives of Gd-DTPA.[42,45] The parameters describing the electronic 
relaxation of Gd (τSO the electronic relaxation rate at very low magnetic field 
and τV the correlation time modulating the electronic relaxation) as well as 
the "global" rotational correlation time τR and the residence time of the 
coordinated water molecule τM were simultaneously fitted. The results are 
shown in table 5-3. 
 
Table 5-3: Parameters obtained from the theoretical fitting of the proton 
NMRD data (T = 37 °C). 
 τR (ns) τM (ns) τSO (ps) τV (ps) 
Gd-DTPA-MA 0.91 680 194 41 
Gd-DTPA-PA 1.12 510 154 39 
Gd-DTPA-SA 1.07 500 127 38 
Gd-DTPAa 0.059 143 82 23 
Gd-DTPABMAb 0.047 1050 85 24 
a: from ref [48]: τR, τSO and τV obtained from the fitting of the proton NMRD 
data, τM obtained from the fitting of the 17O transverse relaxation rates, b: 
calculated at 37 °C with the parameters obtained from the simultaneous 
fitting of EPR, 17O NMR and NMRD data by Powell et al.[46] 
 
The parameters obtained for Gd-DTPA-MA, Gd-DTPA-PA and Gd-DTPA-
SA are quite similar with a rotational correlation time of about 1 ns, a value 
which is two orders of magnitude lower than the rotational correlation time 
calculated by the Stokes Einstein theory for a rigid sphere (τR ranging 
between 285 and 675 ns depending on the micelle size). The observed 
difference can be related to the local motion of the Gd complex within the 
micellar structure. The τM values are similar for the three complexes and 
larger than for the parent compound Gd-DTPA. The insertion of the 
hydrophobic chain of the Gd complex in the micellar structure could prevent 
the exchange of the water molecule. 
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The values for τR presented in table 5-3 are inferior to the ones in table 5-1. 
Surprisingly, this is not reflected by a subsequent decrease but by an increase 
in relaxivity. Moreover, the relaxivity of the Gd-DTPA-SA complex, bearing 
an amide chain of 18 carbon atoms, thus longer than the DPPC chain, is 
comparable to that of its analogues with shorter chains, at the imaging fields. 
The differences could be explained by a more efficient packing in the 
micelles of the monoamide compounds. 
 
5.3.3 Conclusions 
 
The gadolinium(III) complexes of DTPA-MA, DTPA-PA, and DTPA-SA 
ligands were incorporated into mixed micelles to obtain supramolecular 
structures with decreased mobility. The relaxivities of solutions containing 
these micelles are significantly higher than of solutions of Gd-DTPA as a 
result of the reduced mobility of the gadolinium complexes. At imaging 
fields (20 – 60 MHz) all micellar solutions show similar relaxivities, in 
contrast to compounds Gd-DTPA-BPO and Gd-DTPA-BC18, which 
displayed lower relaxivities than their analogues with a shorter chain length. 
This observation suggests that the packing of the monoamide compound Gd-
DTPA-SA is as efficient as that of the analogues with shorter chain length, 
despite its longer chain length than DPPC, in which it is inserted. Comparing 
the relaxivity data of the monoamide compounds with data obtained in the 
previous sections (5.1.2.4 and 5.2.2.5) one can conclude that the relative 
relaxivity gain, as compared with Gd-DTPA is highest for mixed micelles in 
which monoamide complexes are inserted, followed by micelles in which 
bisamide compounds Gd-DTPA-BC1X (X = 4, 6 and 8) are inserted, 
whereas liposomes in which compounds Gd-DTPA-BPX (X = T, H and O) 
are inserted, display the smallest relaxivity gain. 
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5.4 Experimental section 
 
5.4.1 Chemicals  
 
Reagents were obtained from Aldrich Chemical Co. Inc., Acros Organics, 
and Fluka, and used without further purification. DTPA was obtained from 
Koch Light Laboratories. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) was obtained from Genzyme Pharmaceuticals (Switzerland). 
Gadolinium chloride hexahydrate was obtained from GFS chemicals (USA).  
 
5.4.2 Instruments 
 
Elemental analysis was performed on a CE Instruments EA-1110 elemental 
analyser. 1H NMR spectra were run on a Bruker Avance 300, operating at 
300 MHz. IR spectra were measured on a FT IR-spectrometer Bruker IFS66, 
using KBr discs. Mass spectra were run on a Q-tof 2 (Micromass, 
Manchester UK). Samples for the mass spectra were prepared as follows: 2 
mg of the complex was dissolved in 1 ml of methanol. 200 µl of this solution 
was added to 800 µl of a mixture of a 50/50 water-methanol solution. The 
resulting solution was injected with a flow rate of 5 µl/min. Melting points 
were determined by DSC (Mettler-Toledo DSC 821). 
 
5.4.3 Synthesis of the ligands  
 
5.4.3.1 Amphiphilic bis(alkylamide) derivatives of [(Gd-DTPA)(H2O)]2- 
 
DTPA bisanhydride was prepared according to a published procedure.[49] 
DTPA-BC14, DTPA-BC16, and DTPA-BC18 were prepared using the 
method of Jasanda and Nepveu.[50] 
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5.4.3.2 Amphiphilic bisamide derivatives with small side chain groups 
 
Esters of amino acids were synthesized using the procedure of Penney et al. 
[78]; DTPA bisamides with esters of amino acids were prepared using the 
procedure of Zhao et al.[79] 
 
5.4.3.3 Gadolinium DTPA-monoamide complexes 
 
N,N-Bis[2-[bis[2-(1,1-dimethyldethoxy)-2-oxoethyl]amino]ethyl] glycine 
(1): 
This compound was prepared according to a published procedure, see also 
scheme 5-3.[80] 
 
DTPA-monoamides: 
The synthetic procedure is outlined in scheme 5-4. The n-alkylamine (1.27 
mg, 4.72 mmol) was added to 80 mL of a DMF solution of N,N-bis(2[2-(1,1-
dimethylethoxy)-2-oxoethyl]amino]ethyl)-glycine (product 1 in scheme 5-3) 
(2.92 mg, 4.72 mmol). Upon the dropwise addition of 0.8 mL of DEPC 
(diethyl cyanophosphonate) [(EtO)2P(O)CN] (860 mL, 5.28 mmol), the 
reaction mixture was kept at 3 °C using an ice bath. Triethylamine (0.816 
mL, 496 mg, 5.92 mmol) was then added slowly to the solution. After 10 
minutes all of the amine had reacted and the solution was warmed up and 
allowed to stand at room temperature for 30 minutes. DMF was then 
removed by vacuum evaporation. The crude product was washed and phase 
separated in ethyl acetate (150 mL) with a saturated hydrogen carbonate (2 × 
100 mL) and saturated sodium chloride solution (2 × 80 mL) to obtain 
product 2. Product 2 (838 mg, 1.05 mmol) was dissolved in 6 N HCl (8 mL). 
The mixture was stirred at room temperature for 1 hour and was then washed 
with CH2Cl2 (2 x 10 mL). The aqueous solution was dried to obtain DTPA-
stearylamide, product 3. 
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5.4.4 Analytical data for the ligands 
 
5.4.4.1 Amphiphilic bis(alkylamide) derivatives of [(Gd-DTPA)(H2O)]2- 
 
DTPA bisanhydride: Yield: 94%; 1H NMR (δ, DMSO-d6): 3.7 (s, 8 H, 4 × 
CH2); 3.3 (s, 2 H, 1 × CH2); 2.75 (t, 4 H, 2 × CH2); 2.6 (t, 4 H, 2 × CH2). IR: 
ν (cm-1): 2974,2917,2852 (CH alkyl); 1827, 1771 (CO anhydride); 1643 
(COO-). Elem. Anal. Calcd. (found): C14H19N3O8: C, 47.06 (47.16); H, 5.36 
(5.33); N, 11.76 (11.56)%.  
 
DTPA-BC14: Yield: 36.1%; 1H NMR (δ, CF3COOD, ref. CF3COOD at δ = 
11.62 ppm): 0.88 (t, 6 H, 2 × CH3); 1.31 (m, 44 H, 22 × CH2); 1.61 (m, 4 H, 
2 × CH2); 3.39 (t, 4 H, 2 × CH2); 3.80 (m, 4 H, 2 × CH2); 4.08 (m, 4 H, 2 × 
CH2); 4.14 (s, 2 H, CH2); 4.52 (s, 4 H, 2 × CH2); 4.54 (s, 4 H, 2 × CH2). IR: ν 
(cm-1): 3350 (N-H amide); 2960, 2920, 2850 (C-H alkyl); 1655 (CO, amide 
I); 1625 (COOH); 1550 (amide II). Elem. Anal. Calcd. for C42H81N5O8 
(found) C, 64.33 (64.42); H, 10.41 (10.39); N, 8.93 ( 8.99)%. 
 
DTPA-BC16: Yield: 60%; 1H NMR: (δ, CF3COOD, ref. CF3COOD at δ = 
11.62 ppm):  0.91 (t, 6 H, 2 × CH3); 1.34 (m, 52 H, 26 × CH2); 1.64 (m, 4 H, 
2 × CH2); 3.42 (t, 4 H, 2 × CH2); 3.88 (m, 4 H, 2 × CH2); 4.12 (m, 4 H, 2 × 
CH2); 4.18 (s, 2 H, CH2); 4.56 (s, 4 H, 2 × CH2); 4.58 (s, 4 H, 2 × CH2). IR: ν 
(cm-1): 3356 (N-H amide); 2960, 2918, 2849 (C-H alkyl); 1666 (CO, amide 
I); 1624 (COOH); 1541 (amide II). Elem. Anal. Calcd. for C46H89N5O8 
(found) C, 65.76 (65.80); H, 10.68 (10.64); N, 8.34 (8.35)%. 
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DTPA-BC18: Yield: 69%; 1H NMR: (δ, CF3COOD, ref. CF3COOD at δ = 
11.62 ppm): 0.90 (t, 6 H, 2 × CH3); 1.34 (m, 60 H, 30 × CH2); 1.63 (m, 4 H, 
2 × CH2); 3.41 (t, 4 H, 2 × CH2); 3.82 (m, 4 H, 2 × CH2); 4.11 (m, 4 H, 2 × 
CH2); 4.18 (s, 2H, CH2); 4.56 (s, 4 H, 2 × CH2); 4.58 (s, 4 H, 2 × CH2). IR: ν 
(cm-1): 3350 (N-H amide); 2960, 2920, 2850 (C-H alkyl); 1655 (CO, amide 
I); 1625 (COOH); 1550 (amide II). Elem. Anal. Calcd. for C50H97N5O8 
(found) C, 66.99 (66.82); H, 10.90 (10.85); N, 7.81 ( 7.77)%. 
 
5.4.4.2 Amphiphilic bisamide derivatives with small side chain groups 
 
Stearyl Tyrosine Hydrochloride: Yield: 39%; 1H-NMR (δ, DMSO-d6): 
0.84 (t, 3 H, 1 × CH3), 1.21 (m, 32 H, 16 × CH2), 3.31 (m, 2 H, 1 × CH2), 
4.03 (m, 3 H, 1 × CH2 and 1 × CH), 6.69 and 6.98 (2d, 4 H, Ph), 8.23 (m, 3 
H, NH3+). IR: ν (cm-1): 2961, 2918, 2849 (CH alkyl); 1738 (CO ester); 1612 
(NH3+). Elem. Anal. Calcd. (found): C27H49NO3Cl: C, 69.98 (69.12) H, 10.3 
(9.82), N, 2.97 (2.89)%. 
 
Palmityl Tyrosine Hydrochloride: Yield: 44.8%; 1H-NMR (δ, DMSO-d6): 
0.78 (t, 3 H, 1 × CH3), 1.14 (m, 28 H, 14 × CH2), 3.25 (m, 2 H, 1 × CH2), 
3.95 (m, 3 H, 1 × CH2 and 1 × CH), 6.60 and 6.92 (2d, 4 H, Ph), 8.40 (m, 3 
H, NH3+). IR: ν (cm-1): 2956, 2913, 2852 (CH alkyl); 1737 (CO ester); 1616 
(NH3+). Elem. Anal. Calcd. (found): C25H45NO3Cl: C, 67.92 (67.91); H, 10.0 
(10.37); N, 3.17 (3.23)%. 
 
Myristyl Tyrosine Hydrochloride: Yield: 75%; 1H-NMR (δ, DMSO-d6): 
0.88 (t, 3 H, 1 × CH3), 1.27 (m, 24 H, 12 × CH2), 3.35 (m, 2 H, 1 × CH2), 
4.65 (m, 3 H, 1 × CH2 and 1 × CH), 6.76 and 7.03 (2d, 4 H, Ph), 8.54 (m, 3 
H, NH3+). IR: ν (cm-1): 2963, 2925, 2849 (CH alkyl); 1736 (CO ester); 1611 
(NH3+). 
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Stearyl phenylalanine hydrochloride: Yield: 51%; 1H-NMR (δ, DMSO-
d6): 0.83 (t, 3 H, 1 × CH3), 1.22 (m, 32 H, 16 × CH2), 1.38 (m, 2 H, 1 × CH2); 
3.01 (m, 2 H, 1 × CH2), 4.00 (t, 2 H, 1 × CH2), 4.23 (t, 1 H, CH), 7.27 (m, 5 
H, Ph) 8.54 (m, 3 H, NH3+). IR: ν (cm-1): 2956, 2912, 2848 (CH alkyl); 1741 
(CO ester), 1611 (NH3+). 
 
Palmityl phenylalanine hydrochloride: Yield: 18%; 1H-NMR (δ, DMSO-
d6): 0.78 (t, 3 H, 1 × CH3), 1.12 (m, 28 H, 14 × CH2), 1.34 (m, 2 H, 1 × CH2), 
3.06 (m, 2 H, 1 × CH2), 3.91 (t, 2 H, 1 × CH2), 4.16 (t, 1 H, CH), 7.16 (m, 5 
H, Ph), 8.3 (m, 3 H, NH3+). IR: ν (cm-1): 2957, 2923, 2847 (CH alkyl); 1742 
(CO ester); 1612 (NH3+). 
 
Myristyl phenylalanine hydrochloride: Yield: 64%; 1H-NMR (δ, DMSO-
d6): 0.84 (t, 3H, 1 × CH3), 1.22 (m, 24 H, 12 × CH2), 1.43 (m, 2 H, 1 × CH2), 
3.05 (m, 2 H, 1 × CH2), 4.01 (t, 2 H, 1 × CH2), 4.24 (t, 1 H, 1 × CH), 7.27 
(m, 5 H, Ph), 8.58 (m, 3 H, NH3+). IR: ν (cm-1): 2953, 2908, 2852 (CH 
alkyl); 1737 (CO ester); 1607 (NH3+). 
 
Di(acetyl-L-tyrosineoctadecylester)-N,N´´,N´´´triacetic acid (DTPA-
BTO): Yield: 53%; 1H-NMR (δ, DMSO-d6): 0.88 (t, 6 H, 2 × CH3), 1.27 (m, 
60 H, 30 × CH2), 1.64 (m, 2 H, CH2), 2.90 (m, 4 H, 2 × CH2), 3.35 (m, 8 H, 4 
× CH2), 4.10 (m, 12 H, CHNHC=O + N-CH2C=O), 4.50 (m, 4 H, 2 × CH2), 
7.02 and 6.79 (2d, 8 H, 2 × Ph), 7.52 (m, 2 H, 2 × NH). IR: ν (cm-1): 3062 
(N-H amide stretch II); 3030 (phenyl, C-H stretch); 2932, 2842 (C-H alkyl 
stretch); 1740 (CO acid, ester); 1636 (bending, amide I); 1599 and 1500 
(phenyl). 
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Di(acetyl-L-tyrosinehexadecylester)-N’,N’’,N’’’triacetic acid (DTPA-
BTH): Yield: 34.5%; 1H-NMR (δ, DMSO-d6): 0.88 (t, 6 H, 2 × CH3), 1.31 
(m, 44 H, 22 × CH2), 1.70 (m, 2 H, 1 × CH2), 3.03 (m, 4 H, 2 × CH2), 3.41 
(m, 8 H, 4 × CH2), 3.93 (m, 12 H, CHNHC=O+N-CH2C=O), 4.49 (m, 4 H, 2 
× CH2), 7.21 and 6.90 (2d, 8 H, 2 × Ph). IR: ν (cm-1): 3375 (N-H stretch); 
3040 phenyl (C-H stretch); 2922, 2849 (C-H alkyl stretch); 1740 (CO acid, 
ester); 1651 (bending, amide I); 1599 and 1516 (Ph, C6H5). 
 
Di(acetyl-L-tyrosinetetradecylester)-N,N´´,N´´´triacetic acid (DTPA-
BTT): Yield: 35%; 1H-NMR (δ, CD3OD/CDCl3): 0.88 (t, 6 H, 2 × CH3), 
1.27 (m, 44 H, 22 × CH2), 1.63 (m, 4 H, 2 × CH2), 2.94 (m, 4 H, 2 × CH2), 
3.11 (m, 8 H, 4 × CH2), 4.10 (m, 12 H, CHNHC=O+N-CH2C=O), 4.49 (m, 4 
H, 2 × CH2), 7.21 and 6.90 (2d, 8 H, 2 × Ph). IR: ν (cm-1): 3375 (N-H 
stretch); 3040 phenyl (C-H stretch); 2922, 2849 (C-H alkyl stretch); 1740 
(CO acid, ester); 1651 (bending, amide I); 1599 and 1516 (phenyl). 
 
Diethylenetriamine-N,N´´´-di(acetyl-L-phenylalanineoctacecylester)-
N,N´´,N´´´triacetic acid (DTPA-BPO): Yield: 22%; 1H-NMR (δ, DMSO-
d6): 0.89 (t, 6 H, 2 × CH3), 1.27 (s, 60 H, 30 × CH2), 1.59 (m, 4 H, 2 × CH2), 
2.98 (m, 4 H, 2 × CH2), 3.09 (m, 4 H, 2 × CH2), 3.34 (m, 12 H, 
CHNHC=O+N-CH2C=O), 4.08 (m, 4 H, 2 × CH2), 7.27 (m, 10 H, 2 × Ph). 
IR: ν (cm-1): 3390 (N-H stretch); 3088 (N-H amide stretch II); 3031 (C-H 
stretch, phenyl); 2926, 2854 (C-H alkyl stretch); 1740 (CO acid, ester); 1688 
(bending, amide I). 
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Diethylenetriamine-N,N´´´-di(acetyl-L-phenylalaninehexadecylester)-
N,N´´,N´´´triacetic acid (DTPA-BPH): Yield: 15%; 1H-NMR (δ, 
CD3OD/CDCl3): 0.89 (t, 6 H, 2 × CH3), 1.27 (m, 52 H, 26 × CH2), 1.59 (m, 4 
H, 2 × CH2), 2.98 (m, 4 H, 2 × CH2), 3.18 (m, 8 H, 4 × CH2), 4.08 (m, 12 H, 
CHNHC=O+N-CH2C=O), 4.59 (m, 4 H, 2 × CH2), 7.27 (m, 10 H, 2 × Ph). 
IR: ν (cm-1): 3390 (N-H stretch); 3088 (N-H amide stretch II); 3031 (phenyl, 
C-H stretch); 2926, 2854 (C-H alkyl stretch); 1740 (CO acid, ester); 1688 
(bending, amide I). 
 
Diethylenetriamine-N,N´´´-di(acetyl-L-phenylalaninetetradecylester)-
N,N´´,N´´´triacetic acid (DTPA-BPT): Yield: 23.2%; 1H-NMR (δ, 
CD3OD/CDCl3): 0.88 (t, 6 H, 2 × CH3), 1.27 (s, 44 H, 22 × CH2), 1.60 (m, 4 
H, 2 × CH2), 2.98 (m, 4 H, 2 × CH2), 3.20 (m, 8 H, 4 × CH2), 4.09 (m, 12 H, 
CHNHC=O+N-CH2C=O), 4.74 (m, 4 H, 2 × CH2), 7.28 (m, 10 H, 2 × Ph). 
IR: ν (cm-1): 3073 (N-H amide stretch II); 3031 (phenyl, C-H stretch) 2922, 
2849 (C-H alkyl stretch); 1735 (CO acid, ester); 1688 (bending, amide I). 
 
5.4.4.3 Gadolinium DTPA-monoamide complexes 
 
N,N-Bis[2-[bis[2-(1,1-dimethyldethoxy)-2-oxoethyl]amino]ethyl] glycine: 
Yield: 45%; 1H-NMR (δ, DMSO-d6): δ 1.45 (s, 36 H, 12 × CH3), 2.98 (t, 4 
H, 2 × CH2), 3.10 (br, 4 H, 2 × CH2), 3.36 (s, 8 H, 4 × CH2), 3.58 (s, 2 H, 1 × 
CH2). IR: υ (cm-1): 2977, 2935 (C-H alkyl stretch); 1733 (CO, ester); 1646 
(COOH). Mass spectrometry: [M+H]+: 618. 
 
DTPA-SA: Yield: 22%; 1H-NMR (δ, MeOD/CDCl3): δ 0.89 (t, 3H, CH3), 
1.27 (s, 30H, 15 × CH2), 1.55 (m, 2H, CH2), 2.89 and 3.02 (m, 8H, 4 × CH2), 
3.45 (m, 4H, 2 × CH2), 3.92 (s, 8H, 4 × CH2). IR: υ (cm-1): 3432 (N-H 
stretch), 2921, 2843 (C-H alkyl stretch); 1745 (CO acid); 1671 (CO, amide 
I). Mass spectrometry: [M+Na]+: 667; [M+H]+: 645. 
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DTPA-PA: Yield: 12%; 1H-NMR (δ, MeOD, CDCl3): δ 0.83 (t, 3H, CH3), 
1.27 (s, 26H, 13 × CH2), 1.39 (m, 2H, CH2), 2.70 and 3.05 (m, 8H, 4 × CH2), 
4.12 (s, 8H, 4 × CH2). IR: υ (cm-1): 3424 (N-H stretch), 2932, 2851 (C-H 
alkyl stretch); 1745 (CO acid); 1674 (CO, amide I). Mass spectrometry: 
[M+H]+: 617. 
 
DTPA-MA: Yield: 14%; 1H-NMR (δ, MeOD, CDCl3): δ 0.89 (t, 3H, CH3), 
1.27 (s, 22H, 11 × CH2), 1.55 (m, 2H, CH2), 2.89 and 3.02 (m, 8H, 4 × CH2), 
3.45 (m, 4H, 2 × CH2), 3.92 (s, 8H, 4 × CH2). IR: υ (cm-1): 3422 (N-H 
stretch), 2941, 2851 (C-H alkyl stretch); 1745 (CO acid); 1674 (CO, amide 
I). Mass spectrometry: [M+H]+: 589. 
 
5.4.5 Synthesis of the Ln(III) complexes 
 
All complexes were synthesized according to a general procedure as follows: 
a solution of hydrated LnCl3 salt (1.1 mmol) in H2O (1 ml) was added to the 
ligand (1 mmol) dissolved in pyridine (30 ml), and the mixture was heated at 
70°C for 3 hours. The solvents were evaporated under reduced pressure and 
the crude product was then refluxed in ethanol for 1 hour. After cooling to 
room temperature the complex was filtered off and dried in vacuum. The 
absence of free gadolinium was checked with xylenol orange indicator.[51] 
 
5.4.6 Analytical data for the Ln(III) complexes 
 
5.4.6.1 Amphiphilic bis(alkylamide) derivatives of [(Gd-DTPA)(H2O)]2- 
 
Gd-DTPA-BC14: IR: ν (cm-1): 3093 (N-H amide); 2919, 2850 (C-H alkyl); 
1667 (CO, amide I); 1617 (COO- assym. stretch); 1394 (COO- sym. stretch). 
Elem. Anal. Calcd.: GdC42H78N5O8 (found): C, 53.76 (53.49); H, 8.37 (8.64); 
N, 7.32 (7.28) %.ES-MS+: 939 [M+H]+; 961 [M+Na]+; 1430 [3M+2Na]2+.  
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Eu-DTPA-BC14: IR ν (cm-1): 3093 (N-H amide); 2923, 2854 (C-H alkyl); 
1631 (CO, amide I); 1600 (COO- assym. stretch); 1394 (COO- sym. stretch). 
Elem. Anal. Calcd.: EuC42H80N5O9 (found): C, 52.89 (53.04) H, 8.48 (8.38) 
N, 7.36 (7.25) %. ES-MS+: 956.5 [M + Na]+; 1422 [3M + 2Na]2+; 1890 [2M 
+ Na]+. 
 
Pr-DTPA-BC14: IR ν (cm-1): 3088 (N-H amide); 2920, 2850 (C-H alkyl); 
1640 (CO, amide I); 1600 (COO- assym. stretch); 1386 (COO- sym. stretch). 
Elem. Anal. Calcd.: PrC42H78N5O8 (found): C, 54.71 (55.00) H, 8.53 (8.63) 
N, 760 (7.56) %. ES-MS+: 945 [M+Na]+; 1405 [3M+2Na]2+; 1867 
[2M+Na]+.  
 
La-DTPA-BC14: IR: ν (cm-1): 3089 (N-H amide); 2926, 2850 (C-H alkyl); 
1641 (CO, amide I); 1600 (COO- assym. stretch); 1386 (COO- sym. stretch). 
Elem. Anal. Calcd.: LaC42H78N5O8 (found) C, 54.83 (54.37) H, 8.54 (8.39), 
N 7.61 (7.44) %. ES-MS+: 943 [M+Na]+; 1403 [3M+2Na]2+; 1862 
[2M+Na]+. 
 
Gd-DTPA-BC16: IR: ν (cm-1): 3093 (N-H amide); 2960, 2918, 2849 (C-H 
alkyl); 1666 (CO, amide I); 1624 (COO- assym. stretch); 1395 (COO- sym. 
stretch). Elem. Anal. Calcd.: GdC46H86N5O8 (found): C, 55.56 (56.39); H, 
8.72 (8.74); N, 7.04 (7.02) %. ES-MS+: 1017 [M+Na]+; 1514 [3M + 2Na]2+.  
 
Eu-DTPA-BC16: IR: ν (cm-1): 3090 (N-H amide,); 2919, 2850 (C-H alkyl); 
1635 (CO, amide I); 1601 (COO- assym. stretch); 1391 (COO- sym. stretch). 
Elem. Anal. Calcd.: EuC46H88N5O9 (found): C, 54.86 (54.53) H, 8.81 (8.73) 
N, 6.95 (6.80) %. ES-MS+: 1035 [M+Na]+; 1540 [3M+2Na]2+; 2047 
[2M+Na]+. 
 
Pr-DTPA-BC16: IR: ν (cm-1): 3094 (N-H amide); 2921, 2844 (C-H alkyl); 
1635 (CO, amide I); 1596 (COO- assym. stretch); 1395 (COO- sym. stretch). 
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Elem. Anal. Calcd.: PrC46H86N5O8 (found): C, 56.49 (56.61) H, 8.86 (8.74) 
N, 7.16 (7.09) %.ES-MS+: 1001 [M+Na]+; 1490 [3M+2Na]2+; 1977 
[2M+Na]+. 
 
La-DTPA-BC16: IR: ν (cm-1): 3085 (N-H amide); 2920, 2850 (C-H alkyl); 
1667 (CO, amide I); 1624 (COO- assym. stretch); 1385 (COO- sym. stretch). 
Elem. Anal. Calcd.: LaC46H88N5O9 (found): C, 55.58 (55.50) H, 8.92 (8.73) 
N, 7.04 (6.90) %. ES-MS+: 999 [M+Na]+; 1486 [3M+2Na]2+; 1975 
[2M+Na]+. 
 
Gd-DTPA-BC18: IR: ν (cm-1): 3094 (N-H amide); 2960, 2920, 2850 (C-H 
alkyl); 1633 (CO, amide I); 1596 (COO- assym. stretch); 1390 (COO- sym. 
stretch). Elem. Anal. Calcd.: GdC50H96N5O9 (found): C, 56.14 (56.09); H, 
9.05 (9.55); N, 6.55 (6.38) %. ES-MS+: 1073 [M+Na]+; 1599 [3M + 2Na]2+. 
 
Eu-DTPA-BC18: IR: ν (cm-1): 3105 (N-H amide); 2916, 2851 (C-H alkyl); 
1634 (CO, amide I); 1595 (COO- assym. stretch); 1386 (COO- sym. stretch). 
Elem. Anal. Calcd.: EuC50H100N5O11 (found): C, 54.62 (54.58); H, 9.16 
(9.87); N, 6.37 (6.23) %. ES-MS+: 1068 [M+Na]+. 
 
Pr-DTPA-BC18: IR: ν (cm-1): 3089 (N-H amide); 2915, 2844 (C-H alkyl); 
1635 (CO, amide I); 1597 (COO- assym. stretch); 1386 (COO- sym. stretch). 
Elem. Anal. Calcd.: PrC50H96N5O9 (found): C, 57.07 (57.46); H, 9.20 (9.19); 
N, 6.66 (6.57) %.ES-MS+: 1057 [M+Na]+. 
 
La-DTPA-BC18: IR: ν (cm-1): 3083 (N-H amide); 2925, 2850 (C-H alkyl); 
1640 (CO, amide I); 1596 (COO- assym. stretch); 1385 (COO- sym. stretch). 
Elem. Anal. Calcd.: LaC50H98N5O10 (found): C, 56.22 (56.19); H, 9.24 
(8.82); N, 6.56 (6.39) %. ES-MS+: 1055 [M+Na]+. 
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5.4.6.2 Amphiphilic bisamide derivatives with small side chain groups 
 
Gd-DTPA-BTO – [GdT18]: Yield: 75%; IR: ν (cm-1): 2922, 2854 (C-H 
alkyl stretch); 1741 (COO ester); 1621 (bending, amide I); 1599 and 1516 
(phenyl). Elem. Anal Calcd. (found): GdC68H110N5O14(H2O): C: 59.0 
(58.72); H, 8.30 (8.56); N, 5.06 (4.53)%. ES-MS+: 1379: [M+H]+; 1401 
[M+Na]+. 
 
Gd-DTPA-BTH – [GdT16]: Yield: 59%; IR: ν (cm-1): 2922, 2854 (C-H 
alkyl stretch); 1741 (COO ester); 1621 (bending, amide I); 1599 and 1517 
(Ph, C6H5). Elem. Anal Calcd. (found): GdC64H102N5O14(H2O)4: C, 55.1 
(54.85); H, 7.94 (7.72); N, 5.02 (5.15)%. ES-MS+: 1307: [M+H]+; 1329 
[M+Na]+. 
 
Gd-DTPA-BTT – [GdT14]: Yield: 84%; IR: ν (cm-1): 2922, 2854 (C-H 
alkyl stretch); 1741 (COO ester); 1621 (bending, amide I); 1599 and 1517 
(phenyl). Elem. Anal. Calcd.: GdC60H94N5O14(H2O)3: C, 54.51 (55.03); H, 
7.63 (7.66); N, 5.30 (4.98)%. ES-MS+: 1267 [M+H]+; 1289 [M+Na]+; 1900 
[3x(M+H)-H]2+. 
 
La-DTPA-BTT – [LaT14]: IR: ν (cm-1): 2957, 2922, 2850 (C-H alkyl 
stretch); 1736 (COO ester); 1613 (bending, amide I); 1591 and 1515 
(phenyl). ES-MS-: 1245 [M]-; 1282 [M+2H2O]-. 
 
Pr-DTPA-BTT – [PrT14]: IR: ν (cm-1): 2917, 2849 (C-H alkyl stretch); 
1741 (COO ester); 1617 (bending, amide I); 1583 and 1519 (phenyl). ES-
MS+: 1248 [M]-; 1284 [M+2H2O]-. 
 
Gd-DTPA-BPO – [GdP18]: Yield: 88%; IR: ν (cm-1): 2932, 2842 (C-H 
alkyl stretch); 1745 (COO ester); 1620 (bending, amide I); 1599 and 1500 
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(phenyl). Elem. Anal. Calcd. (found): GdC68H110N5O14(H2O)5: C: 55.6 
(55.11); H, 8.23 (7.97); N, 4.76 (5.12)%. ES-MS+: 1347 [M+H]+. 
 
Gd-DTPA-BPH – [GdP16]: Yield: 87%; IR: ν (cm-1): 3068 (N-H stretch 
II); 2932, 2842 (C-H, alkyl stretch); 1740 (COO ester); 1630 (bending, 
amide I); 1599 (phenyl). Elem. Anal. Calcd. (found): 
GdC64H102N5O12(H2O)5: C, 55.67 (55.66); H, 8.17 (7.9); N, 5.07 (4.94)%. 
ES-MS+: 1291 [M+H]+; 1313 [M+Na]+. 
 
Gd-DTPA-BPT – [GdP14]: Yield: 32%; IR: ν (cm-1): 2916, 2850 (C-H 
alkyl stretch); 1738 (COO ester); 1627 (bending, amide I); 1601 and 1490 
(phenyl). Elem. Anal. Calcd. (found): GdC60H94N5O12(H2O)7: C, 52.96 
(52.73); H, 7.99 (8.50); N, 5.15 (5.71)%. ES-MS+: 1235 [M+H]+; 1267 
[M+Na]+; 1852 [3 x (M+H) – H]+. 
 
5.4.6.3 Gadolinium DTPA-monoamide complexes 
 
Gd-DTPA-SA: Yield: 67%; IR: υ (cm-1): 3401 (N-H stretch), 3094 N-H 
amide; 2926, 2848 (C-H alkyl stretch); 1630 (CO, amide I / COO- assym 
stretch). ES-MS+: 800 [M+H]+. 
 
La-DTPA-SA: IR: υ (cm-1): 3401 (N-H stretch), 2916, 2846 (C-H alkyl 
stretch); 1621 (CO, amide I) 1567 (COO- assym stretch). ES-MS-: 799 
[M+H2O]-. 
 
Gd-DTPA-PA: Yield: 61%; IR: υ (cm-1): 3410 (N-H stretch), 3094 N-H 
amide; 2922, 2849 (C-H alkyl stretch); 1630 (CO, amide I / COO- assym 
stretch). ES-MS+: 771 [M]+. 
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Gd-DTPA-MA: Yield: 85.2%; IR: υ (cm-1): 3410 (N-H stretch), 3090 N-H 
amide; 2931, 2856 (C-H alkyl stretch); 1632 (CO, amide I / COO- assym 
stretch). ES-MS+: 743 [M]+. 
 
5.4.7 Sodium and potassium ion content measurements 
Before the compounds were used for incorporation into micelles, the 
potassium and sodium ion content was checked by flame photometry (IL 
943, Instrumentation Laboratories, Massachusetts, USA). The Na+ and K+ 
ion content was measured on a sample that was obtained by extracting with 
500 µL of water the solution of complex (1.7 mg) which was dissolved in 1:1 
chloroform/methanol mixture.  
 
5.4.7.1 Amphiphilic bis(alkylamide) derivatives of [(Gd-DTPA)(H2O)]2- 
Na+ content (mmol:mol of the complex): (Gd-DTPA-BC14) 0.10; (Gd-
DTPA-BC16) 0.15; (Gd-DTPA-BC18) 0.15. K+ content: no K+ was found in 
any of the complexes. 
 
5.4.7.2 Amphiphilic bisamide derivatives with small side chain groups 
Na+ content (mmol:mol of the complex): Gd(DTPA-BTO) 0, Gd(DTPA-
BTT) 0.09, Gd(DTPA-BPO) 0, Gd(DTPA-BPT) 3.3. K+ content: no K+ was 
found in any of the complexes. 
 
5.4.7.3 Gadolinium DTPA-monoamide complexes 
Na+ content (mmol:mol of the complex): Gd-DTPA-SA: 0.4; Gd-DTPA-PA: 
0.1; Gd-DTPA-MA: 0.4 
K+ content: no K+ was found in any of the complexes. 
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5.4.8 Preparation of micelles  
1,2-Dipalmitoyl sn-glycero-3 phosphatidyl choline (DPPC) (225 mg) and the 
complex (25 mg) were dissolved in a 1:1 solution of chloroform: methanol 
(50 ml). Evaporation under reduced pressure yielded a thin film, which was 
then rehydrated with hot water (5 ml, 70 °C). This solution was sonicated for 
15 min using a 70-Watt sonicator while keeping the temperature at 65 °C 
with a thermostatic bath. After the sonication 75 mg of a non-ionic surfactant 
was added (Tween 80 - polyoxyethylene sorbitan monooleate), followed by 
another 15 minutes of sonication. 
 
5.4.9 Preparation of liposomes 
4 mg of the complex and 15 mg of DPPC were mixed to form a 
homogeneous lipid film that was rehydrated with an aqueous solution 
containing 5 % glucose. The mixture was placed on a vortex and was then 
heated to 55 °C. The obtained liposomes were extruded 10 times through 
filters with a porosity of 400 nm. 
 
5.4.10 Determination of micelle/liposome size  
The mean micelle sizes were determined by photon correlation spectroscopy 
performed on a BIC multiangle laser light scattering system at room 
temperature and with a 90° scattering angle (Brookhaven Instruments 
Corporation, Holtsville, USA). The intensity weighted micellar diameter was 
measured on diluted suspensions and calculated by a non-negatively 
constrained least squares (multiple pass) routine.  
 
5.4.9.1 Amphiphilic bis(alkylamide) derivatives of [(Gd-DTPA)(H2O)]2- 
The diameters obtained are as follows: Gd-DTPA-BC14: 15 nm, with Gd-
DTPA-BC16: 20 nm, with Gd-DTPA-BC18: 19 nm.  
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5.4.9.2 Amphiphilic bisamide derivatives with small side chain groups 
(micelles) 
Gd-DTPA-BTO: 455 nm; Gd-DTPA-BTT 183 nm; Gd-DTPA-BPT: 9 nm 
 
5.4.9.3 Amphiphilic bisamide derivatives with small side chain groups 
(liposomes) 
Gd-DTPA-BPO: 115-127 nm; Gd-DTPA-BPH: 140-144 nm; Gd-DTPA-
BPT: 150-160 nm. 
 
5.4.9.4 Gadolinium DTPA-monoamide complexes 
with Gd-DTPA-MA: 13 nm; with Gd-DTPA-PA: 18-19 nm, with Gd-DTPA-
SA: 11 nm. 
 
5.4.11 T1 measurements  
Proton Nuclear Magnetic Relaxation Dispersion (NMRD) profiles were 
recorded between 0.24 mT and 1.2 T with Field Cycling Relaxometers (Field 
Cycling Systems, Oradell, New Jersey, USA or Stelar Spinmaster FFC-2000, 
Stelar S.R.L., Mede, Italy) on 0.6 ml solutions contained in 10 mm o.d. 
tubes. Proton relaxation rates were also measured at 0.47 T, and 1.5 T on 
Minispec PC-120, and mq-60 (Bruker, Karlsruhe, Germany). All samples 
were diluted 10 times and the temperature was maintained at 37 °C. 1H 
NMRD data were fitted according to the theoretical inner-sphere model 
described by Solomon[42] and Bloembergen[43] and to the outer-sphere 
contribution described by Freed.[44] Calculations were performed with a 
previously described software package.[52-53] 
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Chapter 6 
 
 
A NOVEL EFFICIENT MRI CONTRAST AGENT 
CONTAINING TWO PARAMAGNETIC CENTRA 
 
 
 
Te amé sin que yo lo supiera, y busqué tu memoria 
En las casas vacías entré con linterna a robar tu retrato. 
Pero yo ya sabia cómo eras. De pronto 
 
Mientras ibas conmigo te toqué y se detuvo mi vida: 
Frente a mis ojos estabas, reinándome, y reinas. 
Como hoguera en los bosques el fuego es tu reino. 
 
I loved you without knowing I did, and I searched to remember you 
I broke into houses to steal your likeness 
Though I already knew what you were like. And, suddenly 
 
When you were there with me I touched you, and my life 
Stopped: you stood before me, you took dominion like a queen 
Like a wildfire in the forest, and the flame is your dominion 
 (P. Neruda) 
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6.1 Introduction 
 
The rapid development of magnetic resonance imaging (MRI) has been of 
great importance to medical diagnosis. Although excellent soft-tissue images 
are obtained with this technique, early experiments showed that contrast 
agents might increase its diagnostic value immensely. Consequentely, 
parallel with the development of MRI there has been an explosive growth in 
the interest for contrast agents.[1-3] The first contrast agent approved for use 
in humans, [Gd(DTPA)(H2O)]2- is routinely used in clinical magnetic 
resonance imaging under the name Magnevist®. This first generation contrast 
agent distributes into vascular and interstitial space and is classified as an 
‘unspecific agent’ or ‘extracellular fluid agent’. In later years, efforts were 
directed towards the finding of tissue specific contrast agents and towards the 
increase of efficiency by decreasing rotational correlation time. Various 
routes were explored in order to obtain a higher efficiency by a decrease in 
correlation time, among them are incapsulation[4-8] or incorporation[9-10] in 
liposomes, the synthesis of macromolecular Gd3+ chelates such as 
dendrimers,[11] linear polymers [12-14] or proteins,[2, 15-16] and recently the 
synthesis of amphiphilic gadolinium(III) complexes which can self-assemble 
to micelles[17-18] and the introduction of amphiphilic paramagnetic chelates 
into mixed micelles.[19] Alternatively, some tissue specificity could be 
achieved by introduction of a lipophilic moiety on the DTPA chelating 
ligand which led to the development of liver specific contrast agents e.g. 
[Gd(EOB-DTPA)]2-, [20-21] whereas the use of protein binding small Gd3+ 
based molecular agents or polymeric Gd3+ complexes has resulted in the 
development of blood pool agents, suitable for MRA (magnetic resonance 
angiography).[22-25] Recently, necrosis avid contrast agents (NACAs) based 
on Gd3+ metalloporphyrins such as Gadophrin-2 (bis-Gd-mesoporphyrin, 
figure 6-1), have been discovered. [26-28] Although these agents elicit novel 
applications for MRI visualization of acute myocardial infarction and 
therapeutic necrosis,[29-35] the clinical use may be prevented due to 
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phototoxicity, discoloration and other side effects. So far, the necrosis 
affinity with NACAs has been proposed mainly on observational and 
hypothetical bases. [30, 36] In one paper, the accumulation of gadophrin-2 in 
tumoral necrosis was related to an albumin-binding mechanism.[37] If this 
notion holds true, a similar retention in necrotic tissue should be expected for 
any agent with a strong albumin binding capacity.  
 
In this study we describe the synthesis of a novel, highly efficient contrast 
agent, suitable for MRI, with a high HSA affinity. The introduction of two 
metal binding centres in the same ligand proved to be an efficient way to 
improve relaxation capability. The efficiency of the agent was characterized 
by NMRD and evaluated in vivo for necrosis avidity.  
 
The synthesis of the ligand was done in cooperation with the group of prof. 
Alfons Verbruggen at the department of pharmacy, the physicochemical and 
pharmacokinetic evaluation was performed by Dr. Carmen Burtea and prof. 
Luce Vander Elst working in the group of prof. Robert N. Muller at the 
department of organic chemistry at Mons, the in vivo evaluation was done by 
prof. Yicheng Ni working in the group of prof. Guy Marchal at the university 
hospital of K.U.Leuven. 
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Figure 6-1: Structure of gadophrin-2: DTPA derivatized mesoporphyrin. 
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6.2 Results and discussion 
6.2.1 The ligand and complexes 
The ligand was synthesized in high yield according to scheme 6-1; this 
ligand is a structural analogue of the ligand of ECIV-7, a complex that 
displays necrosis avidity[46-47] (figure 6-2). 
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Scheme 6-1: Synthesis of the ligand KA080402. 
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Figure 6-2: structure of the ligand of ECIV-7. 
 
Two DTPA moieties were attached to a bisindole derivative of benzaldehyde 
bearing three methoxy groups. Hydrazine was used as a ‘bridge’ molecule, 
forming two amide bonds, first by reacting with the ethylcarboxylate of the 
ethyl indole-2 carboxylate group. For the second amide bond, the coupling 
with DTPA, a coupling agent (TBTU, o-benzotriazol-1-yl-N,N,N’,N’-
tetramethyluronium tetrafluoroborate, also used in peptide chemistry [38-39]) 
was used.  
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The proton NMR spectrum of the ligand and its labelled structure are shown 
in figure 6-3. 
 
 
(A) 
 
OCH3
OCH3CH3O
N
H
N
H
HN NH
O O
NH HN
O
NNN
HOOC
COOH
COOHHOOC
N N N
COOH
COOH
HOOC COOH
O
(a)
(b)
(c)
(e)
(f)
(g)
(h)
(d)
(j)
(k) (l)
(m)
(n) (o) (p)
(q)
(i)
 
(B) 
Figure 6-3: 1H NMR spectrum of the ligand in D2O solution at pH 6.0 (A) 
and the labelled structure of the ligand (B). 
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Two-dimensional correlation spectroscopy (2D COSY) shown in figure 6-4 
was used as a tool for assigning the proton resonances. While the coupling 
between the following aromatic pairs of protons e-f, f-g, and g-h was clearly 
observed, the cross peaks between k-l and n-o pairs of resonances were more 
difficult to observe due to the broadening of these resonances. 
ppm
6.26.46.66.87.07.27.47.67.88.08.28.4 ppm
6.2
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Figure 6-4: 2D COSY NMR spectrum of the aromatic region of the ligand in 
D2O solution at pH 6.0. 
 
Under slightly alkaline solutions, the ligand readily formed complexes with 
lanthanide(III) ions (Ln = Gd, La, Eu, Pr), as shown in figure 6-5.  
 
IR spectral data of the ligand showed strong absorptions in the region 1690-
1625 cm-1, corresponding to CO stretching modes.[40] A shift of ca 50 cm-1 to 
lower energy was observed for the carbonyl stretching frequencies upon 
complexation, indicating amide oxygen coordination to the lanthanide ion. 
127 
- A novel contrast agent containing two paramagnetic centra - 
 
OCH3
OCH3CH3O
N
H
N
H
HN NH
O O
NH HN
O
NNN
-OOC
COO--OOC
N N N
COO-
-OOC COO-
O-OOC COO-
Ln3+ Ln3+
Figure 6-5: Schematic representation of the lanthanide complex of the 
KA080402 ligand. 
6.2.2 Solution dynamics of the lanthanum(III) complex 
As shown in figure 6-6, complexation of the KA080402 ligand to 
lanthanum(III) causes remarkable changes in the proton NMR spectra in 
terms of shifts and broadening of the resonances. While the proton 
resonances of the ligand are relatively sharp and well separated (spectrum a), 
the resonances of the lanthanum(III) complex at room temperature (spectrum 
b) are very broad and multiple peaks could be observed for the protons 
adjacent to the carboxylic groups. Upon heating the solution to 333 K 
(spectrum c), the coalescence of those protons occurs, and at 368 K 
(spectrum d) severe broadening of all the resonances was observed. These 
spectra are consistent with the occurrence of several interconverting isomers. 
Unfortunately, the available NMR data do not allow any speculation on the 
structures of the isomers present in the solution. On a qualitative basis, at 
least, the observed NMR spectra show that the bulky substituent does not 
prevent formation of different isomers which undergo fast interconversion in 
the solution. 
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Figure 6-6: 1H NMR spectra of the ligand (a) and the lanthanum(III) 
complex at room temperature (b), at 333 K (c) and at 368 K (d). 
6.2.3 Relaxometric characterization 
6.2.3.1 Residence time of the coordinated water molecule 
 
The value of the residence time of the coordinated water molecule τM was 
obtained by the analysis of the temperature dependence of the reduced 
transverse relaxation rate of the water oxygen-17 nucleus in solutions 
containing the gadolinium complexes (figure 6-7). The theoretical 
adjustment of these experimental data was performed as previously described 
assuming the presence of one water molecule in the first coordination 
sphere.[41] This procedure allows for the determination of: i) A/h the 
hyperfine coupling constant between the oxygen nucleus of bound water 
molecules and the Gd3+ ion; ii) parameters describing the electronic 
relaxation times of Gd3+ i.e. the correlation time modulating the electronic 
relaxation, τV, the activation energy, Ev, related to τV and a parameter related 
to the mean-square of the zero field splitting energy, B (B=2.4∆2); iii) 
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parameters related to the water exchange i.e. the enthalpy (∆H#) and entropy 
(∆S#) of the process. At 310 K, the water residence time of Gd2-KA080402 
(520 ns) is much larger than that of the parent compound Gd-DTPA (143±25 
ns) (table 6-1).  
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Figure 6-7: Evolution of the 17O transverse relaxation rate versus 
temperature. 
 
Table 6-1: Parameters obtained from the theoretical fitting of the oxygen-17 
data. 
 Gd-DTPA Gd2-KA080402 
τM 310 (ns) 143 ± 25 520 
∆H≠ (kJ mol-1) 51.5 ± 0.3 50.0 ± 0.1 
∆S≠ (Jmol-1 K-1) 52.1 ± 0.6 49.4 ± 0.3 
A/h (106 rad s-1) -3.4 ± 0.1 -2.8 ± 0.1 
B (1020 s-2) 2.60 ±0.06 3.9 ± 0.07 
τv (298 K, ps) 12.3 ± 0.3 10.7 ± 0.2 
 
130 
- Chapter 6 - 
131 
6.2.3.2 Nuclear magnetic relaxation dispersion (NMRD) measurements 
 
The proton NMRD profile recorded at 310 K is shown in figure 6-8. The 
fittings of the proton NMRD profiles were performed as described in the 
experimental section and include both inner-sphere and outer-sphere 
interactions. Some parameters were fixed during the fitting procedure: d, the 
distance of closest approach for the outer sphere contribution was set at 0.36 
nm, the τM value was obtained by 17O NMR (cfr. supra), and the number of 
water molecules in the first coordination sphere of GdIII was set to one. τV 
(the correlation time modulating the electronic relaxation) and τSO (the 
electronic relaxation time at zero field) were optimised for the outer-sphere 
and the inner-sphere contributions simultaneously. The distance r between 
the protons of the coordinated water molecule and the GdIII ion was set to 
0.31 nm. The relaxivity of Gd2-KA080402 is higher than that of Gd-DTPA 
and can be related to reduced motion and a longer correlation time for the 
electronic relaxation (see table 6-2). 
 
Table 6-2: NMRD profile of Gd2-KA080402 in water at 310 K. 
 τM 310 
(ns) 
τR 310 
(ps) 
τS0 310 
(ps) 
τV 310 
(ps) 
Gd-DTPA  143 59  82 23 
Gd2-KA080402 520  183 79 35 
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Figure 6-8: Proton water NMRD profile of Gd2-KA080402 at 37 °C. The 
NMRD profile of Gd-DTPA has been added for comparison.[41]  
 
6.2.4 Interaction with human serum albumin (HSA) 
Contrast agents can interact with proteins, present in the blood plasma, by 
nonconvalent binding. The most important protein in human blood plasma is 
human serum albumin (HSA), constituting about 4 to 4.5 % of plasma (0.67 
mM). HSA is a large (67 kDa) globular protein that is known to bind a 
variety of molecules (drugs, metabolites, fatty acids) at different sites on the 
protein.[42] Noncovalent interaction of contrast agents with HSA results in a 
slowdown of the molecular tumbling rate of the contrast agent (i.e. the value 
of τR increases), hence increasing its relaxivity. Figure 6-9 displays the 
longitudinal proton relaxation rate in a solution containing 4 % of HSA as a 
function of Gd2-KA080402 concentration (squares). The relaxivity of water 
protons by Gd2-KA080402 is much greater in HSA solution than in pure 
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water, indicating a strong noncovalent interaction. Strong binding to albumin 
limits the amount of free drug, which can extravasate from the blood pool 
into nonvascular space and provides selective vascular relaxation rate 
enhancement. Binding also reduces the fraction of free chelate available for 
glomerular filtration in the kidneys, thus slowing the renal excretion rate and 
contributing to an extended blood half-life, resulting in a longer time period 
for imaging. 
 
Figure 6-9: Proton longitudinal paramagnetic relaxation rate in a solution 
containing 4 % of HSA and increasing amounts of Gd2-KA080402 (squares), 
at 20 MHz and 37 °C, the circles represent relaxation rates in absence of 
HSA. 
 
The fitting of the data according to equation 6-1 provides, on the one hand, 
an estimation of the association constant Ka characterising the interaction 
between HSA and Gd2-KA080402 and on the other, a value of the relaxivity 
of the noncovalently bound complex, r1c. The relaxivity of the free contrast 
agent is r1f. The fitted Ka and r1c values are 1600 M-1 and 25.3 s-1 mM-1 
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respectively, which is much higher than the value for r1f , which is 6.5 s-1 
mM-1. In the fitting procedure, the number of equivalent and independent 
interactions sites (N) was set to 1. 
 
Equation 6-1: 
( ) ( ) ( ) ( )( )   ×××−++×−++×−+××= −− oo21oo1oof1c121of1p1 psN4KaspNKaspNrrsr1000R obs  
6.2.5 Transmetallation 
The thermodynamic stability constant is not directly correlated with the acute 
toxicity of contrast agents. The conditional stability constants at 
physiological pH (7.4) are better indicators of the in vivo degree of chelation 
of the cation. Due to possible transmetallation reactions in the tissue, 
Cacheris et al. have argued that, for DTPA derivatives, it is the selectivity or 
difference in stability between a ligand and Gd3+ vs. that same ligand and 
Zn2+, thermodynamically expressed as Ksel, that determines its in vivo 
toxicity, and have shown that log Ksel at physiological pH correlates with 
toxicity.[43] Transmetallation of the complex by Zn2+ results in the release of 
gadolinium ions in solutions. In the presence of phosphate ions, they form an 
insoluble phosphate complex that does not contribute any longer to the 
proton paramagnetic relaxation rate of the solution. As a consequence, water 
proton relaxation rates decrease during the transmetallation process and its 
evolution can be used to quantitatively monitor the evolution of the system. 
Figure 6-10 displays the data for the Gd2-KA080402 complex, after 5000 
min R1p is decreased to 49% of its initial value, showing that a significant 
transmetallation takes place for the open-chain gadolinium complex, data 
that are comparable with the commercially used Gd-DTPA complex (40% 
after 5000 min). On the other hand, Gd2-KA080402 is more stable than the 
other commercially available Gd-DTPA-BMA (9% after 5000 min; for 
structure: see chapter 3). 
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Figure 6-10: Time evolution of the normalized water proton paramagnetic 
relaxation rate at 37 °C and 20 MHz in solution containing 2.5 mM of Zn2+. 
 
6.2.6 Pharmacokinetic characterization 
A fundamental hypothesis of clinical pharmacokinetics is that a relationship 
exists between the pharmacological effects of a drug and an accessible 
concentration of the drug (e.g. in blood or plasma). Clinical 
pharmacokinetics attempt to provide both a quantitative relationship between 
dose and effect and a framework with which to interpret measurements of 
concentrations of drugs in biological fluids. The various physiological and 
pathophysiological variables that dictate adjustment of dosage in individual 
patients often do so as a result of modification of pharmacokinetic 
parameters. The four most important parameters are clearance, a measure of 
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the body’s efficiency in eliminating the drug; volume of distribution, a 
measure of the apparent space available in the body to contain the drug; 
elimination half-life, a measure of removal of the drug from the body; and 
bioavailability, the fraction of drug absorbed as such into the systemic 
circulation.  
 
The pharmacokinetic profile of Gd2-KA080402 with respect to Gd-DTPA is 
presented in figure 6-11. The pharmacokinetic parameters were calculated by 
using a bi-exponential fit of the plasma concentration versus time curves and 
are presented in table 6-3. The different values indicate that the elimination 
of Gd2-KA080402 is slower than that of Gd-DTPA. The volume of 
distribution is similar, indicating a similar interstitial distribution. However 
the elimination half-lives are much longer with respect to Gd-DTPA, most 
likely because of albumin binding. The relative low volume of distribution 
and the longer elimination half-live indicate that the agent is largely confined 
in the blood vessels for a more prolonged time, so the agent could have some 
potential as a blood pool contrast agent. 
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Figure 6-11: Pharmacokinetic profile of Gd2-KA080402 with respect to Gd-
DTPA in rats. 
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Table 6-3: Pharmacokinetic parameters of Gd2-KA080402 compared with 
those of Gd-DTPA in rats. Td1/2 and Te1/2 are the distribution and elimination 
half lives, respectively; Cltot is the total clearance; VDβ is the distribution 
volume in the elimination phase. 
Parameter Gd2-KA080402 
(n = 4) 
Gd-DTPA 
(n = 3) 
Td1/2 (min) 1.56 ± 0.025  * 0.70 ± 0.039 
Te1/2 (min) 75.93 ± 12.80  ** 14.94 ± 1.25 
Cltot (ml/kg/min) 1.10 ± 0.15  * 8.66 ± 1.18 
VDβ (ml/kg) 0.189 ± 0,016 0.180 ± 0,0046 
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6.2.7 Biodistribution 
LIVER
0
0.2
0.4
0.6
30 min 60 min 120 min
%
 o
f i
nj
ec
te
d 
do
se
 / 
g
 
KIDNEYS
0
10
20
30
40
30 min 60 min 120 min
%
 o
f i
nj
ec
te
d 
do
se
 / 
g
 
HEART
0
0.4
0.8
1.2
1.6
2
2.4
30 min 60 min 120 min
%
 o
f i
nj
ec
te
d 
do
se
 / 
g
 
SPLEEN
0
0.4
0.8
1.2
1.6
2
2.4
30 min 60 min 120 min
%
 o
f i
nj
ec
te
d 
do
se
 / 
g
 
LUNGS
0
0.4
0.8
1.2
1.6
2
2.4
2.8
30 min 60 min 120 min
%
 o
f i
nj
ec
te
d 
do
se
 / 
g
 
Figure 6-12: Biodistribution of Gd2-KA080402 in various organs of rats. 
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Figure 6-13: Comparison of biodistribution of Gd2-KA080402 and Gd-
DTPA 60 min after administration in rats. 
 
Figures 6-12 and 6-13 display the biodistribution of Gd2-KA080402 in 
various organs (figure 6-12) and the comparison with Gd-DTPA, 60 minutes 
after administration (figure 6-13). From figure 6-12 it can be seen that Gd2-
KA080402 is eliminated - just like Gd-DTPA - mainly by the renal route. 
Concentrations found in the kidneys are highest at all times (note that the 
scales of the various histograms of figure 6-12 are different), showing a peak 
uptake after 120 minutes. From figure 6-13 one can conclude that the 
biodistribution of Gd2-KA080402 is similar to that of Gd-DTPA, with Gd2-
KA080402 showing a slightly higher preference for the liver, which is most 
likely attributable to its higher lipophilicity.  
 
6.2.8 In vivo evaluation 
6.2.8.1 General aspects 
The rats tolerated the procedures well including abdominal surgery and MR 
imaging throughout the experiment. No animal death and discernible side 
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effects could be related to the injections of both Gd2-KA080402 and 
Gadophrin-2.  
6.2.8.2 MR imaging 
6.2.8.2.1 Precontrast baseline measurements 
 
In this experiment, a rat was subjected to laparotomy (surgery at the 
abdominal region), in order to induce a reperfused hepatic (liver) infarction 
by temporarily cutting off the blood supply of the right liver lobes for 3 
hours. This way, necrotic tissue (i.e. non viable, dead tissue) is induced, this 
necrotic tissue is used as a model for myocardial infarction. 
 
The characteristic hyperintensity of reperfused liver necrosis on T2-weighted 
MRI was a sign to confirm the success of this rat model (figure 6-14a). 
However, without contrast injection, the infarcted liver lobe appeared 
slightly hypointense to isointense relative to normal liver on T1-weighted 
MRI (figure 6-14b), making diagnosis difficult.  
 
 
Figures 6-14: a b c d (left to right above); a’ b’ c’ d’ (left to right under): 
MR images before administration of Gd2-KA080402 (figure a and b) and 
Gadophrin-2 (figure a’) and after administration of Gd2-KA080402 (figures 
c and d) and Gadophrin-2 (figure b’-d’) of the rat with reperfused liver lobe 
infarction. 
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Figure 6-14a: T2-weighted MRI characterizes the reperfused liver ischemic 
(i.e. not perfused with blood) injury as a hyperintense region (arrow). Figure 
6-14b: On T1-weighted MRI of the same slice as figure 6-14a, without 
contrast injection, the infarcted liver lobe appeared slightly hypointense to 
isointense relative to normal liver, making diagnosis difficult. Figure 6-14c: 
On T1-weighted MRI, after intravenous administration of Gd2-KA080402, a 
prompt contrast enhancement (CE) occurs in normal liver, rendering 
infarcted liver lobe distinguishable as a hypointense zone. Intrahepatic (i.e. 
within the liver) vascular tree in the infarcted lobe is strongly enhanced, 
indicating the presence of reperfusion. Figure 6-14d: At 30 min after Gd2-
KA080402 injection, the contrast between infarcted and normal liver lobes is 
diminished due to signal intensity decay in the normal liver and a slight 
diffusion related CE in the necrotic liver lobe (arrow), which however does 
not persist, i.e. wash-in and washout phenomena. Figure 6-14a’. On T1-
weighted MRI, 24 hours after Gd2-KA080402 injection, the SI (signal 
intensity) is completely normalized in both the normal and infarcted liver 
lobes. Figure 6-14b’. Immediately after Gadophrin-2 injection, an early 
nonspecific CE appears comparable to the early CE with Gd2-KA080402 
(figure 6-14c). Figure 6-14c’. At 30 min after Gadophrin-2 injection, in 
contrast to a continuing SI attenuation with Gd2-KA080402 already at 30 
min postcontrast (figure 6-14d), a reversed contrast (though not yet 
homogeneous) between infarcted and normal liver lobes occurs. Figure 6-
14d’. Up to 24 hours after Gadophrin-2 injection, the SI of the infarcted lobe 
further increased and persisted leading to a positive contrast between 
necrotic and normal liver (arrow). 
 
6.2.8.2.2 Early postcontrast phase 
 
After intravenous administration at the same dose, both Gd2-KA080402 and 
Gadophrin-2 caused a prompt contrast enhancement (CE) in normal liver, 
rendering infarcted liver lobe distinguishable on T1-weighted MRI as a 
hypointense zone (figure 6-14c and b’). Intrahepatic vascular tree in the 
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involved lobe could be visualized with a strong CE (contrast enhancement), 
indicating the presence of reperfusion. With both agents, the peak normal 
liver CE was followed by a similar slow SI decay and accompanied by a 
progressive CE in the necrotic parenchyma (i.e. tissue), which jointly 
diminished the initial negative contrast between infarcted and normal liver 
lobes (figure 6-14d and c’). In contrast to a continuing liver SI attenuation 
with Gd2-KA080402 (figure 6-14d), already at 30 min postcontrast, a 
reversed contrast (though not yet homogeneous) between infarcted and 
normal liver lobes occurred with Gadophrin-2 (figure 6-14c’).  
 
6.2.8.2.3 Delayed postcontrast phase 
 
The SI (signal intensity) of normal and infarcted liver was normalized 
overnight after Gd2-KA080402 injection with no appreciable necrosis/normal 
contrast (CR≈1) (figure 6-14a’). However, the SI of the infarcted lobe further 
increased and persisted up to 24 hours after Gadophrin-2 injection leading to 
a positive contrast between necrotic and normal liver (CR = 1.4) (figure 6-
14d’). This finding was identical to what was reported in a previous study.[36, 
44] 
 
6.2.8.3 Histomorphologic findings 
On gross section (figure 6-15), in contrast to dark reddish normal liver, the 
necrotic lobe stained bluish because of the avidity between injected Evans 
blue and necrotic tissue debris. The macroscopic view (figure 6-15) matched 
perfectly with the MR image even with fine details (figure 6-14d’). 
Microscopically, the reperfused liver infarction showed typical changes of 
hepatocytic autolysis (self destruction of liver cells) and inflammatory 
infiltration with remaining patent blood vessels, as demonstrated 
previously.[36] 
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Figure 6-13: Cross section of the rat closely mimics the corresponding 
T1-weighted MR image (figure 6-14d’). The arrow indicates the infarcted 
liver lobe.  
 
6.2.8.4 Discussion 
Although Gd2-KA080402 does not turn out to be a necrosis avid agent like 
its chemical analogue of ECIV-7,[45-46] with half the normal dose this agent 
appeared to more effectively enhance the tissues such as the liver than does 
the commercially available Gd-DTPA.  
 
6.3 Conclusions 
A new type of contrast agent bearing two paramagnetic centra has been 
synthesized, physicochemically and preclinically evaluated and tested for 
necrosis avidity. NMRD data prove that this agent has a higher relaxivity 
compared to Gd-DTPA and that the relaxivity value increases dramatically in 
vivo due to strong HSA interaction. The interaction with HSA also results in 
longer elimination half-lives and a better confinement in the vascular space 
as proved by pharmacokinetic evaluation. Biodistribution studies show that 
the highly soluble complex is excreted, similarly as Gd-DTPA, by the renal 
pathway. Unfortunately the agent did not show any necrosis avidity, despite 
the structural similarity with ECIV-7, [45-46] and its binding to HSA. Hence, 
the study has also disproved the proposed mechanism of albumin binding for 
the necrosis targetability of NACA’s. Instead it enhanced more effectively 
tissues with half the normal dose, compared to Gd-DTPA. 
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6.4 Experimental section 
6.4.1 Chemicals  
Reagents were obtained from Aldrich Chemical Co. Inc., Acros Organics, 
and Fluka, and used without further purification. Gadolinium chloride 
hexahydrate was obtained from GFS chemicals (USA). Nondefatted human 
albumin (fraction V) was obtained from Sigma (Bornem, Belgium). 
6.4.2 Instruments 
Cfr chapter 5. 
6.4.3 Synthesis of the ligand 
Step 1 
 
Ethyl indole-2-carboxylate (18.9 g, 100 mmol) was dissolved in 200 ml 
ethanol under nitrogen atmosphere; 3,4,5-trimethoxybenzaldehyde (10.8 g, 
55 mmol) was added and the mixture was heated to reflux temperature. 
Concentrated HCl (3.7 ml) was added and the reaction was left for 1 hour. 
After cooling the white product was filtered off and washed thoroughly with 
cold ethanol. The reaction can be followed by TLC CHCl3 : Hexane 1:1 
system by the disappearance of the ethyl indole-2-carboxylate (Rf value = 
0.7) and the appearance of the product spot (Rf = 0.1). Yield 24g = 88% 
1H-NMR (δ DMSO-d6): 1.19 (t, 6H, 2 × CH3); 3.46 (s, 6H, 2 × CH3) 3.66 (s, 
3H, 1 × CH3); 4.23 (d, 4H, 2 × CH2); 6.43 (s, 2H, 2 × CH); 6.55 (d, 2H, 2 × 
CH); 6.69 (t, 2H, 2 × CH); 7.12 (t, 2H, 2 × CH); 7.28 (s, 1H, CH); 7.46 (d, 
2H, CH); 11.69 (s, 2H, 2 × NH). 
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Step 2 
 
Product 1 (16.2 g, 30 mmol) was dissolved in 150 ml of pyridine. Hydrazine 
monohydrate (50ml) in 50 ml of methanol was added and the mixture was 
heated at 100°C for 36 hours. The reaction was followed by HPLC 
appearance of the peak at 7.3 min. (C18 column, 4.6 x 250 mm, detection 
wavelength 254 nm, gradient 5 % CH3CN to 95 % over 20min., elution 
buffer NH4Ac at pH 7 containing 0.5 mM EDTA). After the removal of the 
solvent, 200 ml of H2O was added and the resulting solution was evaporated 
again; this process was repeated until no free hydrazine was left in the 
solution (check with I2). The resulting product was then suspended in 
acetonitrile and the product was filtered off. Yield = 14.1 g, 90%. 
 
Step 3 
 
DTPA (61 gr, 155 mmol) was sonicated in a mixture of 1800 ml of DMSO 
and 50 ml of triethylamine (36 g, 0.36 mol). TBTU (25 g, 78 mmol) was 
added and the mixture was sonicated again for 15 min. Product 2 (10.44 g, 
20 mmol) was added and the mixture was stirred for 1 hour. After removal of 
the solvent the product was dissolved in a concentrated solution of NaHCO3, 
pH was adapted to 7 with concentrated NaOH followed by sonication for  
30 min. The resulting mixture was evaporated and placed on a C18 reversed 
phase column (10 cm x 80 cm), which was then eluted with a 5 L solution of 
ammonium acetate 0.1 M (40 g) in distilled water containing 2.5 % 
methanol, a 3 L solution containing 5% methanol and finally with 3 L of a 
solution containing 10% methanol. The product was collected in 200 ml 
fractions and the purity was checked with HPLC by monitoring the peak at 
4.4 min Yield = 13 g, 51%. 
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6.4.4 Analytical data ligand 
Overall Yield: 40%; 1H-NMR (D2O, pH: 6.0), δ, (ppm): 3.11 (m, 8 H, 2 × N-
CH2); 3.27 (m, 4 H, 2 × N-CH2); 3.37 (m, 4 H, 2 × N-CH2); 3.43 (s, 4 H, 2 × 
CH2-COOH); 3.53 (s, 8 H, 4 × CH2-COOH); 3.65 (s, 9 H, 3 × OCH3); 3.69 
(b, 8 H, 2 × CH2-COOH, 2 × CH2-CO-NH); 6.66 (s, 2 H, Ph); .6.75 (d, 2 H, 
Ph), 6.79 (m, 2 H, Ph), 6.86 (s, 1 H, CH-Ph), 7.19 (m, 2 H, Ph), 7.45 (d, 2 H, 
Ph). IR: ν (cm-1): 3406 (N-H); 3008 (C-H, phenyl); 2917 and 2852 (C-H 
alkyl); 1687 (CO amide I); 1624 (CO acid); 1591 (COO- assym stretch); 
1404 (COO- sym. stretch). Elem. Anal. Calcd.: NaC56N12O23H65(NH4)4 
(found): C: 49.1 (48.66) H: 6.0 (6.39) N: 16.36 (16.33)%. ES-MS+: 1301 
[M+Na]+; 1324 [M-H]+; 662 [M+2Na]2+. 
 
6.4.5 Synthesis of the Ln(III) complexes  
See general procedure in chapter 5 
6.4.6 Analytical data complex 
Note: for mass spec: M = Ln2C56N12O23H62Na2 
 
La complex: Yield: 95%; IR: ν (cm-1): 3401 (N-H); 3016 (C-H, phenyl); 
2922 and 2850 (C-H alkyl); 1630 (CO, amide I); 1590 (COO- assym. 
stretch); 1400 (COO- sym. stretch). Elem. Anal. Calcd.: 
La2C56N12O23H62Na2(H2O)4 (found): C: 40.3 (40.51); H: 4.23 (4.75); N: 
10.08 (10.04)%. ES-MS+: 1615 [M+H++H2O]+; 1637 [M+Na+H2O]+; 796 
[M+2H+]2+. 
 
Gd complex: Yield: 96%; IR: ν (cm-1): 3406 (N-H); 2915 and 2840 (C-H 
alkyl); 1637 (CO amide I); 1585 (COO- assym. stretch); 1404 (COO- sym. 
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stretch). Elem. Anal. Calcd.: Gd2C56N12O23H62Na2(H2O)8(found): 37.87 
(37.65); 4.43 (4.91); 9.47 (9.90). ES-MS+: 1632 [M+H]+; 1610 [M-
Na+2H]+; 795 [M-2Na+4H]2+. 
 
6.4.7  17O NMR measurements 
17O NMR measurements of solutions were performed on 2 ml samples 
contained in NMR (OD 10 mm) tubes on a Bruker AMX-300 spectrometer. 
The temperature was regulated by air or nitrogen flow controlled by a BVT 
2000 unit. An IRFT (Inversion Recovery Fourier Transform) sequence and a 
regression to three parameters on experimental points are used for the 
measure of T1. No field frequency lock was used except for the 
measurements of 17O chemical shifts. 17O tranverse relaxation times of 
distilled water (pH = 6.5-7) were measured using a CPMG (Carr-Purcell 
Meiboom Gill) sequence and a subsequent two parameters fit of the data 
points. The 90° and 180° pulse lengths were 25 and 50 µs, respectively. 17O 
T2 of the complex in aqueous solution was obtained from linewidth 
measurement. The concentration of the samples was inferior to 25 mM.  
6.4.8 NMRD profiles 
Cfr Chapter 5.4.11 
6.4.9 Transmetallation 
Transmetallation by zinc ions was evaluated by the decrease of the water 
longitudinal relaxation rate at 310 K and 20 MHz (Bruker Minispec PC 20) 
of buffered phosphate solutions (pH=7) containing 2.5 mM of the 
gadolinium complex and 2.5 mM of Zn2+.[47] 
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6.4.10 Interaction with HSA 
The binding constant and relaxivity value of Gd2-KA080402 in 4 % HSA 
solution was determined by measuring the proton longitudinal relaxation rate 
at 20 MHz and 37 °C as a function of Gd2-KA080402 concentration. 
6.4.11 Pharmacokinetic characterization 
Adult Wistar rats (269 g ± 6 g, Harlan, The Netherlands) were anesthetized 
with intraperitoneal injection (i.e. injection in the abdomen) of pentobarbital 
(Nembutal®, Sanofi Sante Animale, B-1130 Brussel, Belgium) at a dose of 
60 mg/kg. The rats were then tracheotomised (cut in the trachea) and the left 
carotide was catheterized (i.e. using a kind of tube to withdraw blood) 
(Becton Dickinson Angiocath 0.7 mm x 19 mm) in order to withdraw blood. 
The agent was administered by bolus injection (injecting the complete dose 
in one time) in a femoral vein at a dose of 0.05 mmol/kg; Gd-DTPA, used as 
a control, was injected at a dose of 0.1 mmol/kg. Blood samples were 
collected at 1, 2.5, 5, 15, 30, 45, 60, 90, and 120 min after injection. The 
concentration of gadolinium in the blood was determined by relaxometry at 
37 °C and 60 MHz on a Bruker Minispec. A two compartment distribution 
model was used to calculate the distribution (Td1/2) and elimination (Te1/2) 
half lives, the distribution volume (VDβ), the total clearance (Cltot) and the 
initial blood concentration (C0).[48] The gadolinium blood concentration  was 
converted to plasma concentration assuming a hematocrite value of 0.53.[49] 
6.4.12 Biodistribution 
At the end of the pharmacokinetics experiment, 30 min (3 rats), 60 min (3 
rats) or 120 min (4 rats) after injection, the animals were sacrificed and 
samples of liver, kidneys, heart, lungs, spleen, muscle, blood, and urine were 
collected in order to evaluate the gadolinium content. Except for blood and 
urine (0.3 ml), the samples were weighed, dried overnight at 60 °C, and 
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subsequently digested (up to 0.4 g each sample) in acidic conditions (3 ml 
conc. HNO3, 1 ml H2O2) by microwaves as described above. The gadolinium 
content was determined by ICP-AES. To calculate the percentage of the 
injected dose per organ (%ID/organ), blood volume in the whole rat was 
assumed to be 7 % of the body weight, and muscle mass 14 %.  
 
6.4.13 Procedure in vivo evaluation 
The agent was intravenously injected at a dose of 0.05 mmol/kg. Bis-Gd-
mesoporphyrin (Gadophrin-2) was produced and supplied by the Institut für 
Diagnostikforschung (Berlin, Germany). The gadolinium concentration in 
the batch used was 20 mmol/L with a relaxivity R1 of 9.6 mM-1sec-1 in 
aqueous solution and 16 mM-1sec-1 in 20 % albumin solution[38]. The 
intravenous dose was the same as for the test agent (0.05 mmol/kg). The 
albumin-binding rate was measured at 55 % in rabbit plasma with a 
porphyrin concentration of 0.25 mmol/L and the plasma half-life was 2.5 
hours. The chemical structure and other physicochemical properties have 
been previously described [38,50]. This agent was used as a standard necrosis 
avid contrast agent (NACA) for intraindividual comparison with the test 
agent Gd2-KA080402. 
 
6.4.14 Animal model 
Adult Wistar rats weighing 300-400 grams were anesthetized with 
intraperitoneal injection of pentobarbital (Nembutal®, Sanofi Sante Animale, 
B-1130 Brussels, Belgium) at a dose of 60 mg/kg. Under laparotomy, 
reperfused hepatic infarction was induced by temporarily clamping the hilum 
of the right liver lobes for 3 hours. After reperfusion by declamping hepatic 
inflow, the abdominal cavity was closed with 2-layer sutures and the rats 
were left to recover for 8-24 hours after the surgery.[36-44] 
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6.4.15 MR imaging and quantification 
The above-mentioned anesthesia was also used for imaging. Rats were 
placed supinely into a plastic holder. The tail vein of the rat was cannulated 
with a G27 infusion set connecting to a 1 ml tuberculin syringe loaded with a 
contrast agent.  
 
MR imaging was performed at a 1.5 T Siemens Sonata scanner (Erlangen, 
Germany) using a commercially available 4-channel phased array wrist coil. 
Pilot images of sagittal, coronal and axial planes were obtained for 
positioning subsequent imaging acquisitions. T2-weighted (TR/TE = 5570 ms 
/99 ms, BW 130) turbo spin echo 2-D imaging sequence, with slice thickness 
2 mm (without gap), the field of view 4.6 cm x 8.0 cm, the matrix 240 x 512 
and 4 averaged acquisitions, resulting in about 3 minutes of measurement, 
was applied to verify any ischemic hepatic lesions in the rat. T1-weighted 
(TR/TE = 600 ms /15 ms) 2-D imaging sequence of similar field of view, 
matrix and slice thickness was used to study the contrast agents for in vivo 
signal intensity (SI) enhancement.   
 
All rats were scanned on transverse sections before and after injection of 
Gd2-KA080402. Postcontrast T1-weighted MRI was taken every 10 minutes 
for the first hour (early phase) and up to 24 hours (late phase). If the SI 
particularly in the liver returned to precontrast level at the late phase with the 
test agent Gd2-KA080402, the control agent Gadophrin-2 would be studied 
in the same rat with the same MRI protocol, i.e. intraindividual comparison. 
If the test agent displayed a positive result (i.e. persistent necrosis-specific 
enhancement), interindividual study in different rats was planned, which 
actually was not performed due to the absence of this second probability. The 
SI of necrotic lobe as well as normal liver and the external standard tube 
were measured using a monitor-defined circular region of interest (ROI) with 
100 to 520 pixels. In the same animal, the size and location of the ROI were 
kept constant for measurement at different time points. The obtained SI 
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values were averaged for each time point and plotted in function of time. The 
conspicuity of the necrotic lobe was expressed as contrast ratio (CR) between 
necrotic and normal liver and was calculated as CR = SInecrosis/SInormal 
for each time point. Statistical analyses were done using Microsoft Excel 
version 7.0. 
6.4.16 Imaging - histology correlation 
To visualize the necrosis on macroscopic tissue section, rats were 
intravenously injected with 1 % Evans blue solution one day before sacrifice. 
At the end of imaging studies, rats were euthanized by intravenous overdose 
of pentobarbital and placed in a deep freezer (under -20 °C) overnight in the 
same position as that during MR imaging. The frozen rats were sectioned in 
the transverse plane similar to that on MRI in order to match the imaging and 
histologic findings.  
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Chapter 7 
Self-assembled f-d complexes 
 
No te conoce el toro ni la higuera, 
Ni caballos ni hormigas de tu casa 
No te conoce el niño ni la tarde 
Porque te has muerto para siempre. 
... 
No te conoce nadie. No. Pero yo te canto. 
Yo canto para luego tu perfil y tu gracia. 
La madurez insigne de tu conocimiento. 
Tu apetecia de muerte y el gusto de su boca. 
La tristeza que tuvo tu valiente alegriá. 
 
The bull does not know you, nor the fig tree, 
nor horses, nor the ants on your floors. 
The child does not know you, nor the evening, 
because your death is forever. 
 
No one knows you. No one. But I sing you 
sing your profile and your grace, for later on. 
The signal ripeness of your mastery. 
The way you sought death out, savored its taste. 
The sadness just beneath your gay valor. 
 (F. G. Lorca) 
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7.1 A self-assembling heteropolymetallic chelate as a potential 
necrosis avid imaging agent 
 
7.1.1 Introduction 
 
Desreux and coworkers developed a very new approach towards 
achieving higher relaxivity relies on the formation of a supramolecular 
entity by self-assembly of the gadolinium(III) complex around iron(III) or 
iron(II) ions.[1-3] The increase of molecular weight accompanying the self-
assembly results in a slowdown of the tumbling rate, and hence a higher 
relaxivity. In order to achieve such self-assembly, dipolydentate ligands 
must be designed in such a way that the complexing behaviour of each 
polydentate is selective for one type of metal i.e. one polydentate ligand 
should be specific for Fe2+ or Fe3+ metal ions, whereas the other 
polydentate ligand should be specific for Ln3+ metal ions. In another 
example, the DTPA ligand was modified in such a way that besides the 
gadolinium(III) ion, which coordinated to the DTPA moiety, the binding 
of two iron(III) ions by two salicylamide group was also possible.[4] 
Desreux coupled a 1,10-phenanthroline unit to a DOTA ligand in a way 
that one iron(II) ion was able to bind three 1,10-phenanthroline units 
bearing a Gd(DOTA) moiety.[1] This self-assembly approach has distinct 
advantages: (1) due to a higher molecular weight and a larger molecular 
volume, slow rotational rates and higher relaxivities in MRI are achieved 
without synthetic efforts, since no new covalent bonds are needed to form 
the new species (2) Heterometallic complexes are obtained and in these 
complexes, higher relaxivities may be reached if all metal ions are 
paramagnetic. Dipolydentate chelates containing one type of metal ion 
and featuring high affinity for another type of metal ion can be used for 
detecting that ion in vitro either because of the change in MRI relaxivity 
or the change of a spectroscopic property such as fluorescence or UV-VIS 
absorption. 
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In this study, a Ln(III) binding DTPA moiety was linked with an iron(II) 
binding 1,10-phenanthroline unit, resulting in a heteropolymetallic species 
with increased relaxivity. The Gd3+ complexes with and without the 1,10-
phenanthroline binding iron(II) metal ion were tested in vivo for necrosis 
avidity. This is relevant in an accurate diagnosis of myocardial infarction 
(MI). MI is ranked at the top of morbidity and mortality in industrialized 
countries.[5] Until now, all in vivo methods such as symptoms, 
electrocardiography (ECG) as well as scintigraphy[6] and MRI with and 
without non-specific contrast media are not sufficiently reliable in 
determining quantitatively the infarct size.[7-9] Therefore much effort has 
been put into the development of new agents for cardiac MRI. To date, only 
a limited number of necrosis avid compounds are known: porphyrins such as 
bis-Gd-DTPA mesoporphyrin (Gadophrin-2 and Gadophrin-3, Schering AG) 
were shown to accumulate in necrotic tissue.[10] We were able to show that 
one compound tested also displays necrosis avidity, however, more research 
is necessary to fully validate this claim. 
 
7.1.2 Results and discussion 
7.1.2.1 The ligand and complexes 
 
The heteropolymetallic ligand Querida – Spanish for “darling” – or DTPA-5-
amido-1,10-phenanthroline (2 in scheme 7-1), was synthesized according to 
scheme 7-1. The crucial step in this synthesis was the reduction of 5-nitro-
1,10-phenanthroline to 5-amino-1,10-phenanthroline with Pd/C as a catalyst. 
The use of 5% Pd/C is recommended as 10% Pd/C tends to overreduction. 
Upon recrystallization in ethanol, a lot of product is lost, but the pale yellow 
crystals obtained in this way are without impurities. The ligand readily 
formed complexes with lanthanides (Ln-2) in high yield. Upon addition of a 
FeCl2 solution to an aqueous solution of the lanthanide complex the colour of 
the mixture immediately changed to deep red indicating the formation of a 
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supramolecular structure (see scheme 7-2). Typically, Fe2+ is complexed 
with three gadolinium chelate entities [Gd-2]-, which is confirmed by ICP-
MS measurements on the supramolecular complex, where the relation 
Gd3+:Fe2+ was 3:1. Hence the supramolecular structure is indicated as [(Gd-
2)3Fe]-. 
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Scheme 7-1: Synthesis of the heteropolymetallic chelate Querida. 
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Scheme 7-2: Synthesis of the heteropolymetallic iron(II)-gadolinium(III) 
complex [(Gd-2)3Fe]-. 
 
7.1.2.2 Solution dynamics 
 
Proton NMR spectrum of the diamagnetic [La-2]- and [(La-2)3Fe]- exhibited 
broadening and overlapping of proton resonances in the DTPA region. This 
broadening is indicative of the presence of several interconverting isomers, 
as will be discussed in the case of lanthanide(III) and heterobimetallic  
lanthanide(III)-iron(III) complexes of DTPA-dihydroxyphenethylamine  
(cfr. infra). The phenantroline aromatic resonances of [La-2]- did not exhibit 
any proton NMR shift compared to the free ligand, indicating that 
coordination of lanthanum(III) occurred only at the DTPA unit. However, in 
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the case of [(La-2)3Fe]- these resonances shifted by ca. 1-1.5 ppm upfield 
indicating coordination of phenantroline unit to iron(II). The proton NMR 
spectra of the paramagnetic [Eu-2]- and [(Eu-2)3Fe]- compounds were less 
informative. Very broad peaks in the range from 0 to –20 ppm and from 20-
25 ppm were observed, which is a good indication of europium(III) 
coordination to DTPA. Similarly to the lanthanum(III) analogues, the shift of 
phenantroline NMR resonances compared to the free ligand was only 
observed in the case of the supramolecular complex [(Eu-2)3Fe]- . 
 
7.1.2.3 Luminescence measurements 
 
Absorption 
 
The absorption spectra of Querida (i.e. compound 2) and its complexes are 
given in figure 7-1. They all show an absorption maximum between 250 and 
300 nm. This maximum can be attributed to π → π* transition of the 
phenanthroline moiety and the n → 3s or 3p Rydberg transitions of the 
nitrogen chromophore . The spectra have been recorded from aqueous 
solutions. 
 
Figure 7-1: Absorption spectra of the Querida derivatives. 
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Emission 
 
In lanthanide coordination compounds, one can consider two ways of getting 
the lanthanide to emit light as a result of absorption of light. (i) Direct 
excitation of the lanthanide in one of the 2S+1LJ levels. This mechanism 
involves a f-f transition, which are parity forbidden and therefore very weak. 
Typically, the molar absorptivity ε of such a transition is lower than 10 L 
mol-1 cm-1. Consequently, one needs very high concentrations of lanthanide 
to make sure a reasonable amount of light is absorbed. This can cause 
solubility problems. (ii) Excitation via the ligand. If the ligand has energy 
levels (especially triplet) which match some of the excited energy levels of 
the lanthanide, energy transfer can occur from the ligand to the lanthanide. 
The ligand acts as an antenna and hence this is called antenna effect. Because 
the absorption transitions of the ligand are allowed and therefore very intense 
(often several 104 or 105 L mol-1 cm-1), low concentrations of complex can be 
sufficient to obtain very intense lanthanide-centered luminescence. 
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Figure 7-2: Luminescence spectra of the Eu-Querida, [Eu-2]-, derivatives. 
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In this study, Eu3+ complexes have been used to probe the first coordination 
sphere of the Eu3+ ion in all three DTPA derivatives. If complexation of the 
phenanthroline moiety to Fe2+ or Zn2+ would alter the local symmetry of the 
Eu3+ ion, this should be visible in the emission spectrum of the Eu3+ ion. [11] 
Alternatively, if part of the excitation energy would be lost in the Fe2+ or the 
Zn2+ ions, this should reduce the luminescence intensity of the Eu3+ 
emission, although making conclusions from intensity changes in 
luminescence studies can be extremely tricky. The luminescence spectra of 
the three Querida derivatives are shown in figure 7-2. As can be seen, the 
shape of the peaks in all three spectra look very similar, indicating that the 
local environment of the Eu3+ ion in first coordination sphere is virtually the 
same in all three complexes. Thus, the effect of complexation of Fe2+ or Zn2+ 
at the phenanthroline position does not influence the local symmetry of the 
Eu3+ ion. All three complexes have been excited in the ligand, at the 
wavelength of the Querida absorption band shown in figure 7-1 (283.5 nm). 
The absorbance of the three complexes at this wavelength had been adjusted 
to nearly the same value, presuming that the same amount of light would be 
absorbed by all three complexes, so that rather reliable comparisons could be 
made of the luminescence intensities. It can be noticed that the luminescence 
intensity of the [(Eu-2)xZn] derivative is about the same as that of the parent 
Eu3+ compound. The luminescence intensity of the [(Eu-2)3Fe]- derivative, 
however, is much lower (excitation slits had been opened even further than 
in the other experiments - to obtain a sufficiently strong signal - while the 
emission slits remained at the same position, thus resulting in the same 
spectral resolution of 0.35 nm for the emission spectrum). 
 
The fact that the [(Eu-2)3Fe]- derivative behaves differently compared to the 
[(Eu-2)xZn] derivative and the parent Eu3+ complex is confirmed by the time-
resolved measurements, shown in figures 7-3a and 7-3b. While the 
luminescence decay signal of the [(Eu-2)xZn] derivative and the parent  
[Eu-2]- complex can be fitted by a single exponential, the decay signal of the 
[(Eu-2)3Fe]- derivative is more complex and can only be accurately described 
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by a bi-exponential function. The raw signal decays almost immediately to 
much smaller values before the typical lanthanide luminescence decay 
pattern can be observed. This means that the initial luminescence is quenched 
very efficiently, resulting in low intensity. Without a more detailed 
investigation, however, it is difficult to explain the energy transfer processes 
and quenching mechanisms in this system. 
 
 
Figure 7-3a: Luminescence decay signals of the Querida derivatives [Eu-2]- 
and [(Eu-2)xZn]. 
168 
- chapter 7 - 
 
. 
Figure 7-3b: Luminescence decay signals of the Querida derivative 
[(Eu-2)3Fe]- up: raw signal, under: bi-exponential fit. 
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7.1.2.4 Relaxation rates of [(Gd-2)3Fe]- 
 
Figure 7-4 displays the relaxation rates of a 0.2 mM solution of the 
[(Gd-2)3Fe]- complex. Since relaxivity is defined as the change in relaxation 
rate for a 1 mM solution, it is not yet possible to compare the data to Gd-
DTPA. Nevertheless data clearly indicate that through the inclusion of 
multiple paramagnetic centra in one supramolecular structure, much higher 
relaxivities are obtained than for Gd-DTPA, here this is already the fact for a 
0.2 mM solution at low fields. The fitting of the data was not yet possible 
since this requires the rewriting of the Solomon-Bloembergen equations, due 
to the presence of an Fe2+ ion. 
 
Figure 7-4: Relaxation rates of a solution containing 0.2 mM [(Gd-2)3Fe]-. 
 
170 
- chapter 7 - 
171 
7.1.2.5 In vivo evaluation 
 
7.1.2.5.1 General aspects 
The agents were intravenously injected at a dose of 0.05 mmol/kg. The rats 
tolerated well the procedures including abdominal surgery and MR imaging 
throughout the experiment. No animal death and discernible side effects 
could be related to the injections of both Gd-2 and [(Gd-2)3Fe]-.  
 
7.1.2.5.2 MR imaging 
Precontrast baseline measurements 
The focal hyperintensity in the right liver lobe on T2-weighted MRI 
confirmed the presence of reperfused and incomplete right liver lobe 
ischemic injury and focal dorsal muscle necrosis (figures 7-5a and 7-6a). 
However, without contrast injection, the infarcted liver lobe appeared 
slightly hypointense or isointense relative to normal liver on T1-weighted 
MRI (figures 7-5b and 7-6b), making diagnosis difficult.  
 
Early postcontrast phase 
After intravenous administration at the same dose, both Gd-2 and  
[(Gd-2)3Fe]- caused a prompt contrast enhancement (CE) in normal liver, 
rendering infarcted liver tissue distinguishable on T1-weighted MRI as a 
relatively hypointense zone (figures 7-5c and 7-6c). With both agents, the 
peak normal liver CE was followed by a similar slow SI decay and 
accompanied by a progressive CE in the necrotic parenchyma, which jointly 
diminished the initial negative contrast between infarcted and normal liver 
lobes (figures 7-5d,f and 7-6d,e).  
 
Delayed postcontrast phase 
While the SI of normal and infarcted liver returned to precontrast level 
(CR≈1.0) 12 hours after injection with Gd-2 (figure 7-6f), a minimal degree 
of delayed necrosis/normal contrast enhancement (CR = 1.2) developed in 
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the rat injected with [(Gd-2)3Fe]- (figure 7-6e,f). The alcohol induced 
muscular necrosis was also positively enhanced (figure 7-6e,f). 
 
 
 
Figures 7-5a-d (top: left to right) and e-g (under: left to right): T1-weighted 
MR images before administration of Gd-2 (a) and 1’ (b), 10’ (c), 20’ (d), 30’ 
(e), 12 hours (f) after administration of Gd-2; 7-5g: T2-weighted MRI image. 
 
7-5a: On T1-weighted MRI, without contrast injection, the infarcted liver 
tissue appeared isointense relative to normal liver, making diagnosis 
difficult.  
7-5b-d: On T1-weighted MRI, shortly after intravenous administration of  
Gd-2, a prompt contrast enhancement (CE) occurs in normal liver, 
rendering infarcted liver lobe distinguishable as a hypointense zone. 
Intrahepatic vascular tree in the infarcted lobe is also enhanced, indicating 
the presence of reperfusion. The normal and infarcted liver became almost 
isointense 30 min after contrast because of gradually decreased SI in the 
normal and increased SI in the infarcted liver. 
7-5f: Twelve hours after contrast, the contrast between normal and infarcted 
liver tissues returned to precontrast level.  
7-5g: T2-weighted MRI before sacrifice characterized the reperfused liver 
ischemic injury as a hyperintense region (arrow). 
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Figures 7-6a-d (top: left to right) and e-g (under: left to right): T1-weighted 
MR images before administration of [(Gd-2)3Fe]- (a) and 1’ (b), 20’ (c), 30’ 
(d), 12 hours (e), 24 hours (f) after administration of [(Gd-2)3Fe]-; 7-6g: T2-
weighted MRI image. 
 
7-6a: On precontrast T1-weighted MRI, the infarcted liver tissue appeared 
isointense relative to normal liver, making diagnosis difficult.   
7-6b-d: On T1-weighted MRI, shortly after intravenous administration of 
[(Gd-2)3Fe]-, a prompt CE occured in normal liver, rendering infarcted liver 
tissues (red arrows) and necrotic muscle (black arrow) distinguishable as 
hypointense zones. The normal and infarcted liver and muscle became 
isointense 30 min after contrast because of gradually decreased SI in the 
normal and increased SI in the infarcted tissues. 
7-6e-f: Twelve and 24 hours after contrast, a persistent CE occured between 
normal and necrotic tissues. 
7-6g. T2-weighted MRI before sacrifice characterized the reperfused liver 
ischemic injury (red arrows) and alcohol induced dorsal muscular necrosis 
as hyperintense regions (black arrow). 
 
Histomorphologic findings 
 
Macroscopically, the infarcted area appeared paler than normal liver in the 
rat with Gd-2 (figure 7-7a). On gross section of the rat with [(Gd-2)3Fe]- 
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(figure 7-7b), in contrast to dark colored normal liver, the necrotic lesions 
stained bluish because of the avidity between injected Evans blue and 
necrotic tissue debris. The macroscopic views (figures 7-7a and 7-7b) 
matched well with the MR images (Fig. 7-5a,g and 7-6a,g). Microscopically, 
the reperfused liver infarction showed typical changes of hepatocytic 
autolysis and inflammatory infiltration with remaining patent blood vessels, 
as demonstrated previously. 
 
 
 
 
 
 
 
 
 
Figure 7-7a: Transverse section of the rat injected with Gd-2. The infarcted 
liver (arrow) looked paler than normal liver. S stands for stomach. 
 
 
 
 
 
 
 
 
 
Figure 7-7b: Cross section of the rat injected with [(Gd-2)3Fe]-. The cross 
sections closely mimic the corresponding T2-weighted (figure 7-6g) and T1-
weighted (figure 7-6f) MRI. Red and black arrows indicate the infarcted liver 
and necrotic muscle respectively. S stands for stomach.  
 
174 
- chapter 7 - 
175 
7.1.2.5.3 Discussion 
 
The chemical structures Gd-2 and [(Gd-2)3Fe]- displayed potent contrast 
enhancement in organs including the liver with longer duration than when 
Gd-DTPA is used. Besides, [(Gd-2)3Fe]- seems to be a necrosis avid contrast 
agent as proved by MRI-histomorphological correlation study. The slight 
modification in spatial configuration of the chemical structure between these 
two CAs may be attributable for such a functional difference. Further 
investigation may be warranted to gain deeper insight into the issue.    
 
7.1.3 Conclusions 
 
In summary, we have shown that, by coupling a 1,10 phenantroline unit to 
the lanthanide binding DTPA moiety, the formation of a highly paramagnetic 
supramolecular structure is possible. This supramolecular structure is easily 
obtained by mixing an aqueous solution of the lanthanum(III) complex of the 
ligand with an aqueous solution of Fe2+ ions and is indicated by an 
immediate change of color. Luminescence studies show that the local 
coordination environment of the lanthanum (III) ion remains unaffected upon 
formation of the supramolecular structure. The first data on relaxation rates 
suggest that the relaxivity of the [(Gd-2)3Fe]- complex is much higher than 
Gd-DTPA, making the compound interesting as a potential imaging agent. 
Moreover this complex seems to be a necrosis avid contrast agent as proved 
by MRI-histomorphological correlation study.  
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7.2 A self assembling heteropolymetallic chelate based on a 
dihydroxyphenethylamide derivative of DTPA 
 
7.2.1 Introduction 
 
In this study, a Ln(III) binding DTPA moiety was linked with an iron(III) 
binding catechol group, resulting in a heteropolymetallic species with 
increased relaxivity.  
 
7.2.2 Results and discussion 
7.2.2.1 Ligand and complexes 
 
The synthesis of the “Draga” - Serbian for ‘darling’ - or DTPA-
dihydroxyphenethylamine compound, 5, (see scheme 7-4) turned out to be 
quite tedious (see scheme 7-3). At first a literature method was followed,[12] 
where monofunctional DTPA (i.e. DTPA with only the middle carboxylic 
acid group unprotected) is coupled with an amine using DEPC (diethyl 
cyanophosphonate) as a coupling agent. Using this method, the coupling 
with dopamine yielded a mixture of coupled product, free DTPA and free 
dopamine, most likely because of ester formation by reaction with the 
phenolic groups of dopamine. To avoid this reaction, the methoxy protected 
3,4-dimethoxyphenethylamine was used. However deprotection with BBr3 
failed. In another attempt the benzyl protected 3,4-
(dibenzyloxy)phenethylamine was successfully used, however, surprisingly 
traces of reacted DEPC were found in the NMR of the end product (despite 
phase separation with NaHCO3 and brine after coupling).  
 
Finally, Draga, 5, was prepared in three steps according to scheme 7-4, using 
TBTU as a coupling agent. The deprotection of the catechol was achieved by 
catalytic hydrogenation of the dibenzyloxy group, while the deprotection of 
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the terminal carboxylic groups was accomplished by acid catalysed 
hydrolysis of the ester group.  
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Scheme 7-3: Several attempts to synthesize the DTPA-
dihydroxyphenethylamine (Draga) ligand. 
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Scheme 7-4: Synthesis of the DTPA-dihydroxyphenethylamine (Draga) 
ligand. 
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The proton NMR spectrum of 5 and its labelled structure are shown in figure 
7-8. 
 
Figure 7-8: 1H NMR spectrum of the ligand. 
 
The signals were assigned on the basis of assignments for other DTPA 
derivatives, the integration of the resonances, and conventional proton-proton 
2D correlation spectroscopy (2D COSY), shown in figure 7-9. 
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Figure 7-9: 2D COSY NMR spectrum of 5 in D2O at pH 3.5. 
 
Upon varying the pH of the solution from 0.5 to 3.5, the change of chemical 
shifts of the non-labile protons of the ligand was clearly observed. In general, 
all the DTPA resonances experienced downfield shifts, since it is known that 
protonation causes deshielding of the protons which are close to the 
protonation sites.[13] 
 
The modification of the parent DTPA ligand to the derivative 5, does not 
affect the ability of DTPA moiety to bind lanthanide ions.[14-16] Under 
slightly alkaline solution, the ligand readily formed a complex with the 
lanthanide(III) ions (Ln = La, Eu, Gd). IR spectra of the ligand showed 
strong absorptions in the regions 3000-3700 and 1650-1750 cm-1, 
corresponding to the NH and CO stretching modes, respectively. Upon 
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complexation, shifts of approximately 80 cm-1 to lower energy were 
observed for the carbonyl stretching frequencies of the ligand, indicating 
carboxylic and amide oxygen coordination to the lanthanide ion. The ArC-O 
stretching frequency of the catechol group at 1250 cm-1 did not shift, 
implying that the catechol group was not involved in coordination to 
lanthanide(III). This was supported by measuring proton NMR spectrum of 
diamagnetic [La-5] complex which showed that catechol resonances 
remained unaffected upon coordination of 5 to lanthanum(III), while the 
DTPA resonances broadened significantly, which is indicative of the 
lanthanum(III) coordination.[17] These findings are consistent with previous 
studies which have shown that DTPA-derivatives in which the amide group 
is attached to the middle nitrogen coordinate to lanthanide(III) ions via four 
acetate oxygens, three nitrogen atoms and carbonyl oxygen of the amide 
group, while the ninth co-ordination site is occupied by a water molecule.[12, 
18] 
Addition of Fe(acac)3 to a basic aqueous solution of [Ln-5]- resulted in an 
immediate change of colour from light yellow to very dark violet. The UV-
VIS spectrum of the solution at pH 5.8 exhibited a ligand-to-metal charge-
transfer (LMCT) absorption of λmax = 572 nm, which is typical of iron(III)-
catechol complexes. Upon increasing pH to 9.2 the blue-violet solution 
changes to crimson and hypsochromic shift to λmax = 489 nm was observed 
(figure 7-10). This behaviour is consistent with that of other iron(III)-
catechol complexes, in which the cation:ligand ratio depends on the pH 
value. The UV-VIS data of iron(III)-catechol complexes at various pH values 
are in close agreement with those observed in figure 7-7.[19-20] 
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Figure 7-10: UV-VIS spectra of the iron(III)-catechol complex at two pH 
values: dashed line: pH 9.2, full line: pH 5.8. 
 
The formation of tris iron-catechol complex with [Ln-5]- would imply that a 
supramolecular complex was formed according to scheme 7-5. However, 
based only on UV-VIS data it is difficult to prove weather the DTPA moiety 
is still bound to the lanthanide(III) ion. It is, however, very unlikely that 
binding of the catechol group in [Ln-5]- to iron(III) would drastically alter 
the stability of the parent complex and cause decomplexation of [Ln-5]-, 
since it is known that DTPA and its various derivatives form very stable 
complexes with lanthanide ions.  
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Scheme 7-5: Synthesis of the iron-catechol complex with [Ln-5]-. 
 
In recent years electrospray ionisation mass spectrometry (ESI-MS) has been 
proven as a very useful method for the analysis of self-assembled 
supramolecular complexes. The results obtained by ESI-MS have been 
regarded as indicative of the solution behaviour of a species rather than the 
gas phase behaviour (for examples of ESI analysis of oligonuclear metal 
complexes see literature [21-24]). Nonetheless, ESI studies of such 
supramolecular complexes remain non-trivial, and often require the empirical 
variation of the spray parameters, namely the solvents and ionisation 
conditions used. In the case of supramolecular complex [(Ln-5)3Fe]6- the 
calculation of the exact molecular weight is additionally complicated since 
the ninth coordination site on lanthanide(III) ion may be occupied by a water 
molecule. Since there are three lanthanide ions present, in theory one can 
expect presence of minimum zero and maximum three water molecules in 
the supramolecular complex, so that its general formula may be described as 
[(Ln-5)3Fe(H2O)n]6-, n = 0-3. In the ESI spectrum of Gd-Fe complex in the 
positive detection mode we were able to observe a weak peak at m/z 2167.8, 
which correspond to {[(Gd-5)3Fe]6- + 3Na+ + 4H+}+, and a strong cluster 
peak at m/z at 1092.7, which can be assigned to {[(Gd-5)3Fe(H2O)2]6- + 2Na+ 
+ 6H+}2+. The isotopic distribution of this cluster is very similar to the 
theoretically calculated pattern, as shown in figure 7-11. Attempts to record 
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the ESI spectra in the negative detection mode were unsuccessful since 
mostly fragmentation products were observed.  
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Figure 7-11: Isotope distribution of the peak cluster at m/z 1092.7 for the 
gadolinium(III)-iron(III) complex: (a) calculated; (b) experimental.
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7.2.2.2 Solution dynamics 
 
For NMR studies, a diamagnetic analogue of [(Ln-5)3Fe]6- in which iron(III) 
was replaced by gallium(III), [(Ln-5)3Ga]6-, was synthesized. Diamagnetic 
gallium(III) complexes are often used as NMR probes of iron(III) complexes 
since they exhibit very similar coordination chemistry.[25] We have 
synthesized two gallium(III) complexes for NMR studies: [(La-5)3Ga]6- and 
[(Eu-5)3Ga]6-. The proton NMR spectrum of [(La-5)3Ga]6- at room 
temperature was quite complex due to the broadening and overlapping of 
proton resonances in the DTPA region. Lowering the temperature of the 
solution to 278 K did not result in significant improvement of the spectra. 
However, the proton NMR spectra of the [(Eu-5)3Ga]6- complex was much 
more informative since the paramagnetic ion increased the chemical shift 
range for CH2 protons and reduced their overlap. At room temperature (298 
K), the 1H NMR spectrum of [(Eu-5)3Ga]6- also exhibited broad peaks in the 
range between –25 ppm and 25 ppm. This shifting of DTPA resonances is a 
clear indication of DTPA coordination to a paramagnetic ion. Lowering the 
temperature resulted in separation of the resonances, so that relatively sharp 
signals could be observed at 258 K. Unfortunately, the exact distinction 
between ethylenic and acetate resonances was not possible since this would 
require use of a partially deuterated ligand. It is, however, reasonable to 
assume that analogous to the previously assigned proton NMR spectra of the 
parent Eu-DTPA complex, the acetate resonances in general experience 
significant up-field shifts, while the ethylenic protons are shifted down-field 
upon complexation.[17] In theory, eight possible enantiomers of the bound 
ligand are possible, and since four of those geometries are mirror images of 
the other four, for each group of magnetically equivalent protons in the [(Eu-
5)3Ga]6- four signals can be expected. The examination of the NMR spectra 
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shown in figure 7-12 suggests that the spectra are consistent with the 
occurrence of either two static structures or two pairs of interconverting 
isomers. However, broadening of the resonances upon increasing the 
temperature of the solution supports the view that the observed spectral 
pattern in [(Eu-5)3Ga]6- - NMR spectra are consistent with the occurrence of 
several interconverting isomers. Unfortunately, the available NMR data do 
not allow any speculation on the structures of the isomers present in the 
solution. On a qualitative basis, at least, the observed NMR spectra show that 
within the supramolecular complex, formation of different isomers which 
undergo fast interconversion in the solution takes place.  
 
Figure 7-12: 1H NMR spectra of [(Eu-5)3Ga]6- in MeOD: a) at 258 K, b) at 
278 K, c) at 298 K and d) at 318 K. 
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7.2.2.3 Luminesence measurements 
 
Absorption 
 
The absorption spectra of the various Draga complexes are given in figure 7-
13. They all show similar absorption maxima between 280 and 290 nm. 
These maxima can be attributed to the π → π* transition of the benzene ring 
of the catechol moiety and the n → 3s or 3p Rydberg transitions of the 
nitrogen chromophore. The spectra have been recorded in aqueous solutions. 
 
Figure 7-13: Absorption spectra of the Draga complexes. 
 
Emission 
 
In this study, Eu3+ complexes have been used to probe the first coordination 
sphere of the Eu3+ ion in all three DTPA derivatives. If complexation of the 
catechol moiety to Fe3+ or Ga3+ would alter the local symmetry of the Eu3+ 
ion, this should be visible in the emission spectrum of the Eu3+ ion.[11] 
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Figure 7-14: Luminescence spectra of the DRAGA derivatives. 
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Alternatively, if part of the excitation energy would be lost in the Fe3+ or the 
Ga3+ ions, this should reduce the luminescence intensity of the Eu3+ 
emission, although making conclusions from intensity changes in 
luminescence studies can be extremely tricky. The luminescence spectra of 
the three Draga derivatives are shown in figure 7-14. 
As can be seen, all three spectra look very similar, indicating that the local 
environment of the Eu3+ ion in first coordination sphere is virtually the same 
in all three complexes. Thus, the effect of complexation of Fe3+ or Ga3+ at the 
catechol position does not influence the local symmetry of the Eu3+ ion. All 
three complexes have been excited in the ligand, at the exact maxima of the 
absorption bands shown in figure 7-14. The absorbance of the three 
complexes at these maxima had been ajusted to nearly the same value, 
presuming that the same amount of light would be absorbed by all three 
complexes, so that rather reliable comparisons could be made of the 
luminescence intensities. It can be noticed that the luminescence intensity of 
both the Fe3+ or Ga3+ derivatives is lower than that of the parent compound. 
However, stating that the influence of the Fe3+ or Ga3+ ion is felt by the Eu3+ 
ion, hence quenching the luminescence, would be very hazardous. Indeed, 
the intensity differences do not span several orders of magnitude and the 
power output of the Xe lamp used for excitation of the complexes is not 
constant in the whole wavelength range either, so one cannot be certain that 
indeed the same amount of light has been absorbed by all three complexes. 
However, one thing is very clear: a pronounced influence of the transition 
metal ions on the Eu3+ centered luminescence, as can be seen in systems with 
low-spin Fe2+,[11] is not present in the complexes studied here. 
 
7.2.2.4 Relaxation rates 
 
Figure 7-15 displays the relaxation rates of a 0.1 mM solution of the 
[(Gd-5)3Fe]6- complex. Since relaxivity is defined as the change in relaxation 
rate (in s-1) produced by unit change in concentration (in mM), thus the 
relaxation rate for a 1 mM solution, it is not yet possible to compare the data 
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to Gd-DTPA. Nevertheless data clearly indicate that through the inclusion of 
multiple paramagnetic centra in one supramolecular structure, much higher 
relaxivities are obtained than for Gd-DTPA. The fitting of the data was not 
yet possible since this requires the rewriting of the Solomon-Bloembergen 
equations, due to the presence of the paramagnetic Fe3+ ion. 
 
Figure 7-15: Relaxation rates of a 0.1 mM solution of the [(Gd-5)3Fe]6- 
complex. 
 
7.2.3 Conclusions 
In summary, we have shown that, by using a dihydroxyphenethylamide 
derivative of DTPA, the formation of a highly paramagnetic supramolecular 
structure is possible. This supramolecular structure is easily obtained by 
mixing an aqueous solution of the lanthanum(III) complex of the ligand with 
an aqueous solution of Fe3+ ions and is indicated by an immediate change of 
color. Luminescence studies show that the local coordination environment of 
the lanthanum (III) ion remains unaffected upon formation of the 
supramolecular structure. The first data on relaxation rates suggest that the 
relaxivity of the [(Gd-5)3Fe]6- complex is much higher than Gd-DTPA, 
making the compound interesting as a potential imaging agent.
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7.3 Heterobimetallic gadolinium(III)-iron(III) complex of DTPA-
bis(3-hydroxytyramide) 
 
7.3.1 Introduction 
Here, a route to a monomeric gadolinium(III)-iron(III) complex, derived 
from DTPA and 3-hydroxytyramine (dopamine), was investigated. The 
ligand DTPA-bis(3-hydroxytyramide), DTPA(HTA)2 has been described for 
the first time by White.[27] The complexes were characterized in solution by 
means of visible absorption spectroscopy, electron spray ionisation mass 
spectrometry (ESI-MS), and nuclear magnetic resonance (NMR) 
spectroscopy and the results indicate that only one type of species with well-
defined structure has been formed in solution. 
 
7.3.2 Results and discussion 
 
The ligand DTPA-bis(3-hydroxytyramide), DTPA(HTA)2, was obtained by 
reaction between DTPA bis(anhydride) and 3-hydroxytyramine (dopamine) 
(scheme 7-6). The modification of the parent DTPA ligand to the bis-amide 
derivative 1, does not affect the ability of DTPA to bind lanthanide ions 
(scheme 7-7).[28-29] Under slightly alkaline solution the ligand readily formed 
complex 2 with the gadolinium(III) ion. IR spectra of the ligand showed 
strong absorptions in the regions 3000-3700 and 1650-1750 cm-1, 
corresponding to the NH and CO stretching modes, respectively. Shifts of ca 
40 cm-1 to lower energy were observed for the carbonyl stretching 
frequencies upon complexation, indicating amide oxygen coordination to the 
lanthanide ion. These findings are consistent with previous studies which 
have shown that DTPA bis(amide) derivatives coordinate to lanthanide(III) 
ions via three acetate oxygens, three nitrogen atoms and two carbonyl 
oxygens of the amide group, while the ninth co-ordination site is occupied by 
a water molecule.[14, 29] Since the IR stretching frequencies for the catechol 
group overlap to some extent with the carbonyl stretching frequencies it was 
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difficult to say based on the IR spectra whether the catechol group was 
involved in coordination to gadolinium(III). However, proton NMR 
spectrum of analogous diamagnetic [La-DTPA(HTA)2] complex indicated 
that catechol resonances remained unaffected upon coordination of 1 to 
lanthanum(III), while the DTPA resonances broadened significantly, which 
is indicative of the lanthanum(III) coordination.[17] Further evidence for the 
existence of 2 in the solution was obtained from the electrospray mass 
spectrum, in which a peak detected in positive mode at m/z 841 was 
consistent with structure 2. 
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Scheme 7-6: Synthesis of  DTPA-bis(3-hydroxytyramide), DTPA(HTA)2. 
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Scheme 7-7: Synthesis of the gadolinium(III)-iron(III) heterobimetallic 
complex of DTPA-bis(3-hydroxytyramide). 
 
Complexation of 2 with [Fe(NTA)(H2O)2] proceeded rapidly in a slightly 
basic water solution (scheme 7-7). An immediate colour change from yellow 
to dark violet was a strong indication of formation of an iron catecholate 
complex.[29] This is illustrated in figure 7-16 which shows the visible 
absorption spectra of [Fe(NTA)(H2O)2] and of complex 3. The  
[Fe(NTA)(H2O)2] has no chromophores absorbing in the visible region, but 
its addition to 2 resulted in the appearance of a strong absorption band with a 
maximum at 595 nm. This band has been assigned as catechol-to-Fe(III) 
charge-transfer transitions has been earlier detected in several [Fe(NTA)]-
catechol complexes.[30] 
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Figure 7-16: Visible absorption spectra of [Fe(NTA)(H2O)2] (dashed line) 
and of complex 3 (full line) in water solution.  
 
The role of the NTA ligand is to prevent formation of polymeric species in 
the solution which would be likely to form if [Fe(H2O)6]3+ was used as 
source of iron. The evidence that definite species were formed in solution 
was provided from the negative mode electrospray ionisation mass 
spectrometry. Only the single cluster in the region from 678 to 686 m/z was 
detected, which corresponds to [3 + 2 Na+]2-. The isotopic distribution of this 
cluster is very similar to the theoretically calculated pattern, as shown in 
figure 7-17. The simplicity of the ES-MS spectrum can be attributed to the 
thermodynamic stability and kinetic inertness of the complex. The possibility 
of iron(III) replacing gadolinium(III) ion in the DTPA-like coordination cage 
of the ligand is very unlikely, since no change in UV-VIS spectra and no 
discoloration of 3 have been observed, even not in solutions which were 
standing for several weeks. The exchange between the lanthanide(III) and 
iron(III) centres was also not detected in relaxation studies on analogous 
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heterobimetallic gadolinium(III)-iron(III) complexes in which DTPA ligand 
was di-substituted with the p-amino-salicilic moiety.[4]  
670 672 674 676 678 680 682 684 686 688 690 692 694
0
20
40
60
80
100
(a)
R
el
at
iv
e 
Ab
un
da
nc
e
m/z
670 672 674 676 678 680 682 684 686 688 690 692 694
0
20
40
60
80
100
(b)
686.1
685.2
684.3
683.3
682.3
681.3
680.3
679.3
678.3
R
el
at
iv
e 
Ab
un
da
nc
e
m/z
 
Figure 7-17: Isotope distribution of the peak cluster at m/z 682.3 for the 
gadolinium(III)-iron(III) complex 3: (a) calculated; (b) experimental  
 
7.3.3 Conclusions 
In summary, we have shown that heterobimetallic paramagnetic complexes 
can be obtained by using DTPA-bis(3-hydroxytyramide) as the ligand, and 
with gadolinium(III) and iron(III) as the paramagnetic centers. Special 
attention has been paid to avoid the formation of polymeric species. These 
paramagnetic polymetallic species have a potential as MRI contrast agents.[1-
3] 
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7.4 Experimental 
 
7.4.1 Chemicals 
 
Reagents were obtained from Aldrich Chemical Co., Acros Organics and 
Fluka, and used without further purification. DTPA was obtained from Koch 
Light Laboratories. Lanthanide chlorides were obtained from GFS chemicals 
(USA). 
 
7.4.2 Instruments 
 
UV-VIS spectra were measured on a Shimadzu UV-1601PC spectrometer. 
The ESI-MS measurements were performed on a Thermo Finnigan LCQ 
Advantage mass spectrometer. ICP-MS was performed on a Jobin Yvon JY 
70+, Longjumeau, France. Luminescence measurements were performed on 
a Edinburg instruments FS900 Steady State Spectrofluorimeter. Absorption 
spectra of the various Draga complexes were recorded with a Varian Cary 
5000 spectrophotometer at room temperature. 
 
7.4.3 Synthesis of the ligands 
 
7.4.3.1 Heteropolymetallic chelate Querida 
 
5-amino-1,10-phenanthroline was synthesized in two steps according to a 
literature method.[31-32]  
 
Product (1): 618 mg (1 mmol) of N,N-bis(2-{bis[2-(1,1-dimethylethoxy)-2-
oxoethyl]amino} ethyl)-glycine was dissolved in 20 ml of dry DCM. Two 
equivalents of dry triethylamine and 1.5 equivalents of TBTU (o-
benzotriazol-1-yl-N,N,N’,N’-tetramethyluronium tetrafluoroborate) were 
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added. 195 mg (1 mmol) of 5-amino-1,10-phenanthroline was then added to 
the solution. The reaction mixture was stirred at room temperature for 2 
hours. DCM was removed by vacuum evaporation after completion. The 
crude product was phase separated in ethyl acetate (40 ml) with a saturated 
sodium bicarbonate (2 × 30 ml) and saturated sodium chloride solution (2 × 
20 ml). Evaporation of ethyl acetate yielded product 1 (see scheme 7-1). 
 
Product (2): Product (1) was dissolved in 6M HCl (10 ml). The mixture was 
stirred at room temperature for 1 hour and was then washed with CH2Cl2 (2 × 
10 ml). The aqueous solution was dried to yield product 2 (see scheme 7-1). 
 
7.4.3.2. Heteteropolymetallic chelate Draga 
 
A schematic summary of the synthesis of Gd-DTPA-
dihydroxyphenethylamine is outlined in scheme 7-3.  
 
Product (3): N,N-bis(2-{bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino} 
ethyl)-glycine (mDTPA), 1, (618 mg, 1 mmol) was dissolved in 20 ml of dry 
DMF. Dry triethylamine (0.5 ml, 0.36 g, 3.6 mmol) and TBTU [o-
benzotriazol-1-yl-N,N,N’,N’-tetramethyluronium tetrafluoroborate] (481.5 
mg, 1.5 mmol) were added and the mixture was stirred for 10 min at room 
temperature. 3,4-(Dibenzyloxy)phenethylamine hydrochloride 2 (370 mg, 1 
mmol) was then added to the solution. The reaction mixture was stirred at 
room temperature and followed by TLC through observing the depletion of 
free 3,4- (Dibenzyloxy)phenethylamine (Rf = 0.4) with the eluent 
CH2Cl2/CH3OH/NH4OH (9:1:0.1). DMF was then removed by vacuum 
evaporation. The crude product was washed and phase separated in ethyl 
acetate (40 ml) with a sodium bicarbonate (2 × 30 ml) and saturated sodium 
chloride solution (2 × 20 ml). Product 3 was obtained. Its purity was 
confirmed by using TLC (Rf = 0.82). 
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Product (4): Product 3 was dissolved in MeOH (20 ml), and 5 % Pd on 
carbon (0.5 g) was added. The suspension was stirred over 5 hrs under a 
hydrogen atmosphere at room temperature. The mixture was filtered over 
celite and evaporated to yield product 4. 
 
Product (5): Product 4 was dissolved in 6 N HCl (10 ml). The mixture was 
stirred at room temperature for 1 hour and was then washed with CH2Cl2 (2 × 
10 ml). The aqueous solution was dried and compound 5 was obtained. 
 
7.4.3.3 Heterobimetallic gadolinium(III)-iron(III) complex of DTPA-bis(3-
hydroxytyramide) 
 
The DTPA-bis(anhydride) and [Fe(NTA)(H2O)2], where NTA is 
nitrilotriacetic acid, were synthesized according to previously reported 
procedures.[26-27]. 
 
[DTPA(HTA)2] (1): To a solution of DTPA-bis(anhydride) (0.357 g; 1 
mmol) in dry DMF (30 ml), 3-hydroxytyramine hydrochloride (0.379 g; 2 
mmol) was added and the reaction mixture was heated at 60 °C for 5 hours. 
After the removal of the solvent, the product was washed with ethanol and 
dried in vacuo overnight. 
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7.4.4 Analytical data for the ligands 
 
7.4.4.1 Heteropolymetallic chelate Querida 
 
5-amino-1,10-phenanthroline: Yield: 15%; 1H NMR (DMSO), δ (ppm): 
6.13 (s, 2H, NH2), 6.87 (s, 1H), 7.52 (m, 1H), 7.75 (m, 1H), 8.05 (d, 1H), 
8.67 (m, 2H), 9.05 (d, 1H). IR ν (cm-1): 3414, 3336 (NH2 bending), 1638 
(NH2 stretch). ES-MS+: 196 [M+H]+; 391 [2M+H]+.  
 
Product (1): Yield: 57%, 1H NMR (CDCl3), δ (ppm): 1.44 (s, 36 H, tBu), 
2.6-2.8 (m, 4 H, N-CH2), 2.8 (s, 2 H, N-CH2-CO), 2.9 (m, 4 H, N-CH2), 3.31 
(s, 8 H, N-CH2-COOH), 7.63 (m, 2 H, phen), 8.23 (d, 1 H, phen), 8,74 (d, 1 
H, phen), 9.11 (d, 1 H, N-CH phen), 9.20 (d, 1 H, N-CH phen). IR ν (cm-1): 
1727 (COO assym stretch), 1654 (amide I). ES-MS+: 795 [M+H]+.  
 
Product (2): Yield: 36%, 1H-NMR (D2O), δ (ppm): 3.41 (m, 4 H, N-CH2), 
3.51 (CH2-CO-NH) 3.63 (s, 2 H, N-CH2-CO) 3.98 (s, 8H, N-CH2-COOH), 
8.0-8.1 (m, 2 H, phen), 8.25 (s, 1 H, phen), 8.76 (d, 1 H, phen), 8.92 (d, 1 H, 
phen), 9.08 (d, 1 H, phen), 9.13 (d, 1 H, phen). IR ν (cm-1): 1739 (COO 
assym stretch), 1630 (amide I). ES-MS(+): 571 [M+H]+.  
 
7.4.3.2. Heteropolymetallic chelate Draga 
 
Product (3): Yield 77%, 1H-NMR (CDCl3), δ (ppm): 1.40 (s, 36 H, tBu), 
2.6-2.8 (m, 4 H, N-CH2), 3.0 (s, 2 H, N-CH2-CO), 3.0-3.1 (m, 4 H, N-CH2), 
3.43 (s, 8H, N-CH2-COOH), 3.99 (m, 4 H Ph-CH2-CH2), 5.12 (s, 4 H Ph-
CH2-O), 6.7-7.0 (m, 3 H, Ph), 7.3-7.5 (m, 10 H, Ph). ES-MS+: 933 [M+1]+; 
955 [M+Na+]+. 
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Product (4): Yield 78%; 1H-NMR (CDCl3), δ (ppm): 1.44 (s, 36 H, tBu), 
2.6-2.8 (m, 4 H, N-CH2), 3.0-3.1 (m, 4 H, N-CH2), 3.34 (s, 8H, N-CH2-
COOH), 3.48 (s, 2 H, N-CH2-CO), 3.98 (m, 4 H Ph-CH2-CH2), 6.5-6.9 (m, 3 
H, Ph). ES-MS+: 753 [M+H]+; 1505 [2M+H]+ 
 
Product (5): Yield 97%; 1H-NMR (CDCl3), δ (ppm): 2.60 (m, 2 H, Ph-CH2), 
2.95 (m, 4 H, N-CH2), 3.24 (m, 4 H, N-CH2), 3.36 (CH2-CO-NH) 3.45 (s, 2 
H, N-CH2-CO) 3.83 (s, 8H, N-CH2-COOH), 6.5-6.8 (m, 3 H, Ph). IR ν (cm-
1): 1736 (CO free acid); 1642 (amide I); 1253 (Ar-CO stretch). Elemental 
analysis: Calcd. (found): C22H28O11N4Na4(H2O)4: C: 38.38 (38.66); H 5.27 
(5.56), N: 8.14 (8.36)%. ES-MS+: 529 [M+H]+. 
 
7.4.3.3 Heterobimetallic ligand DTPA-bis(3-hydroxytyramide) 
 
[DTPA(HTA)2] (1): Yield: 95 %; 1H NMR (D2O), δ (ppm): 2.61 (t, 4 H, 2 × 
N-CH2); 2.95 (t, 4 H, 2 × N-CH2); 3.10 (m, 4 H, 2 × CH2-NH-CO); 3.37 (m, 
4 H, 2 × CH2-Ph); 3.50 (s, 2 H, CH2-COOH); 3.56 (s, 4 H, 2 × CH2-COOH); 
3.68 (s, 4 H, 2 × CH2-CO-NH); 6.56-6.82 (m, 6 H, Ph). IR ν (cm-1): 1740 
(CO free acid), 1647 (amide I), 1521 (amide II), 1258 (Ar-CO stretch). ES-
MS+: 664, [M+H]+. 
- chapter 7 - 
201 
7.4.5 Synthesis of the Ln(III) complexes 
 
Cfr general method chapter 5. 
 
7.4.6 Analytical data complexes 
 
7.4.6.1 Lanthanide complexes with ligand Querida 
 
La complex: Yield: 50%; IR ν (cm-1): 2965 (CH alkyl); 1630 (CO amide); 
1581 (COO- assym stretch); 1404 (COO- symm stretch); ES-MS-: 706 [M]-. 
 
Eu complex: Yield: 99%; IR ν (cm-1): 2964, 2925 (CH alkyl); 1633 (CO 
amide); 1590 (COO- assym stretch); 1404 (COO- symm stretch); ES-MS-: 
720 [M]-. 
 
Gd complex: Yield: 93%; IR ν (cm-1): 2978, 2916 (CH alkyl); 1634 (CO 
amide); 1586 (COO- assym stretch); 1409 (COO- symm stretch); ES-MS-: 
725 [M]-. 
 
7.4.6.2 Lanthanide complexes with ligand Draga 
 
La complex: IR ν (cm-1): 1616 (amide I), 1405 (COO- sym.); ES-MS-: 663 
[M]-.  
 
Eu complex: IR ν (cm-1): 1607 (amide I), 1582 (COO- assym.), 1409 (COO- 
sym.); ES-MS-: 677 [M]-. 
 
Gd complex: IR ν (cm-1): 1617 (amide I), 1586 (COO- assym.), 1409 (COO- 
sym.); ES-MS-: 682 [M]-. 
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7.4.6.3 Gadolinium complex with DTPA-bis(3-hydroxytyramide) 
 
Gd-DTPA(HTA)2 (2): Yield: 95%; IR ν (cm-1): 2923, 2852 (CH alkyl), 
1602 (COO- asym. stretch), 1408 (COO- sym stretch). ES-MS+: 841, 
[M+Na]+. 
 
7.4.7 Synthesis of the mixed Fe(II)/Fe(III)-Ln(III) complexes 
 
7.4.7.1 Iron(II)-lanthanide complexes with ligand Querida 
 
Complexes were made by mixing FeCl2.4H2O with 3 equivalents of the 
lanthanide complex in water. The colour of the mixture immediately changed 
to dark red indicating complexation and the solution was stirred at room 
temperature for 3 hours. After evaporation the complex was washed with 
ethanol and vacuum dried. 
 
7.4.7.2 Iron(III)-lanthanide complexes with ligand Draga 
 
The pH of a 0.6 mmol solution of [Gd-DTPA(HTA)] in water was adjusted 
to 8.0 with a 0.1 solution of NaOH, while bubbling nitrogen through the 
solution. Tris(acetyacetonato)iron(III) (0.2 mmol) in methanol was then 
slowly added while keeping the solution under inert atmosphere. The 
immediate change of colour of the mixture from colourless to dark violet 
indicated spontaneous complexation of iron with the catechol group. After 
stirring the solution for one hour at room temperature, the solvent was 
evaporated. The crude product was then redissolved in a small quantity of 
methanol and precipitated by slowly adding acetone. The microcrystalline 
product was then isolated by centrifuge and vacuum dried overnight. 
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7.4.7.3 Iron(III)-Gadolinium(III) complex with DTPA-bis(3-
hydroxytyramide) 
 
[Fe(NTA)]2 -[Gd-DTPA(HTA)2] (3): The pH of a 1 mmol solution of [Gd -
DTPA(HTA)2] in water was adjusted to 8.0 with a 0.1 solution of NaOH, and 
a solution of 2 mmol of [Fe(NTA)(H2O)2] was slowly added. After the 
volume of the solution was reduced by solvent evaporation in vacuo, acetone 
was added upon which the bimetallic complex precipitated as 
microcrystalline solid. It was filtered off and dried in vacuum over night. 
 
7.4.8 Analytical data polymetallic complexes 
 
7.4.8.1 Iron(II)-lanthanide complexes with ligand Querida 
 
FeGdQuerida: ICP-MS data for the [(Gd-2)3Fe]- complex: 0.2 mM Fe : 0.58 
mM Gd. 
 
7.4.8.2 Iron(III)-lanthanide complexes with ligand Draga 
 
FeGdDraga: IR ν (cm-1): 1616 (amide I), 1589 (COO- assym stretch), 1404 
(COO- sym. stretch); ES-MS+: M = [(GdC22H26O11N4)3Fe]6- = 2096: 2165 = 
[M+H2O+4H+2Na]+; 1091 = [M+4H+4Na]2+; 1072 = [M+H2O+7H+Na]2+; 
767 = [M+9Na]3+; 391 = [M+H+11Na]6+; 377 = [M+5H+7Na]6+.  
 
GaLaDraga: IR ν (cm-1): 1618 (amide I), 1599 (COO- assym. stretch), 1408 
(COO- sym. stretch); ES-MS-: M = [(LaC22H26O11N4)3Ga]6- = 2052: 699 = 
[M+H+2Na]3-.  
 
GaEuDraga: IR ν (cm-1): 1619 (amide I), 1596 (COO- assym.), 1407 (COO- 
sym.); ES-MS-: M = [(LaC22H26O11N4)3Ga]6- = 2094: 775 = [M+3Na]3-. 
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7.4.8.3 Iron(III)-Gadolinium(III) complex with DTPA-bis(3-
hydroxytyramide) 
 
[Fe(NTA)]2-[Gd-DTPA(HTA)2] (3): ES-MS(-): 682, [M+2Na+]2-,  
IR ν (cm-1): 2923, 2852 (CH alkyl), 1610 (COO- asym. stretch), 1417 (COO- 
sym stretch). UV-VIS, λmax=595 nm. 
 
7.4.9 In vivo evaluation Gd-2 and [(Gd-2)3Fe]- 
 
See chapter 6 for all technical details. 
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Chapter 8 
 
Bisphenetylamide derivatives of Gd-DTPA as 
potential receptor specific MRI contrast agents 
 
Rayando el sol 
Rayando por ti 
Esta pena me duele 
Me quema sin tu amor 
No me has llamado 
Estoy desesperado 
Son muchas lunas 
Las que te he llorado 
Rayando el sol 
Desesperación 
Es mas facil llegar al sol 
Que a tu corazón 
 
Reaching for the sun 
Reaching for you 
This sorrow hurts me 
Burns me without your love 
You haven’t called me 
I’m desperate 
There’s been many moons 
That I’ve cried over you 
Reaching for the sun 
Desperate 
It’s easier to touch the sun 
Than your heart 
 (Maná) 
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8.1 Introduction 
Magnetic resonance imaging (MRI) contrast agents (CA) are unique 
diagnostics, which increase the water proton relaxation of tissue and enhance 
the contrast between tissues on MRI scans. Most of the work with contrast 
agents has dealt with the use of gadolinium(III) complexes, since this metal 
ion is highly paramagnetic due to the presence of seven unpaired electrons in 
its f shell. New developments in molecular imaging applications has 
prompted the development of a novel class of CA characterized by a higher 
contrasting ability and improved targeting capabilities.[1] These agents would 
then allow to study more diseases noninvasively and quantitatively at the 
molecular level. In attempts to achieve tissue specificity, a number of 
contrast agents have been synthesized. This led to the discovery of liver,[2-5] 
lymph node[6-9] and necrosis specific agents, [10-12] and blood pool agents. [13-
16] The tissue specificity of these agents is merely based upon properties such 
as molecular size, charge and lipophilicity. For example, the molecular size 
of the agent may result in its filtration by the kidneys (e.g. Gd-DTPA 
Magnevist) or confinement in the vascular space (blood pool agents e.g. 
Gd-DTPA labelled polylysine or polydextran[17-18]), whereas liver specific 
agents can pass into the hepatocytes by pinocytosis, passive diffusion c.q. 
carrier-mediated systems, e.g. Gd-BOPTA.[19] The mechanisms by which the 
recently discovered necrosis avid agents work are based mainly on 
observational and hypothetical bases.[20,21] In one article, the accumulation of 
gadophrin-2 in tumoral necrosis is related to an albumin-binding 
mechanism.[22] Finally, low molecular weight chelates, polymeric agents as 
well as polymeric micelles can be used as lymph node specific agents. [3,23] 
Nevertheless, despite these inventions, there is still a demand for new tumor-
pathology- or receptor-specific agents. Since most of a specific cell-cell 
interaction or recognition is regulated via special proteins, receptor targeting 
can be attained by mimicking signal peptides. For example, adhesive proteins 
present in extracellular matrices and in blood such as fibrinogen and 
collagens contain the tripeptide arginine-glycine-aspartic acid as their cell 
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recognition site[24,25] Using this binding domain or similar sequences, small 
peptides can be designed to target receptors. [26,27] Additionally, some 
receptors have an affinity for certain classes of substrates such as amino 
acids or catechol amines. [28-31] These receptors may also bind molecules that 
resemble the substrate, e.g. a derivative of an amino acid that is present in a 
peptide substrate[30] or an amide derivative of a naturally occurring catechol 
amine such as dopamine. Furthermore, the localisation of the catechol 
containing agent may also depend on their respective reduction-oxidation 
properties. [32-33] In this aspect, it is realistic to assume that new specific low-
molecular weight peptides coupled to high relaxivity moieties may be a 
practical approach for moving molecular imaging into clinical MR reality.  
 
In this study the synthesis of three bisphenethylamide derivatives of DTPA is 
described. Their corresponding complexes with GdIII were characterized by 
NMRD and NMR.  
 
8.2 Results and discussion  
8.2.1 The Ligands and complexes 
The ligands DTPA-bis-tyramide (DTPA(TA)2), DTPA-bis-3-
hydroxytyramide (DTPA(HTA)2) and DTPA-bis-phenylalanine ethyl ester 
(DTPA(PAE)2) were synthesized according to Scheme 8-1.  
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R1
R2
NH2
R3
+        2NN N
COOH
O
O
O
O
O
O
N N N
COOHHOOC
C NH
O
CHN
OR2 R2COOH
R1 R1
R3 R3
1) GdDTPA(HTA)2: R1 = OH, R2 = OH, R3 = H 
2) GdDTPA(TA)2: R1 = H, R2 = OH, R3 = H
3) GdDTPA(PAE)2: R1 = H, R2 = H, R3 = COOEt  
Scheme 8-1: Synthesis of the DTPA-bisphenetylamide ligands. 
 
Under slightly alkaline solutions, they all readily formed complexes with 
GdIII, as shown in figure 8-1. IR spectral data of all ligands showed strong 
absorptions in the regions 1630-1650 cm-1, corresponding to CO stretching 
modes.[34] Shifts of ca 10 to 20 cm-1 to lower energy were observed for the 
carbonyl stretching frequencies upon complexation, indicating amide oxygen 
coordination to the lanthanide ion. These findings are consistent with 
previous studies which have shown that DTPA bis(amide) derivatives 
coordinate to LnIII via three acetate oxygens, three nitrogen atoms and two 
carbonyl oxygens of the amide group, while the ninth co-ordination site is 
occupied by a water molecule.[35-38]  
212 
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N N N
COO-
C NH
O
CHN
O COO
-
-OOC
OH2
R2
R1
R2
R1
R3 R3
1) GdDTPA(HTA)2: R1 = OH, R2 = OH, R3 = H 
2) GdDTPA(TA)2: R1 = H, R2 = OH, R3 = H
3) GdDTPA(PAE)2: R1 = H, R2 = H, R3 = COOEt  
Figure 8-1: Schematic representation of the Ln-DTPA-BC18 complex. The 
ligand coordinates to lanthanide ion via three acetate oxygens, three 
nitrogen atoms and two carbonyl oxygens of the amide group, while a water 
molecule occupies the ninth co-ordination site. 
 
8.2.2 1H NMR studies of the lanthanide complexes of 
DTPA(HTA)2, DTPA(TA)2 or DTPA(PAE)2 ligands 
 
The geometry of the nine-coordinate La-DTPA(HTA)2 La-DTPA(TA)2, and 
La-DTPA(PAE)2 complexes can be best described by a tricapped trigonal 
prism,[39] with the DTPA(HTA)2 , DTPA(TA)2 or DTPA(PAE)2 ligand 
arranged around the lanthanide ion in such a way that eight different 
enantiomers are possible. Since four of the isomers are the mirror image of 
the other four, in theory, four sets of signals should be observed for each 
ligand. However, the rapid interconversion of the isomers on the NMR time 
scale very often leads to a reduction of the number of NMR signals [40] 
Proton NMR spectra of La-DTPA(HTA)2 La-DTPA(TA)2, and La-
DTPA(PAE)2 were measured in water solutions and their NMR spectra were 
compared with the NMR spectra of the corresponding free ligand. As figure 
8-2 shows, the proton resonances of the DTPA(TA)2 ligand are sharp and 
well defined. Upon lanthanum(III) coordination, the resonances become 
broad and presence of multiple species could be detected. The broadening of 
the peaks is a good indication for the presence of various isomers which are 
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formed upon coordination of the lanthanum(III) ion to DTPA(TA)2 ligand. 
Due to the broadening and overlapping of the peaks the assignment of the 
proton resonances was rather difficult. Upon increasing the temperature of 
the La-DTPA(TA)2 solution to 333 K, an exchange process between different 
isomers takes place, which leads to the coalescence of a couple of 
resonances, so that broad bumps are being observed in the NMR spectrum 
(Figure 8-2c). The La-DTPA(HTA)2 and La-DTPA(PAE)2 complexes 
showed similar behaviour. It is important to note that upon coordination of 
the lanthanum(III) to the DTPA(TA)2 or DTPA(HTA)2 ligand, no change in 
the chemical shift of aromatic protons was observed. This indicates that the 
phenolic groups of the ligand do not coordinate to the lanthanum(III) ion. 
The NMR spectra of Eu-DTPA(HTA)2 Eu-DTPA(TA)2, and Eu-
DTPA(PAE)2 showed similar features: they all contained broad humps in the 
regions between –20 to 0 ppm, and 20 to 35 ppm. The significant shift of 
proton resonances is consistent with the coordination of the ligand to the 
paramagnetic europium(III) ion. The exact distinction between ethylenic and 
acetate resonances was not possible since this would require use of partially 
deuterated ligand. Analogous to the previously assigned proton NMR spectra 
of the parent Eu-DTPA complexes, we can assume that the acetate 
resonances experience significant down-field shift, while the ethylenic 
protons are shifted up-field.[41] 
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Figure 8-2: 1H-NMR spectra in D2O of the DTPA(TA)2 ligand at RT (a), La-
DTPA(TA)2 complex at RT (b) and La-DTPA(TA)2 complex at 333 K (c). 
 
8.2.3 Relaxometric characterization 
8.2.3.1 Residence time of the coordinated water molecule 
 
The value of the residence time of the coordinated water molecule τM was 
obtained by analysis of the temperature dependence of the reduced transverse 
relaxation rate of the water oxygen-17 nucleus in solutions containing the 
gadolinium complexes (figure 8-3). Obviously, the curves are different for 
the three complexes. The shift of the maximum of the curve of Gd-
DTPA(PAE)2 to higher temperatures indicates a slower exchange rate than 
for the other complexes. The theoretical adjustment of these experimental 
data was performed as previously described assuming the presence of one 
water molecule in the first coordination sphere.[42] This procedure allows for 
the determination of: i) A/h the hyperfine coupling constant between the 
oxygen nucleus of bound water molecules and the Gd3+ ion; ii) parameters 
describing the electronic relaxation times of Gd3+ i.e. the correlation time 
modulating the electronic relaxation, τV, the activation energy, Ev, related to 
τV and a parameter related to the mean-square of the zero field splitting 
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energy, B (B=2.4∆2); iii) parameters related to the water exchange i.e. the 
water residence time τM and the enthalpy (∆H#) and entropy (∆S#) of the 
process. At 310 K, the water residence time τM of Gd-DTPA(TA)2 (171±19 
ns) is slightly larger than that of the parent compound Gd-DTPA (143±25 ns) 
(table 8-1). For Gd-DTPA(HTA)2, τM310  is equal to 240±18 ns whereas for 
Gd-DTPA(PAE)2, a much larger value is obtained (846±40 ns). 
1/T (K-1)
0.0028 0.0030 0.0032 0.0034 0.0036
1/
T 2
R
(s
-1
)
1e+5
1e+6
Gd-DTPA(HTA)2
Gd-DTPA-(TA)2
Gd-DTPA-(PAE)2
Gd-DTPA
 
Figure 8-3: 17O transverse relaxation rate of aqueous solutions of the 
gadolinium complexes as a function of the temperature. 
 
Table 8-1: Parameters obtained from the theoretical fitting of the oxygen-17 
data. 
 Gd-DTPA-(TA)2 Gd-DTPA-(HTA)2 Gd-DTPA-(PAE)2 
τM310(ns) 171±19 240±18 846±40 
τV298 (ps) 10.2±0.4 6.0±0.3 15.5±1.1 
B (1020s-2) 2.83±0.11 3.26±0.12 2.19±0.17 
Ev (kJ/mol) 14.6±2.5 3.9±2.3 17.1±4.2 
A/h(106 rad s-1) -4.47±0.05 -4.50±1.14 -3.72±0.13 
∆H#(kJmol-1) 47.7±0.2 48.8±0.1 39.7±0.1 
∆S#(Jmol-1K-1) 38.3±0.3 38.9±0.3 -0.9±0.2 
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8.2.3.2 Nuclear magnetic relaxation dispersion (NMRD) measurements 
 
The proton NMRD profiles recorded at 310 K are shown on figure 8-4. 
Despite the similarity in molecular weights, the profiles of the three 
gadolinium complexes are different: the proton relaxivity of Gd-DTPA(TA)2 
and Gd-DTPA(PAE)2 are similar and slightly increased as compared to that 
of Gd-DTPA and the relaxivity of Gd-DTPA(HTA)2 is markedly larger. The 
fittings of the proton NMRD profiles were performed as described in the 
experimental section and include both inner sphere and outer-sphere 
interactions.[43-45] Some parameters were fixed during the fitting procedure: 
d, the distance of closest approach for the outer sphere contribution was set at 
0.36 nm, τM values were those obtained by 17O NMR, and the number of 
water molecules in the first coordination sphere of GdIII was set to one. τV 
and τSO (the electronic relaxation time at zero field) were optimized for the 
outer sphere and the inner-sphere contributions simultaneously. The distance 
r between the protons of the coordinated water molecule and the Gd ion was 
set to 0.31 nm. The fitting of the experimental data of Gd-DTPA(TA)2 gave 
values for the various parameters close to those of Gd-DTPA except for the 
rotational correlation time which is, as expected, larger (table 8-2). Similarly, 
for Gd-DTPA(PAE)2, the theoretical fitting gave parameters in good 
agreement with the expectation. The value of τR is slightly increased as 
compared to that of Gd-DTPA(TA)2. For Gd-DTPA(HTA)2 which has a 
molecular weight close to that of Gd-DTPA(TA)2, the value of τR obtained 
from the fitting is about doubled. Such an increase of τR could be due to 
intermolecular interactions with subsequent formation of dimers or polymers.  
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Figure 8-4: Proton water NMRD profile of DTPA(TA)2, DTPA(HTA)2 and 
DTPA(PAE)2 at 37 °C. The NMRD profile of Gd-DTPA has been added for 
comparison.[42]  
 
Table 8-2: Parameters obtained from the fitting of the proton NMRD data. 
 τR (ps) τso (ps) τv (ps) τM (ns) 
Gd-DTPA 59 82 23 143 
Gd-DTPA(TA)2 72 96 22 172 
Gd-DTPA(HTA)2 135 78 34 240 
Gd-DTPA(PAE)2 89 97 31 840 
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8.3 Conclusions  
 
In summary, three highly soluable, low molecular weight bisamide 
derivatives of DTPA were synthesized and were physicochemically 
evaluated by multinuclear NMR and NMRD. Water residence times were 
evaluated by 17O-NMR and revealed that the water residence time of Gd-
DTPA(PEA)2 was higher than for Gd-DTPA(TA)2 and Gd-DTPA(HTA)2, 
probably because of the presence of a bulky ethyl ester group near the water 
coordination site. Indeed, this is supported by a study on an extensive series 
of Gd-DTPA bis(amide) derivatives, which revealed that substituents close 
to the first coordination sphere, have a relatively weak influence (i.e. the 
change of water residence time lies in the same order of magnitude) on the 
water residence time.[46] NMRD data revealed that the proton relaxivity of 
Gd-DTPA(TA)2 and Gd-DTPA(PAE)2 are similar and slightly higher, 
compared to that of Gd-DTPA. The relaxivity of Gd-DTPA(HTA)2, which 
has a molecular weight close to that of Gd-DTPA(TA)2, is markedly higher. 
This is caused by a much slower rotational rearrangement due to 
intermolecular interactions with subsequent formation of dimers or polymers.  
 
8.4 Experimental 
8.4.1 Synthesis of the ligands 
DTPA(PAE)2 
To a solution of DTPA-bis(anhydride) (0.357 g, 1 mmol) in dry DMF (30 
ml), L-phenylalaninethylester hydrochloride (0.459 g ; 2 mmol) was added 
and the reaction mixture was heated at 60°C for 5 hours. After the removal of 
the solvent, the product was dissolved in ethanol and precipitated by adding 
diethylether. The precipitate was then dried in vacuo overnight. 
 
DTPA(TA)2 
To a solution of DTPA-bis(anhydride) (0.357 g, 1 mmol) in dry DMF (30 
ml), tyramine (0.274 g ; 2 mmol) was added and the reaction mixture was 
- Bisphenetylamide derivatives - 
220 
heated at 60 °C for 5 hours. After the removal of the solvent, the product was 
washed with ethanol and dried in vacuo overnight. 
 
 
DTPA(HTA)2 
To a solution of DTPA-bis(anhydride) (0.357 g ; 1 mmol) in dry DMF (30 
ml), 3-hydroxytyramine hydrochloride (0.379 g ; 2 mmol) was added and the 
reaction mixture was heated at 60°C for 5 hours. After the removal of the 
solvent, the product was washed with ethanol and dried in vacuo overnight. 
 
8.4.2 Analytical data ligands 
DTPA(PAE)2: Yield: 94%, 1H NMR (D2O), δ (ppm): 3.02 (m, 4 H, 2 × N-
CH2); 3.1-3.4 (m, 8 H, 2 × N-CH2, 2 × CH2-NH-CO); 3.23 (s, 4 H, 2 × CH2-
COOH); 3.60 (s, 2 H, CH2-COOH); 3.85 (s, 4 H, 2 × CH2-CO-NH); 4.13 (m, 
4 H, 2 × CH2-Ph); 7.1-7.4 (m, 10 H, Ph). IR: ν (cm-1): 2972, 2952, 2876 (CH 
alkyl); 1733 (CO ester); 1677 (CO acid); 1633 (amide I); 1534 (amide II). 
Elem. Anal. Calcd.: (found): C34H43N5O12(H2O)3: C, 53.18 (52.55); H, 6.43 
(6.31); N, 9.12 (9.4)%. ES-MS+: 744 [M+H]+; 766 [M+Na]+; 1487 
[2M+H]+. 
 
DTPA(TA)2: Yield: 95%; 1H NMR (D2O), δ (ppm): 2.67 (t, 4 H, 2 × N-
CH2); 2.92 (t, 4 H, 2 × N-CH2); 3.03 (m, 4 H, 2 × CH2-NH-CO); 3.13 (s, 4 H, 
2 × CH2-COOH); 3.31 (s, 4 H, 2 × CH2-CO-NH); 3.35 (t, 4 H, 2 × CH2-Ph); 
3.49 (s, 2 H, CH2-COOH); 6.73 (d, 4 H, Ph); 7.03 (d, 4 H, Ph). IR: ν (cm-1): 
1635 (CO amide I); 1510 (amide II). Elem. Anal. Calcd.: (found): 
C30H41N5O10: C, 57.04 (57,36); H, 6.54 (6.68); N, 11.09 (11.38)% ES-MS+: 
632 [M+H]+; 654 [M+Na]+. 
 
DTPA(HTA)2: Yield: 95%; 1H NMR (D2O), δ (ppm),: 2.61 (t, 4 H, 2 × N-
CH2); 2.95 (t, 4 H, 2 × N-CH2); 3.10 (m, 4 H, 2 × CH2-NH-CO); 3.37 (m, 4 
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H, 2 × CH2-Ph); 3.50 (s, 2 H, CH2-COOH); 3.56 (s, 4 H, 2 × CH2-COOH); 
3.68 (s, 4 H, 2 × CH2-CO-NH); 6.56-6.82 (m, 6 H, Ph). IR: ν (cm-1): 1740 
(CO acid), 1647 (amide I), 1521 (amide II). Elem. Anal. Calcd.: (found): 
C30H38N5O12Na3(H2O): C, 48,18 (48.63), H, 5.39 (5.60) N, 9.37 (8.97)% ES-
MS+: 664: [M+H]+; 686 [M+Na]+; 700 [M+2H2O+H]+. 
 
8.4.3 Analytical data complexes 
 
La-DTPA(TA)2: IR ν (cm-1): 2981 (CH alkyl); 1634 (amide I); 1585 (COO 
assym stretch); 1411 (COO- sym stretch). ES-MS-: 766 [M]-; 802 
[M+2H2O]-; 1532 [2M]-. 
 
Eu-DTPA(TA)2: IR ν (cm-1): 1622 (amide I); 1594 (COO assym stretch); 
1406 (COO- sym stretch). ES-MS-: 780 [M]-; 818 [M+H2O]-; 1560 [2M]-. 
 
Gd-DTPA(TA)2: Yield: 53%; IR ν (cm-1): 1627 (amide I); 1595 (COO- 
assym. stretch); 1399 (COO- sym stretch). ES-MS+: 785 [M+H]+; 821 
[M+2H2O+H]+; 1571 [2M+H]+; 1607 [M+2H2O+H]+. 
 
La-DTPA(PAE)2: IR ν (cm-1):1730 (CO ester); 1610 (amide I); 1411 (COO- 
sym stretch). ES-MS-: 878 [M]-; 914 [M+2H2O]-; 1757 [2M]-, 1792 
[2M+2H2O]-. 
 
Eu-DTPA(PAE)2: IR ν (cm-1): 2975, 2926 (CH alkyl); 1740 (CO ester); 
1626 (amide I); 1582 (COO- assym stretch); 1403 (COO- sym stretch). .ES-
MS-: 892 [M]-; 928 [M+2H2O]-; 1784 [2M]-. 
 
Gd-DTPA(PAE)2: Yield: 35%; IR ν (cm-1): 1733 (CO ester); 1622 (CO 
amide I); 1589 (COO- assym stretch); 1388 (COO- symm stretch). ES-MS+: 
897 [M+H]+; 1795 [M+H]+. 
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La-DTPA(HTA)2: IR ν (cm-1): 2971 (CH alkyl), 1628 (CO amide I), 1591 
(COO- assym stretch); 1392 (COO- sym stretch). ES-MS(-): 799 [M]-; 834 
[M+2H2O]-; 1598 [2M]-. 
 
Eu-DTPA(HTA)2: IR ν (cm-1): 2983, 2916 (CH alkyl); 1620 (amide I); 
1579 (COO- assym stretch). ES-MS+: 813 [M+H]+; 836 [M+Na]+. 
 
Gd-DTPA(HTA)2: Yield: 95%; IR: υ (cm-1): 2923, 2852 (CH alkyl), 1628 
(CO amide I), 1602 (COO- assym. stretch), 1408 (COO- sym stretch); ES-
MS+: 841 [M+Na+]+. 
 
8.4.4 Sodium and potassium ion content measurements 
Na+ content (mmol:mol of the complex): Gd-DTPA(TA)2: 0.0; Gd-
DTPA(PAE)2: 0.7; Gd-DTPA(HTA)2: 0.0. K+ content: no K+ was found in 
any of the complexes. 
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Tu no tienes la culpa mi amor 
Que el mundo está tan feo 
Tu no tienes la culpa mi amor 
De tanto tiroteo 
Vas por la calle llorando 
Lagrimas de oro 
 
It isn’t your fault my love 
That the world is so ugly 
It isn’t your fault my love 
For so much shooting 
You walk the streets crying 
Golden tears 
 (Manu Chao) 
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9.1 DTPA-bisperfluoroalkylamides as micellar systems 
9.1.1 Justification 
Perfluorinated surfactants are known to have a low CMC (critical micelle 
concentration). DTPA-bisamide derivatives with a relative small alkyl chain 
are water soluble and hence could spontaneously form micelles at low 
concentration. The synthetic procedure is outlined in scheme 9-1. The 
acylation of pentadecafluorooctanoic acid was performed according to a 
standard procedure.[1] The conversion to an amide was performed by adding 
the acylchloride to a large volume of concentrated ammonia (to prevent the 
formation of dimers) the crude product was then evaporated to dryness and 
further dried in vacuo.  The reduction was done with diborane in THF 
according to a published procedure. [2] 
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Scheme 9-1: Outline of the synthesis of the DTPA-bisperfluorinated 
alkylamide. 
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9.1.2 Analytical data 
Ligand synthesis 
 
(1): Elem. Anal. Calcd.: (found): C8H2NF15O: C: 23.3 (22.5); H: 0.44 (0.94); 
N: 3.02 (3.63)%. 
(2): ES-MS+: 399: [M]+ ; 417: [M+H2O]+ 
(3): Elem. Anal. Calcd.: (found): C30H27N5F30: C: 34.1 (34.65); H: 2.41 
(3.46), N: 6.2 (6.93)%.  
 
Gd complex 
 
Elem. Anal. Calcd.: (found): C30H22N5O8F30Gd(H2O)3: 26.5 (25.13); 2.1 
(3.92); 5.14 (5.42)%. 
ES-MS+: No peaks that could be explained, some Gd-isotopic distribution at 
548, 569, 593, 624. 
IR: 1595 (COO- assym. stretch); 1409 (COO- symm stretch). 
 
9.2 Mixed f-d systems: theory not converted into practice 
9.2.1 Justification 
Some substituted phenanthrolines and bisquinolines could be used to make 
supramolecular structures that should contain four to six lanthanide ions. The 
syntheses are outlined in schemes 9-2 to 9-4. For the first synthesis, for the 
first two steps, a literature method was followed. [3] The coupling of the acyl 
chloride product with hydrazine failed, which also failed for the bisquinoline 
derivative. 
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Scheme 9-2: Outline of the synthesis of a 1,10-phenanthroline-4,4’-diamide 
based system. 
 
Analytical data 
(1) Yellow crystals as reported in literature [3] immediately reacted to yield 
product (2). 
(2) Elem. Anal. Calcd.: (found): C14H8N2O4: C: 62.7 (59.08); H: 3.01 (3.19); 
N: 10.44 (10.30). 
(3) Elem. Anal. Calcd.: (found): C14H6N2O2Cl2: C: 55.11 (51, 67); H: 1.98 
(3.27); N: 9.18 (9.19)%. 
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Scheme 9-3: Various attempts to synthesise a bisquinoline based ligand for 
mixed f-d complexation, (mDTPA stands for mono functional DTPA, i.e. 
DTPA with only the middle carboxylic acid group unprotected). 
 
Analytical data 
(1) Elem. Anal. Calcd.: (found): C20H10N2O4Cl2(KCl)2: C: 42,86 (42,20); H: 
1,8 (2,07); N: 5,00 (4,62)%. 
(2) and (3): some mass spec evidence of (2): coupling with hydrazine, peak 
at 372, some NMR indications (aromatic region, nitrogen protons) but 
impure, low yields… 
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Scheme 9-4: Another route for the synthesis of a bisquinoline based ligand 
for mixed f-d complexation. 
 
Analytical data 
(1) ES-MS+: 754: [M+Na]+: carbazate coupled; 654: [M+Na]+ hydrazine 
coupled. 
(2) coupling to bisquinoline failed/ deprotection of carbazate coupled product 
failed. 
232 
- Chapter 9 - 
9.3 Novel contrast agents bearing two metal centers 
 
Several attempts were made in order to make necrosis avid contrast agents 
with two paramagnetic metal centers. Generally the strategy was to condense 
two substituted pyrrole or indole moieties with an aromatic aldehyde. The 
obtained product would then be coupled to two DTPA molecules by a 
hydrazine “bridge”. 
Cl
O OEt
O O
N
H
COOEt
+
   H2O
NH3 conc.  
Scheme 9-5: Synthesis of a substituted pyrrole.[2-3] 
 
The purity of the compound was checked by TLC (1:1 hexane:chloroform), 
yielding one spot with Rf = 0.6. 
N
H
COOEt
2 +
HCl conc.
N
H
COOEt
N
H
EtOOC
CHO
Ri
R1 =
O C6H13R2 =
R3 =
R
 
Scheme 9-6: Condensation of a pyrrole with several aromatic aldehydes, the 
dashed line indicates where the R group is attached. 
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Comment: of these compounds only the anthracene based was successfully 
made (as checked on TLC, CHCl3:Hex 1:1, Rf = 0.2) but the coupling to 
hydrazine failed. For the other two compounds no suitable chromatographic 
system was found to purify the brown slurry. 
Cl
O OEt
O O
N
COOEt
+
      H2O
excess aniline
 
Scheme 9-9: Synthesis of an aromatic substituted pyrrole. 
 
This aniline based pyrrole was synthetized in a similar way as the former 
one. The product was purified on a silica column using a gradient of 1:3 
CHCl3: Hexane to 1:2 CHCl3:Hex system. Purity was checked by TLC, one 
single spot on a 1:2 CHCl3:Hex system, Rf = 0.3. 
N
COOEt
2 +
OCH3CH3O
OCH3
CHO
OCH3CH3O
OCH3
NN
COOEtEtOOC
HCl conc.
ArAr  
Scheme 9-7: Condensation of an aromatic aldehyde with another pyrrole 
derivative. 
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Scheme 9-8: An indigo based system. 
 
Comment: indigo is a blue colorant that has some necrosis avidity, a direct 
coupling could have yielded a nice contrast agent. Unfortunately this 
coupling failed. 
 
9.4 Other attempts and future ideas 
9.4.1 Evans blue 
Evans blue is a cheap colorant that is used to color necrotic tissue, contrast 
agents based on this molecule could have affinity for necrotic tissue as well. 
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Scheme 9-9: Synthesis of a contrast agent based on evans blue. 
 
Comment: There is some NMR evidence that the compound was formed. 
However, most likely the reaction is not complete (no mass spec could be 
obtained since the mass was out of the detectable range). Preparative 
separation on a reversed phase column would be the best solution; however 
this was not done due to lack of time and expertise to find a suitable elution 
system, moreover the available HPLC works only semi preparative, which is 
not desirable if one wants to separate on gram scale. Handling the product 
itself is also quite tricky, because it makes you blue all over (no pun 
intended). 
236 
- Chapter 9 - 
9.4.2 Melamine  
Here an attempt was made to prepare a compound that is able to bind three 
metal centers. 
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Scheme 9-10: Synthesis of a melamine based contrast agent. 
 
Comment: mass spec evidence that the compound has formed, but with 
impurities of the incomplete reacted melamine (melamine with 1 and 2 
equivalents of mDTPA). Purification of the deprotected product by dialysis 
failed (the yield was virtually nothing). Here again, purification of the 
deprotected product by reversed phase HPLC would probably be the best 
separation method (cfr. 9.5.1). 
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Summary 
 
The clinical introduction of magnetic resonance imaging (MRI) in the early 
1980s, together with the breath-taking progress in computer technology, 
revolutionized diagnostic imaging. Today, multidimensional imaging has 
become a reality, producing images within seconds, without time-consuming 
data processing. These techniques allow physicians to accurately diagnose 
many pathologies non-invasively. The use of paramagnetic contrast agents 
makes the method even more sensitive and the diagnosis more specific. The 
use of paramagnetic substances for increasing and controlling the magnetic 
relaxation of water protons has found wide application in MRI. The attention 
has been primarily focused on complexes of Gd(III), since this metal ion 
couples a large magnetic moment with a long electron spin relaxation time, 
two properties that ensure an optimum efficiency for nuclear spin relaxation 
of the interacting nuclei. Unfortunately, this metal ion is toxic at the 
concentrations needed for medical imaging. Toxicity of the free metal ion 
can however be reduced dramatically by coordinating this ion with a strongly 
binding ligand that occupies most of the available coordination sites. In 
general, two types of ligands and derivatives thereof have been suggested: 
the macrocyclic DOTA ligand and the DTPA ligand. The anionic complexes 
Gd(DTPA)2- (Magnevist®) and Gd(DOTA)- (Dotarem®) were the first 
complexes entered into clinical practice and represent the reference 
compounds for the development and the evaluation of new agents. 
 
In this study, various routes to improve the performance of DTPA-based 
contrast agents were explored. One of the main goals was to find efficient 
ways to reduce the rotational motion of DTPA derivatives by assembling 
supramolecular structures. In a first step, amphiphilic DTPA bis(amide) and 
monoamide derivatives with various chain lengths were incorporated in 
mixed micelles or in liposomes, and their relaxation behaviour in aqueous 
solution was investigated. It was found that the relaxivity (i.e. the change in 
relaxation rate of water protons (in s-1), produced by a contrast agents per 
unit change in concentration (in mM)) of solutions containing mixed 
micelles in which amphiphilic bis(alkylamide) derivatives of DTPA are 
incorporated, is higher than for the hydrophilic Gd(DPTA)2- as a result of a 
decrease in mobility of the gadolinium complexes. It was also found that, for 
bisamides, when the alkyl chain of the incorporated complex is longer than 
the alkyl chain of DPPC (the main constituent of the micelle) the 
immobilization inside the micellar structure is less effective. In a second 
step, the influence of small side chain groups on the formation of micelles 
was investigated. Bisamide compounds with aliphatic chains made of the 
amino acid phenylalanine or tyrosine, esterified with n-alkyl alcohols, were 
synthesized. It was found that the presence of aryl side groups prevents the 
formation of monodisperse (i.e. one kind of size distribution) micelles. 
Moreover, in case of the phenylalanine derivatives, the micelles were 
unstable. In the latter case, instead of micelles, liposomes were prepared 
which were monodisperse. The relaxivities of solutions of these 
supramolecular structures are also higher than Gd(DTPA)2- as a result of the 
reduced mobility of the gadolinium complexes but the relaxivity gain is 
lower compared to micellar solutions in which amphiphilic bis(alkylamide) 
derivatives of DTPA are incorporated, most likely due to a less efficient 
packing or increased local mobility, a phenomenon which is supported by 
NMR-studies. Here as well, it was found that when the alkyl chains are 
longer than the alkyl chains of DPPC - in which the compound is inserted - 
the relaxivity gain is lower. In a third step, amphiphilic n-alkyl monoamide 
derivatives of DTPA with varying alkyl chain length, were synthesized. 
Those derivatives were then incorporated in mixed micelles. The relaxivities 
of solutions containing these micelles are significantly higher than 
Gd(DTPA)2- as a result of the reduced mobility of the gadolinium 
complexes. At imaging fields (20 – 60 MHz) all micellar solutions show 
similar relaxivities, in contrast to the observation with the bisamide 
compounds. This observation suggests that the packing of the monoamide 
compound with the longest chain is as efficient as the packing of the 
analogues with shorter ones; although the size of the first compound has a 
longer chain length than DPPC, in which it is inserted. Comparing the 
relaxivity data of the monoamide compounds with data obtained with 
bisamides, one can conclude that the relative relaxivity gain, as compared 
with Gd(DTPA)2- is highest for mixed micelles in which monoamide 
complexes are inserted, followed by micelles in which bisamide compounds 
with n-alkyl chains are inserted, whereas liposomes in which bisamides 
complexes with side chains are inserted, display the smallest relaxivity gain. 
 
Another approach towards achieving higher relaxivity relies on the formation 
of a supramolecular entity by self-assembly of a gadolinium(III) complex 
around an iron(III) or iron(II) ion. In a first study, a lanthanide(III) binding 
DTPA moiety was linked with an iron(II) binding 1,10-phenanthroline unit. 
A supramolecular structure was easily obtained by mixing lanthanide 
complexes of this ligand with an aqueous solution of Fe2+, resulting in a 
heteropolymetallic species with increased relaxivity. Luminescence studies 
show that the local coordination environment of the lanthanide(III) ion 
remains unaffected upon formation of the supramolecular structure. 
Moreover this supramolecular structure displays necrosis avidity. 
 
In a second study a Ln(III) binding DTPA moiety was linked with an 
iron(III) binding catechol group, resulting in a heteropolymetallic species 
with increased relaxivity. The supramolecular structure was easily obtained 
by mixing an aqueous solution of the lanthanide(III) complex of the ligand 
with an aqueous solution of Fe3+ ions as indicated by an immediate change of 
color. Luminescence studies show that the local coordination environment of 
the lanthanide(III) ion remains unaffected upon formation of the 
supramolecular structure. The first data on relaxation rates suggest that the 
relaxivity of the [(Gd-5)3Fe]6- complex is much higher than Gd(DTPA)2-, 
making the compound interesting as a potential imaging agent. 
 
In a third study, a route to a monomeric gadolinium(III)-iron(III) complex, 
derived from DTPA and 3-hydroxytyramine (dopamine), was investigated. 
The heterobimetallic paramagnetic complex can be obtained by using  
DTPA-bis(3-hydroxytyramide) as the ligand, and with gadolinium(III) and 
iron(III) as the paramagnetic centers. 
 
Another goal of this study was to find agents that display necrosis (i.e. dead 
tissue) avidity, which is important in the diagnosis of myocardial infarction. 
For this, a structural analogue of an agent that displays necrosis avidity, 
ECIV-7, has been synthesized. This structure bears two paramagnetic centra 
and was physicochemically and preclinically evaluated and tested for 
necrosis avidity. The NMRD data prove that this agent has a higher 
relaxivity compared to Gd(DTPA)2- and that the relaxivity value increases 
dramatically in vivo due to strong HSA (human serum albumine) interaction. 
The interaction with HSA also results in longer elimination half-lives and a 
better confinement in the vascular space as proved by pharmacokinetic 
evaluation. Biodistribution studies show that the highly soluble complex is 
excreted, similarly as Gd(DTPA)2-, by the renal pathway. Unfortunately the 
agent did not show any necrosis avidity but instead it enhanced more 
effectively tissues with half the normal dose, compared to Gd(DTPA)2-. 
 
Finally, three highly soluble, low molecular weight bisamide derivatives of 
DTPA were synthesized and were physicochemically evaluated by 
multinuclear NMR and NMRD. The water residence time of one of those 
complexes, Gd-DTPA(PEA)2, was higher than the other two,  
Gd-DTPA(TA)2 and Gd-DTPA(HTA)2, because of the presence of a bulky 
ethyl ester group near the water coordination site. NMRD data revealed that 
the proton relaxivity of Gd-DTPA(TA)2 and Gd-DTPA(PAE)2 compounds 
are similar and slightly higher, compared to that of Gd(DTPA)2-. The 
relaxivity of the compound Gd-DTPA(HTA)2, which has a molecular weight 
close to that of Gd-DTPA(TA)2, is markedly higher, which is caused by a 
much slower rotational rearrangement due to intermolecular interactions with 
subsequent formation of dimers or polymers.  
Samenvatting 
 
De introductie van de magnetische resonantie beeldvormingstechniek (MRI) 
in de vroege jaren tachtig leidde, mede dankzij de ontwikkelingen in de 
computertechnologie, tot een ware revolutie op het gebied van diagnose door 
beeldvorming. Vandaag de dag kunnen multidimensionale beelden van de 
inwendige weefsels van een patiënt gemaakt worden in luttele seconden tijd. 
De magnetische resonantie beeldvormingstechniek laat de geneesheer toe om 
zeer precies en non-invasief een diagnose te stellen. Met behulp van 
contraststoffen worden de verkregen beelden nog duidelijker en kan de 
diagnose nog specifieker worden. Het gebruik van paramagnetische stoffen, 
om de magnetische relaxatie van waterprotonen te sturen en te verhogen, 
heeft een brede toepassing in de magnetische resonantie beeldvorming 
gevonden. De aandacht ging hierbij voornamelijk naar complexen met het 
lanthanide ion Gd(III), aangezien dit metaalion een groot magnetisch 
moment koppelt aan een lange elektronische relaxatietijd, twee 
eigenschappen die bijdragen tot een optimale efficiëntie voor de 
kernspinrelaxatie van de interagerende kernen. Helaas is het Gd(III) toxisch 
bij de benodigde concentratie voor medische beeldvorming. De toxiciteit van 
het vrije ion kan echter drastisch gereduceerd worden indien men dit ion 
coördineert met een sterk bindend ligand dat de meeste beschikbare 
coördinatiesites bezet. Het macrocyclische DOTA ligand en het DTPA 
ligand zijn twee liganden met sterk lanthanide bindende eigenschappen. De 
anionische complexen Gd(DTPA)2- (Magnevist®) en Gd(DOTA)- 
(Dotarem®) waren de eerste complexen die klinisch werden toegepast als 
contraststoffen en ze worden dan ook als referentie gebruikt voor de 
ontwikkeling en evaluatie van nieuwe contraststoffen. 
 
In deze studie werden verschillende wegen bewandeld om de efficiëntie van 
op DTPA gebaseerde contraststoffen te verbeteren. Eén van de voornaamste 
doelstellingen was om de rotationele mobiliteit te verlagen van derivaten van 
DTPA door het vormen van supramoleculaire structuren. 
 
In een eerste stap werden amfifiele DTPA bis(amide) en monoamide 
derivaten met verschillende ketenlengte geïncorporeerd in gemengde 
micellen of in liposomen, en hun relaxatiegedrag in waterige oplossing werd 
nagegaan. De relaxiviteit van waterige oplossingen (i.e. de verandering van 
relaxatiesnelheid van water protonen (in s-1), geïnduceerd door een contrast 
stof per concetratie-eenheid (in mM)) die deze gemengde micellen bevatten, 
was hoger, relatief ten opzichte van het hydrofiele Gd(DPTA)2- als gevolg 
van een gereduceerde mobiliteit van de geïncorporeerde gadolinium 
complexen. Bij bisamidederivaten, waarvan de ketenlengte van het 
geïncorporeerd complex langer is dan de alkyl keten van DPPC (het 
hoofdbestanddeel van de micel) is de immobilisatie in de micel minder 
efficiënt. 
 
In een tweede stap werd de invloed van kleine zijgroepen op de vorming van 
micellen nagegaan. Bisamide verbindingen met alifatische ketens bestaade 
uit het aminozuur fenylalanine of tyrosine, veresterd met n-alkyl alcoholen, 
werden gesynthetiseerd. De aanwezigheid van aryl zijgroepen voorkomt de 
vorming van monodisperse (één enkele groottedistributie) micellen. 
Bovendien zijn micellen gebaseerd op fenylalaninederivaten, onstabiel. Van 
de laatste soort verbindingen werden monodisperse liposomen gemaakt. De 
relaxiviteit van oplossingen van deze supramoleculaire structuren is ook 
hoger dan Gd(DTPA)2- hetgeen een gevolg is van een verminderde 
mobiliteit, maar de winst in relaxiviteit is kleiner dan voor bis(alkylamide) 
derivaten van Gd(DTPA)2- met vergelijkbare ketenlengte. Waarschijnlijk is 
deze vaststelling het gevolg van een minder efficiënte stapeling of van een 
grotere lokale mobiliteit, hetgeen wordt ondersteund door NMR-studies. 
Tevens werd ook hier de vaststelling gedaan dat, als de alkylketen langer is 
dan die van DPPC, de winst in relaxiviteit kleiner is. 
 
In een derde stap werden amfifiele n-alkyl monoamidederivaten van DTPA, 
met verschillende alkylketenlengtes, gemaakt. Deze derivaten werden 
vervolgens geïncorporeerd in gemengde micellen. De relaxiviteit van 
waterige oplossingen die deze micellen bevatten waren duidelijk hoger dan 
Gd(DPTA)- as gevolg van een gereduceerde mobiliteit van de gadolinium 
complexen. Bij de frequenties die men gebruikt voor beeldvorming (20 – 60 
MHz) vertonen alle micellaire oplossingen een vergelijkbare relaxiviteit, in 
tegenstelling tot de waarnemingen bij bisamideverbindingen. Uit deze 
waarneming kan men afleiden dat de stapeling van monoamide verbindingen 
met de langste ketenlengte binnen een micel even efficiënt is als de stapeling 
van monamidederivaten met kortere ketenlengte. Wanneer men de 
relaxiviteitsgegevens van de monoamide derivaten gaat vergelijken met 
bisamidederivaten, relatief ten opzichte van Gd(DTPA)2-, kan men besluiten 
dat de winst in relaxiviteit het hoogst is voor micellaire oplossingen waarin 
monoamidederivaten zijn geïncorporeerd, gevolgd door micellen waarin 
bis(alkylamide) verbindingen geïncorporeerd zijn, terwijl liposomen waarin 
bisamidecomplexen met zijgroepen geïncorporeerd zijn, de kleinste 
relaxiviteitswinst oplevert. 
 
Een andere benadering om een hogere relaxiviteit te bereiken berust op de 
vorming van een supramoleculaire structuur door zelfassemblage van een 
gadolinium(III) complex rond een ijzer(III)- of ijzer(II)-ion. In een eerste 
studie werd het lanthanide bindende DTPA ligand gekoppeld met een 
ijzer(II) bindende 1,10-fenantroline eenheid. Een supramoleculaire structuur 
werd op eenvoudige wijze bekomen door het mengen van 
lanthanidecomplexen van dit ligand met een Fe2+ bevattende waterige 
oplossing, wat resulteert in de vorming van een heteropolymetallische 
supramoleculaire structuur met een verhoogde relaxiviteit. Luminescentie 
studies tonen aan dat de lokale coördinatieomgeving van het lanthanide(III) 
ion niet wordt aangetast bij de vorming van deze supramoleculaire structuur. 
Bovendien blijkt deze supramoleculaire structuur necrosespecifiek te zijn. 
 
In een tweede studie werd het lanthanide bindende DTPA ligand gekoppeld 
met een ijzer(III)-bindende catechol eenheid. Ook hier werd een 
supramoleculaire structuur op eenvoudige wijze bekomen door een 
lanthanidecomplex van het ligand te mengen met een Fe3+ bevattende 
waterige oplossing. Luminescentiestudies tonen aan dat de lokale 
coördinatieomgeving van het lanthanide(III) ion niet wordt aangetast bij de 
vorming van deze supramoleculaire structuur. De eerste gegevens tonen 
tevens aan dat de relaxiviteit van deze verbinding veel hoger is dan 
Gd(DTPA)2-.  
 
In een derde studie werd een manier om een monomeer gadolinium(III)-
ijzer(III) complex, afgeleid van DTPA en 3-hydroxytyramine (dopamine), 
gezocht. Het heterobimetallisch, paramagnetisch complex kan bekomen 
worden door DTPA-bis(3-hydroxytyramide) als ligand te gebruiken en 
gadolinium(III) en ijzer(III) als paramagnetische centra. 
 
Een ander doel van deze studie was het vinden van stoffen die necrose (i.e. 
dood celweefsel) specifiek zijn, hetgeen belangrijk is in de diagnose van een 
hartinfarct. Hiervoor werd een structureel analoog van de necrosespecifieke 
stof ECIV-7 gemaakt. Deze structuur draagt twee paramagnetische centra en 
werd fysicochemisch en preklinisch geëvalueerd en getest voor necrose 
aktiviteit. NMRD data tonen aan dat de stof een hogere relaxiviteit heeft in 
vergelijking met Gd(DTPA)2- en dat de relaxiviteit drastisch stijgt in vivo als 
gevolg van een niet-covalente interactie met HSA (humaan serum albumine). 
Deze interactie zorgt ook voor langere eliminatie halfwaardetijden en een 
betere restrictie van de stof tot de bloedvaten. Biodistributiestudies tonen aan 
dat het goed oplosbare complex, net zoals Gd(DTPA)2-, voornamelijk door 
de nier wordt verwijderd. Helaas vertoont deze stof geen necrosespecificiteit, 
hoewel de efficiëntie van de contraststof in vivo tweemaal zo hoog is dan 
Gd(DTPA)2-. 
 
Ten slotte werden drie sterk oplosbare bisamide derivaten van DTPA, met 
een laag moculair gewicht, gesynthetiseerd. Deze stoffen werden 
fysicochemisch geëvalueerd met multinucleaire NMR en NMRD. De 
waterresidentietijd van één van deze complexen, Gd-DTPA(PEA)2, was 
tweemaal hoger dan de overige twee, Gd-DTPA(TA)2 en Gd-DTPA(HTA)2. 
Deze waarneming is het gevolg van de aanwezigheid van de ethylestergroep 
nabij de water coördinatiesite. NMRD data tonen aan dat de 
protonrelaxiviteit van Gd-DTPA(TA)2 en Gd-DTPA(PAE)2 verbindingen 
vergelijkbaar zijn en enigzins hoger zijn dan Gd(DTPA)2-. De relaxiviteit van 
Gd-DTPA(HTA)2, die een vergelijkbaar moleculair gewicht heeft als Gd-
DTPA(TA)2, is merkelijk hoger, wat veroorzaakt wordt door een 
gereduceerde mobiliteit ten gevolge van intermoleculaire interakties die 
dimeer of polymeervorming tot gevolg hebben. 
